Document:

<PAGE>

                                                                    EXHIBIT 10.3

                              EMPLOYMENT AGREEMENT

      THIS EMPLOYMENT AGREEMENT (this "Agreement") is entered into by and
between Santarus, Inc., a Delaware corporation (the "Company"), and C. Christine
Simmons ("Executive"), and shall be effective as of July 27, 2004 (the
"Effective Date").

      WHEREAS, the Company desires to employ Executive, and Executive desires to
be employed by the Company, on the terms and subject to the conditions set forth
herein; and

      NOW, THEREFORE, in consideration of the mutual promises herein contained,
the parties agree as follows:

      1. Definitions. As used in this Agreement, the following terms shall have
the following meanings:

            (a) Board. "Board" means the Board of Directors of the Company.

            (b) Bonus. "Bonus" means an amount equal to the average of the
bonuses awarded to Executive for each of the three (3) fiscal years prior to the
date of termination, or such lesser number of years as may be applicable if
Executive has not been employed for three (3) full years on the date of
termination. For purposes of determining Executive's "Bonus," to the extent
Executive received no bonus in a year due to a failure to meet the applicable
performance objectives, such year will still be taken into account (using zero
(0) as the applicable bonus) in determining Executive's "Bonus" for purposes of
Section 4. If any portion of the bonuses awarded to Executive consisted of
securities or other property, the fair market value thereof shall be determined
in good faith by the Board.

            (c) Cause. "Cause" means any of the following:

                  (i) the commission of an act of fraud, embezzlement or
dishonesty by Executive that has a material adverse impact on the Company or any
successor or affiliate thereof;

                  (ii) a conviction of, or plea of "guilty" or "no contest" to,
a felony by Executive;

                  (iii) any unauthorized use or disclosure by Executive of
confidential information or trade secrets of the Company or any successor or
affiliate thereof that has a material adverse impact on any such entity;

                  (iv) Executive's gross negligence, insubordination or material
violation of any duty of loyalty to the Company or any other material misconduct
on the part of Executive;

<PAGE>

                  (v) Executive's ongoing and repeated failure or refusal to
perform or neglect of Executive's duties as required by this Agreement, which
failure, refusal or neglect continues for fifteen (15) days following
Executive's receipt of written notice from the Board or the CEO stating with
specificity the nature of such failure, refusal or neglect; or

                  (vi) Executive's breach of any material provision of this
Agreement;

provided, however, that prior to the determination that "Cause" under this
Section 1(c) has occurred, the Company shall (w) provide to Executive in
writing, in reasonable detail, the reasons for the determination that such
"Cause" exists, (x) other than with respect to clause (v) above which specifies
the applicable period of time for Executive to remedy his or her breach, afford
Executive a reasonable opportunity to remedy any such breach, (y) provide the
Executive an opportunity to be heard prior to the final decision to terminate
the Executive's employment hereunder for such "Cause" and (z) make any decision
that such "Cause" exists in good faith.

            The foregoing definition shall not in any way preclude or restrict
the right of the Company or any successor or affiliate thereof to discharge or
dismiss Executive for any other acts or omissions, but such other acts or
omissions shall not be deemed, for purposes of this Agreement, to constitute
grounds for termination for Cause.

            (d) Change of Control. "Change of Control" means and includes each
of the following:

                  (i) the acquisition, directly or indirectly, by any "person"
or "group" (as those terms are defined in Sections 3(a)(9), 13(d) and 14(d) of
the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the
rules thereunder) of "beneficial ownership" (as determined pursuant to Rule
13d-3 under the Exchange Act) of securities entitled to vote generally in the
election of directors ("voting securities") of the Company that represent fifty
percent (50%) or more of the combined voting power of the Company's then
outstanding voting securities, other than:

                        (A) an acquisition by a trustee or other fiduciary
      holding securities under any employee benefit plan (or related trust)
      sponsored or maintained by the Company or any person controlled by the
      Company or by any employee benefit plan (or related trust) sponsored or
      maintained by the Company or any person controlled by the Company, or

                        (B) an acquisition of voting securities by the Company
      or a corporation owned, directly or indirectly by the stockholders of the
      Company in substantially the same proportions as their ownership of the
      stock of the Company;

            Notwithstanding the foregoing, the following event shall not
constitute an "acquisition" by any person or group for purposes of this Section
1(d): an acquisition of the Company's securities by the Company that causes the
Company's voting securities beneficially owned by a person or group to represent
fifty percent (50%) or more of the combined voting power of the Company's then
outstanding voting securities; provided, however, that if a person or group
shall become the beneficial owner of fifty percent (50%) or more of the combined

                                        2
<PAGE>

voting power of the Company's then outstanding voting securities by reason of
share acquisitions by the Company as described above and shall, after such share
acquisitions by the Company, become the beneficial owner of any additional
voting securities of the Company, then such acquisition shall constitute a
Change of Control; or

                  (ii) during any period of two (2) consecutive years,
individuals who, at the beginning of such period, constitute the Board together
with any new director(s) (other than a director designated by a person who shall
have entered into an agreement with the Company to effect a transaction
described in clauses (i) or (iii) of this Section 1(d)) whose election by the
Board or nomination for election by the Company's stockholders was approved by a
vote of at least two-thirds (2/3) of the directors then still in office who
either were directors at the beginning of the two (2) year period or whose
election or nomination for election was previously so approved, cease for any
reason to constitute a majority thereof; or

                  (iii) the consummation by the Company (whether directly
involving the Company or indirectly involving the Company through one or more
intermediaries) of (x) a merger, consolidation, reorganization, or business
combination or (y) a sale or other disposition of all or substantially all of
the Company's assets or (z) the acquisition of assets or stock of another
entity, in each case other than a transaction:

                        (A) which results in the Company's voting securities
      outstanding immediately before the transaction continuing to represent
      (either by remaining outstanding or by being converted into voting
      securities of the Company or the person that, as a result of the
      transaction, controls, directly or indirectly, the Company or owns,
      directly or indirectly, all or substantially all of the Company's assets
      or otherwise succeeds to the business of the Company (the Company or such
      person, the "Successor Entity") directly or indirectly, at least a
      majority of the combined voting power of the Successor Entity's
      outstanding voting securities immediately after the transaction, and

                        (B) after which no person or group beneficially owns
      voting securities representing fifty percent (50%) or more of the combined
      voting power of the Successor Entity; provided, however, that no person or
      group shall be treated for purposes of this clause (B) as beneficially
      owning fifty percent (50%) or more of combined voting power of the
      Successor Entity solely as a result of the voting power held in the
      Company prior to the consummation of the transaction; or

                  (iv) the Company's stockholders approve a liquidation or
dissolution of the Company.

            (e) Good Reason. "Good Reason" means Executive's voluntary
resignation following any one or more of the following that is effected without
Executive's written consent:

                  (i) the relocation of the office of Executive more than fifty
(50) miles from Executive's principal place of employment as of the Effective
Date or to a location outside of San Diego County;

                                        3
<PAGE>

                  (ii) a change in Executive's position that materially reduces
his or her duties or responsibilities;

                  (iii) a reduction in Executive's base salary or target bonus
as an employee of the Company, other than pursuant to a Company-wide reduction
of base salaries and target bonuses for employees of the Company generally; or

                  (iv) the Company's breach of any material provision of this
Agreement; provided, that Executive shall (w) provide to the Company in writing,
in reasonable detail, notice of such breach and (x) afford the Company a
reasonable opportunity to remedy any such breach.

            (f) Permanent Disability. Executive's "Permanent Disability" shall
be deemed to have occurred if Executive shall become physically or mentally
incapacitated or disabled or otherwise unable fully to discharge his or her
duties hereunder for a period of ninety (90) consecutive calendar days or for
one hundred twenty (120) calendar days in any one hundred eighty (180)
calendar-day period. The existence of Executive's Permanent Disability shall be
determined by the Company on the advice of a physician chosen by the Company and
the Company reserves the right to have the Executive examined by a physician
chosen by the Company at the Company's expense.

            (g) Stock Awards. "Stock Awards" means all stock options, restricted
stock and such other awards granted pursuant to the Company's stock option and
equity incentive award plans or agreements and any shares of stock issued upon
exercise thereof.

      2. Services to Be Rendered.

            (a) Duties and Responsibilities. Executive shall serve as Vice
President, Regulatory Affairs and Quality Assurance, of the Company. In the
performance of such duties, Executive shall report directly to the CEO and shall
be subject to the direction of the CEO and to such limits upon Executive's
authority as the Board or the CEO may from time to time impose. Executive hereby
consents to serve as an officer and/or director of the Company or any subsidiary
or affiliate thereof without any additional salary or compensation, if so
requested by the Board. Executive shall be employed by the Company on a full
time basis. Executive's primary place of work shall be the Company's facility in
San Diego, California, or such other location within San Diego County as may be
designated by the CEO from time to time. Executive shall also render services at
such other places within or outside the United States as the CEO may direct from
time to time, however, Executive's primary place of work shall not be relocated
more than fifty (50) miles from his or her primary place of work as of the
Effective Date or outside San Diego County without Executive's prior consent.
Executive shall be subject to and comply with the policies and procedures
generally applicable to senior executives of the Company to the extent the same
are not inconsistent with any term of this Agreement.

            (b) Exclusive Services. Executive shall at all times faithfully,
industriously and to the best of his or her ability, experience and talent
perform to the satisfaction of the Board and the CEO all of the duties that may
be assigned to Executive hereunder and shall devote substantially all of his or
her productive time and efforts to the performance of such

                                        4
<PAGE>

duties. Subject to the terms of the Employee Confidentiality and Invention
Assignment Agreement referred to in Section 5(b), this shall not preclude
Executive from devoting time to personal and family investments or serving on
community and civic boards, or participating in industry associations, provided
such activities do not interfere with his or her duties to the Company, as
determined in good faith by the CEO. Executive agrees that he or she will not
join any boards, other than community and civic boards (which do not interfere
with his or her duties to the Company), without the prior approval of the CEO.

      3. Compensation and Benefits. The Company shall pay or provide, as the
case may be, to the Executive the compensation and other benefits and rights set
forth in this Section 3.

            (a) Base Salary. The Company shall pay to Executive a base salary of
$209,355.12 per year, payable in accordance with the Company's usual pay
practices (and in any event no less frequently than monthly). Executive's base
salary shall be subject to review annually by and at the sole discretion of the
Compensation Committee of the Board.

            (b) Bonus. Executive shall participate in any Management Incentive
Compensation Plan adopted by the Company or in such other bonus plan as the
Board may approve for the senior executives of the Company.

            (c) Benefits. Executive shall be entitled to participate in benefits
under the Company's benefit plans and arrangements, including, without
limitation, any employee benefit plan or arrangement made available in the
future by the Company to its senior executives, subject to and on a basis
consistent with the terms, conditions and overall administration of such plans
and arrangements. The Company shall have the right to amend or delete any such
benefit plan or arrangement made available by the Company to its senior
executives and not otherwise specifically provided for herein.

            (d) Expenses. The Company shall reimburse Executive for reasonable
out-of-pocket expenses incurred in connection with the performance of his or her
duties hereunder, subject to (i) such policies as the Company may from time to
time establish, and (ii) Executive furnishing the Company with evidence in the
form of receipts satisfactory to the Company substantiating the claimed
expenditures.

            (e) Paid Time Off. Executive shall be entitled to such periods of
paid time off ("PTO") each year as provided under the Company's PTO policy and
as otherwise provided for senior executive officers, but in no event shall
Executive be entitled to less than four (4) weeks of PTO.

            (f) Equity Plans. Executive shall be entitled to participate in any
equity or other employee benefit plan that is generally available to senior
executive officers, as distinguished from general management, of the Company.
Except as otherwise provided in this Agreement, Executive's participation in and
benefits under any such plan shall be on the terms and subject to the conditions
specified in the governing document of the particular plan.

            (g) Acceleration Upon a Change of Control. Subject to any additional
acceleration of exercisability described in Sections 4(b), (c) and (d) below, in
connection with a

                                        5
<PAGE>

Change of Control (as defined in Section 1 above), the vesting and
exercisability of fifty percent (50%) of Executive's outstanding Stock Awards
shall be automatically accelerated. The foregoing provision is hereby deemed to
be a part of each such Stock Award and to supersede any less favorable provision
in any agreement or plan regarding such Stock Award.

      4. Termination and Severance. Executive shall be entitled to receive
benefits upon termination of employment only as set forth in this Section 4:

            (a) At-Will Employment; Termination. The Company and Executive
acknowledge that Executive's employment is and shall continue to be at-will, as
defined under applicable law, and that Executive's employment with the Company
may be terminated by either party at any time for any or no reason, with or
without notice. If Executive's employment terminates for any reason, Executive
shall not be entitled to any payments, benefits, damages, award or compensation
other than as provided in this Agreement. Executive's employment under this
Agreement shall be terminated immediately on the death of Executive.

            (b) Termination by Death. If Executive's employment is terminated by
death, Executive's estate shall be entitled to receive (i) Executive's fully
earned but unpaid base salary, through the date of death at the rate then in
effect, plus all other amounts to which Executive is entitled under any
compensation plan or practice of the Company at the time of Executive's death,
(ii) Executive's annual base salary as in effect immediately prior to the date
of death, payable over the twelve (12) month period commencing on the date of
death in equal monthly installments, (iii) an amount equal to Executive's Bonus
for the year in which Executive's death occurs prorated for the period during
such year Executive was employed prior to his or her death, payable over the
twelve (12) month period commencing on the date of death in equal monthly
installments, and (iv) for the period beginning on the date of death and ending
on the date which is twelve (12) full months following the date of death, the
Company shall pay for and provide Executive's dependents with healthcare and
life insurance benefits coverage to the extent such dependents were receiving
such benefits prior to the date of Executive's death, including, if necessary,
paying the costs associated with continuation coverage pursuant to the
Consolidated Omnibus Budget Reconciliation Act of 1985, as amended ("COBRA"). In
addition, if Executive's employment is terminated by death, the vesting and/or
exercisability of Executive's outstanding Stock Awards shall be automatically
accelerated on the date of death as to the number of shares that would vest over
the twelve (12) months following Executive's death under the applicable vesting
schedules had Executive remained continuously employed by the Company during
such period. Except as otherwise provided above with respect to accelerated
vesting, if Executive's employment is terminated by death, the provisions of the
award agreements governing Executive's Stock Awards regarding the exercisability
of such Stock Awards following Executive's death shall apply.

            (c) Termination for Permanent Disability. If Executive's employment
is terminated by the Company for Permanent Disability, Executive shall be
entitled to receive (i) Executive's fully earned but unpaid base salary, through
the date of termination at the rate then in effect, plus all other amounts to
which Executive is entitled under any compensation plan or practice of the
Company at the time such payments are due, (ii) Executive's annual base salary
as in effect immediately prior to the date of termination, payable over the
twelve (12) month period

                                        6
<PAGE>

commencing on the date of termination in equal monthly installments, (iii) an
amount equal to Executive's Bonus for the year in which the date of termination
occurs prorated for the period during such year Executive was employed prior to
the date of termination, payable over the twelve (12) month period commencing on
the date of termination in equal monthly installments, and (iv) for the period
beginning on the date of termination and ending on the date which is twelve (12)
full months following the date of termination (or, if earlier, the date on which
Executive accepts employment with another employer that provides comparable
benefits in terms of cost and scope of coverage), the Company shall pay for and
provide Executive and his or her dependents with healthcare and life insurance
benefits which are substantially the same as the benefits provided to Executive
immediately prior to the date of termination, including, if necessary, paying
the costs associated with continuation coverage pursuant to COBRA. In addition,
if Executive's employment is terminated by the Company for Permanent Disability,
the vesting and/or exercisability of Executive's outstanding Stock Awards shall
be automatically accelerated on the date of termination as to the number of
shares that would vest over the twelve (12) months following Executive's date of
termination under the applicable vesting schedules had Executive remained
continuously employed by the Company during such period. Except as otherwise
provided above with respect to accelerated vesting, if Executive's employment is
terminated by Permanent Disability, the provisions of the award agreements
governing Executive's Stock Awards regarding the exercisability of such Stock
Awards following Executive's disability shall apply.

            (d) Termination without Cause or for Good Reason.

                  (i) Termination Apart From Change of Control. If Executive's
employment is terminated by the Company without Cause or by Executive for Good
Reason more than three (3) months prior to a Change of Control or more than
twelve (12) months following a Change of Control, Executive shall be entitled to
receive, in lieu of any severance benefits to which Executive may otherwise be
entitled under any severance plan or program of the Company, the benefits
provided below:

                        (A) the Company shall pay to Executive his or her fully
      earned but unpaid base salary, when due, through the date of termination
      at the rate then in effect, plus all other amounts to which Executive is
      entitled under any compensation plan or practice of the Company at the
      time of termination;

                        (B) Executive shall be entitled to receive severance pay
      in an amount equal to the sum of:

                                (1) Executive's base salary as in effect
            immediately prior to the date of termination for the twelve (12)
            month period following the date of termination, payable over the
            twelve (12) month period commencing on the date of termination in
            equal monthly installments, plus

                                (2) an amount equal to Executive's Bonus for the
            year in which the date of termination occurs prorated for the period
            during such year Executive was employed prior to the date of

                                        7
<PAGE>

            termination, payable over the twelve (12) month period commencing on
            the date of termination in equal monthly installments;

                        (C) The vesting and/or exercisability of each of
      Executive's outstanding Stock Awards shall be automatically accelerated on
      the date of termination as to the number of Stock Awards that would vest
      over the twelve (12) month period following the date of termination had
      Executive remained continuously employed by the Company during such
      period;

                        (D) for the period beginning on the date of termination
      and ending on the date which is twelve (12) full months following the date
      of termination (or, if earlier, the date on which Executive accepts
      employment with another employer that provides comparable benefits in
      terms of cost and scope of coverage), the Company shall pay for and
      provide Executive and his or her dependents with healthcare and life
      insurance benefits which are substantially the same as the benefits
      provided to Executive immediately prior to the date of termination,
      including, if necessary, paying the costs associated with continuation
      coverage pursuant to COBRA; and

                        (E) Executive shall be entitled to executive-level
      outplacement services at the Company's expense, not to exceed $15,000.
      Such services shall be provided by a firm selected by Executive from a
      list compiled by the Company.

                  (ii) Termination In Connection With Change of Control. If
Executive's employment is terminated by the Company without Cause or by
Executive for Good Reason within three (3) months prior to or twelve (12) months
following a Change of Control, Executive shall be entitled to receive, in lieu
of any severance benefits to which Executive may otherwise be entitled under any
severance plan or program of the Company, the benefits provided below:

                        (A) the Company shall pay to Executive his or her fully
      earned but unpaid base salary, when due, through the date of termination
      at the rate then in effect, plus all other amounts to which Executive is
      entitled under any compensation plan or practice of the Company at the
      time of termination;

                        (B) Executive shall be entitled to receive severance pay
      in an amount equal to the sum of:

                                (1) Executive's base salary as in effect
            immediately prior to date of termination for the twelve (12) month
            period following the date of termination, payable, at Executive's
            option, either over the twelve (12) month period commencing on the
            date of termination in equal monthly installments or in a lump sum
            within thirty (30) days following the consummation of the Change of
            Control, plus

                                (2) an amount equal to Executive's Bonus for the
            year in which the date of termination occurs prorated for the period
            during such year Executive was employed prior to the date of
            termination, payable, at Executive's option, either over the twelve
            (12) month period commencing on the date of

                                        8
<PAGE>

            termination in equal monthly installments or in a lump sum within
            thirty (30) days following the consummation of the Change of
            Control;

                        (C) The vesting and/or exercisability of all of
      Executive's outstanding unvested Stock Awards shall be automatically
      accelerated on the date of termination;

                        (D) for the period beginning on the date of termination
      and ending on the date which is twelve (12) full months following the date
      of termination (or, if earlier, the date on which Executive accepts
      employment with another employer that provides comparable benefits in
      terms of cost and scope of coverage), the Company shall pay for and
      provide Executive and his or her dependents with healthcare and life
      insurance benefits which are substantially the same as the benefits
      provided to Executive immediately prior to the date of termination,
      including, if necessary, paying the costs associated with continuation
      coverage pursuant to COBRA;

                        (E) Executive shall be entitled to executive-level
      outplacement services at the Company's expense, not to exceed $15,000.
      Such services shall be provided by a firm selected by Executive from a
      list compiled by the Company; and

                        (F) The payments and benefits provided for in this
      Section 4(d)(ii) shall only be payable in the event Executive's employment
      is terminated by the Company without Cause or by Executive for Good Reason
      within three (3) months prior to or twelve (12) months following a Change
      of Control. If Executive's employment is terminated by the Company without
      Cause or by Executive for Good Reason prior to a Change of Control and
      such Change of Control is not consummated within three (3) months
      following such termination, then Executive shall receive the payments and
      benefits described in Section 4(d)(i) and shall not be eligible to receive
      any of the payments and benefits described in this Section 4(d)(ii).

            (e) Termination for Cause or Voluntary Resignation Without Good
Reason. If Executive's employment is terminated by the Company for Cause or by
Executive without Good Reason (other than as a result of Executive's death or
Permanent Disability), the Company shall not have any other or further
obligations to Executive under this Agreement (including any financial
obligations) except that Executive shall be entitled to receive (i) Executive's
fully earned but unpaid base salary, through the date of termination at the rate
then in effect, and (ii) all other amounts or benefits to which Executive is
entitled under any compensation, retirement or benefit plan or practice of the
Company at the time of termination in accordance with the terms of such plans or
practices, including, without limitation, any continuation of benefits required
by COBRA or applicable law. In addition, if Executive's employment is terminated
by the Company for Cause or by Executive without Good Reason (other than as a
result of Executive's death or Permanent Disability), all vesting of Executive's
unvested Stock Awards previously granted to him or her by the Company shall
cease and none of such unvested Stock Awards shall be exercisable following the
date of such termination. The foregoing shall be in addition to, and not in lieu
of, any and all other rights and remedies which may be available to the Company
under the circumstances, whether at law or in equity.

                                        9
<PAGE>

            (f) Release. As a condition to the Executive's receipt of any
post-termination benefits described in this Agreement, Executive shall execute a
Release (the "Release") in a form reasonably acceptable to the Company. Such
Release shall specifically relate to all of Executive's rights and claims in
existence at the time of such execution, including any claims related to
Executive's employment by the Company and his or her termination of employment,
and shall exclude any continuing obligations the Company may have to Executive
following the date of termination under this Agreement or any other agreement
providing for obligations to survive Executive's termination of employment.

            (g) Exclusive Remedy. Except as otherwise expressly required by law
(e.g., COBRA) or as specifically provided herein, all of the Executive's rights
to salary, severance, benefits, bonuses and other amounts hereunder (if any)
accruing after the termination of Executive's employment shall cease upon such
termination. In the event of a termination of Executive's employment with the
Company, the Executive's sole remedy shall be to receive the payments and
benefits described in this Section 4. In addition, Executive acknowledges and
agrees that he or she is not entitled to any reimbursement by the Company for
any taxes payable by Executive as a result of the payments and benefits received
by Executive pursuant to this Section 4, including, without limitation, any
excise tax imposed by Section 4999 of the Internal Revenue Code of 1986, as
amended.

            (h) No Mitigation. Executive shall not be required to mitigate the
amount of any payment provided for in this Section 4 by seeking other employment
or otherwise, nor shall the amount of any payment or benefit provided for in
this Section 4 be reduced by any compensation earned by Executive as the result
of employment by another employer or self-employment or by retirement benefits;
provided, however, that loans, advances or other amounts owed by Executive to
the Company may be offset by the Company against amounts payable to Executive
under this Section 4; provided, further, that, as provided in Sections 4(c) or
(d), Executive's right to continued healthcare and life insurance benefits
following his or her termination of employment will terminate on the date on
which he or she accepts employment with another employer that provides
comparable benefits in terms of cost and scope of coverage.

            (i) Return of the Company's Property. If Executive's employment is
terminated for any reason, the Company shall have the right, at its option, to
require Executive to vacate his or her offices prior to or on the effective date
of termination and to cease all activities on the Company's behalf. Upon the
termination of his or her employment in any manner, as a condition to the
Executive's receipt of any post-termination benefits described in this
Agreement, Executive shall immediately surrender to the Company all lists, books
and records of, or in connection with, the Company's business, and all other
property belonging to the Company, it being distinctly understood that all such
lists, books and records, and other documents, are the property of the Company.
Executive shall deliver to the Company a signed statement certifying compliance
with this Section 4(i) prior to the receipt of any post-termination benefits
described in this Agreement.

            (j) Waiver of the Company's Liability. Executive recognizes that his
or her employment is subject to termination with or without Cause for any reason
and therefore Executive agrees that Executive shall hold the Company harmless
from and against any and all

                                       10
<PAGE>

liabilities, losses, damages, costs and expenses, including but not limited to,
court costs and reasonable attorneys' fees, which Executive may incur as a
result of the termination of Executive's employment. Executive further agrees
that Executive shall bring no claim or cause of action against the Company for
damages or injunctive relieve based on a wrongful termination of employment.
Executive agrees that the sole liability of the Company to Executive upon
termination of this Agreement shall be that determined by this Section 4. In the
event this covenant is more restrictive than permitted by laws of the
jurisdiction in which the Company seeks enforcement thereof, this covenant shall
be limited to the extent permitted by law.

      5. Certain Covenants.

            (a) Noncompetition. Except as may otherwise be approved by the
Board, during the term of Executive's employment, Executive shall not have any
ownership interest (of record or beneficial) in, or have any interest as an
employee, salesman, consultant, officer or director in, or otherwise aid or
assist in any manner, any firm, corporation, partnership, proprietorship or
other business that engages in any county, city or part thereof in the United
States and/or any foreign country in a business which competes directly or
indirectly (as determined by the Board) with the Company's business in such
county, city or part thereof, so long as the Company, or any successor in
interest of the Company to the business and goodwill of the Company, remains
engaged in such business in such county, city or part thereof or continues to
solicit customers or potential customers therein; provided, however, that
Executive may own, directly or indirectly, solely as an investment, securities
of any entity which are traded on any national securities exchange if Executive
(x) is not a controlling person of, or a member of a group which controls, such
entity; or (y) does not, directly or indirectly, own one percent (1%) or more of
any class of securities of any such entity.

            (b) Confidential Information. Executive and the Company have entered
into the Company's standard employee confidentiality and invention assignment
agreement (the "Employee Confidentiality and Invention Assignment Agreement").
Executive agrees to perform each and every obligation of Executive therein
contained.

            (c) Solicitation of Employees. Executive shall not during the term
of Executive's employment and for the applicable severance period for which
Executive receives severance benefits following any termination hereof pursuant
to Section 4(c) or (d) above (regardless of whether Executive elects payment of
severance amounts payable thereunder in a lump sum) (the "Restricted Period"),
directly or indirectly, solicit or encourage to leave the employment of the
Company or any of its affiliates, any employee of the Company or any of its
affiliates.

            (d) Rights and Remedies Upon Breach. If Executive breaches or
threatens to commit a breach of any of the provisions of this Section 5 (the
"Restrictive Covenants"), the Company shall have the following rights and
remedies, each of which rights and remedies shall be independent of the other
and severally enforceable, and all of which rights and remedies shall be in
addition to, and not in lieu of, any other rights and remedies available to the
Company under law or in equity:

                                       11
<PAGE>

                  (i) Specific Performance. The right and remedy to have the
Restrictive Covenants specifically enforced by any court having equity
jurisdiction, all without the need to post a bond or any other security or to
prove any amount of actual damage or that money damages would not provide an
adequate remedy, it being acknowledged and agreed that any such breach or
threatened breach will cause irreparable injury to the Company and that money
damages will not provide adequate remedy to the Company; and

                  (ii) Accounting and Indemnification. The right and remedy to
require Executive (i) to account for and pay over to the Company all
compensation, profits, monies, accruals, increments or other benefits derived or
received by Executive or any associated party deriving such benefits as a result
of any such breach of the Restrictive Covenants; and (ii) to indemnify the
Company against any other losses, damages (including special and consequential
damages), costs and expenses, including actual attorneys' fees and court costs,
which may be incurred by them and which result from or arise out of any such
breach or threatened breach of the Restrictive Covenants.

            (e) Severability of Covenants/Blue Pencilling. If any court
determines that any of the Restrictive Covenants, or any part thereof, is
invalid or unenforceable, the remainder of the Restrictive Covenants shall not
thereby be affected and shall be given full effect, without regard to the
invalid portions. If any court determines that any of the Restrictive Covenants,
or any part thereof, are unenforceable because of the duration of such provision
or the area covered thereby, such court shall have the power to reduce the
duration or area of such provision and, in its reduced form, such provision
shall then be enforceable and shall be enforced. Executive hereby waives any and
all right to attack the validity of the Restrictive Covenants on the grounds of
the breadth of their geographic scope or the length of their term.

            (f) Enforceability in Jurisdictions. The Company and Executive
intend to and do hereby confer jurisdiction to enforce the Restrictive Covenants
upon the courts of any jurisdiction within the geographical scope of such
covenants. If the courts of any one or more of such jurisdictions hold the
Restrictive Covenants wholly unenforceable by reason of the breadth of such
scope or otherwise, it is the intention of the Company and Executive that such
determination not bar or in any way affect the right of the Company to the
relief provided above in the courts of any other jurisdiction within the
geographical scope of such covenants, as to breaches of such covenants in such
other respective jurisdictions, such covenants as they relate to each
jurisdiction being, for this purpose, severable into diverse and independent
covenants.

            (g) Definitions. For purposes of this Section 5, the term "Company"
means not only Santarus, Inc., but also any company, partnership or entity
which, directly or indirectly, controls, is controlled by or is under common
control with Santarus, Inc.

      6. Insurance. The Company shall have the right to take out life, health,
accident, "key-man" or other insurance covering Executive, in the name of the
Company and at the Company's expense in any amount deemed appropriate by the
Company. Executive shall assist the Company in obtaining such insurance,
including, without limitation, submitting to any required examinations and
providing information and data required by insurance companies.

                                       12
<PAGE>

      7. Arbitration. Except as provided in Section 5, any claim or controversy
arising out of or relating to this Agreement shall be settled by arbitration in
San Diego, California, in accordance with the Commercial Arbitration Rules of
the American Arbitration Association, and judgment on the award rendered by the
arbitrator may be entered in any court having jurisdiction. Each party shall
select one arbitrator and the two arbitrators so chosen will select a third
arbitrator who shall act as the sole arbitrator of any dispute. Each party shall
pay the fees of its own attorneys, the expenses of its witnesses and all other
expenses connected with presenting its case; however, Executive and the Company
agree that, except as may be prohibited by law, the arbitrator may, in his or
her discretion, award reasonable attorneys' fees to the prevailing party. Other
costs of the arbitration, including the cost of any record or transcripts of the
arbitration, administrative fees, the fee of the sole arbitrator, and all other
fees and costs, shall be borne by the Company.

      8. General Relationship. Executive shall be considered an employee of the
Company within the meaning of all federal, state and local laws and regulations
including, but not limited to, laws and regulations governing unemployment
insurance, workers' compensation, industrial accident, labor and taxes.

      9. Miscellaneous.

            (a) Modification; Prior Claims. This Agreement sets forth the entire
understanding of the parties with respect to the subject matter hereof,
supersedes all existing agreements between them concerning such subject matter,
and may be modified only by a written instrument duly executed by each party.

            (b) Assignment; Assumption by Successor. The rights of the Company
under this Agreement may, without the consent of Executive, be assigned by the
Company, in its sole and unfettered discretion, to any person, firm, corporation
or other business entity which at any time, whether by purchase, merger or
otherwise, directly or indirectly, acquires all or substantially all of the
assets or business of the Company. The Company will require any successor
(whether direct or indirect, by purchase, merger or otherwise) to all or
substantially all of the business or assets of the Company expressly to assume
and to agree to perform this Agreement in the same manner and to the same extent
that the Company would be required to perform it if no such succession had taken
place; provided, however, that no such assumption shall relieve the Company of
its obligations hereunder. As used in this Agreement, the "Company" shall mean
the Company as hereinbefore defined and any successor to its business and/or
assets as aforesaid which assumes and agrees to perform this Agreement by
operation of law or otherwise.

            (c) Survival. The covenants, agreements, representations and
warranties contained in or made in Sections 4, 5, 7 and 9 of this Agreement
shall survive any termination of Executive's employment.

            (d) Third-Party Beneficiaries. This Agreement does not create, and
shall not be construed as creating, any rights enforceable by any person not a
party to this Agreement.

                                       13
<PAGE>

            (e) Waiver. The failure of either party hereto at any time to
enforce performance by the other party of any provision of this Agreement shall
in no way affect such party's rights thereafter to enforce the same, nor shall
the waiver by either party of any breach of any provision hereof be deemed to be
a waiver by such party of any other breach of the same or any other provision
hereof.

            (f) Section Headings. The headings of the several sections in this
Agreement are inserted solely for the convenience of the parties and are not a
part of and are not intended to govern, limit or aid in the construction of any
term or provision hereof.

            (g) Notices. All notices, requests and other communications
hereunder shall be in writing and shall be delivered by courier or other means
of personal service (including by means of a nationally recognized courier
service or professional messenger service), or sent by telex or telecopy or
mailed first class, postage prepaid, by certified mail, return receipt
requested, in all cases, addressed to:

            If to the Company or the Board:

            Santarus, Inc.
            10590 West Ocean Air Drive
            Suite 200
            San Diego, CA 92130
            Attention:  Legal Affairs Department

            If to Executive:

            C. Christine Simmons
            5437 Panoramic Lane
            San Diego, CA 92121

All notices, requests and other communications shall be deemed given on the date
of actual receipt or delivery as evidenced by written receipt, acknowledgement
or other evidence of actual receipt or delivery to the address. In case of
service by telecopy, a copy of such notice shall be personally delivered or sent
by registered or certified mail, in the manner set forth above, within three
business days thereafter. Any party hereto may from time to time by notice in
writing served as set forth above designate a different address or a different
or additional person to which all such notices or communications thereafter are
to be given.

            (h) Severability. All Sections, clauses and covenants contained in
this Agreement are severable, and in the event any of them shall be held to be
invalid by any court, this Agreement shall be interpreted as if such invalid
Sections, clauses or covenants were not contained herein.

            (i) Governing Law and Venue. This Agreement is to be governed by and
construed in accordance with the laws of the State of California applicable to
contracts made and to be performed wholly within such State, and without regard
to the conflicts of laws principles thereof. Except as provided in Sections 5
and 7, any suit brought hereon shall be brought in the state or federal courts
sitting in San Diego, California, the parties hereto hereby

                                       14
<PAGE>

waiving any claim or defense that such forum is not convenient or proper. Each
party hereby agrees that any such court shall have in personam jurisdiction over
it and consents to service of process in any manner authorized by California
law.

            (j) Non-transferability of Interest. None of the rights of Executive
to receive any form of compensation payable pursuant to this Agreement shall be
assignable or transferable except through a testamentary disposition or by the
laws of descent and distribution upon the death of Executive. Any attempted
assignment, transfer, conveyance, or other disposition (other than as aforesaid)
of any interest in the rights of Executive to receive any form of compensation
to be made by the Company pursuant to this Agreement shall be void.

            (k) Gender. Where the context so requires, the use of the masculine
gender shall include the feminine and/or neuter genders and the singular shall
include the plural, and vice versa, and the word "person" shall include any
corporation, firm, partnership or other form of association.

            (l) Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same Agreement.

            (m) Acceleration of Stock Awards. For purposes of this Agreement, to
the extent the vesting and/or exercisability of any of Executive's outstanding
Stock Awards and/or the lapsing of any restrictions with respect to Stock Awards
that Executive holds shall be accelerated pursuant to this Agreement, if any
Stock Award had previously been partially exercised such that an unexercised
portion of the Stock Award still remains outstanding as of the date of such
acceleration, the vesting acceleration provisions of this Agreement shall be
applied to the total number of shares subject to such Award that consist of (i)
then unvested exercised shares that were previously acquired upon the partial
exercise of such Stock Award, plus (ii) the remaining unexercised portion of the
Stock Award. The acceleration of vesting shall be first applied toward the
unvested previously exercised shares such that no unexercised shares shall vest
on an accelerated basis in accordance with the provisions of this Agreement
unless and until all of the unvested exercised shares subject to such Stock
Award have first vested. In addition, the acceleration of vesting shall be
applied to each Stock Award individually.

            (n) Construction. The language in all parts of this Agreement shall
in all cases be construed simply, according to its fair meaning, and not
strictly for or against any of the parties hereto. Without limitation, there
shall be no presumption against any party on the ground that such party was
responsible for drafting this Agreement or any part thereof.

            (o) Withholding and other Deductions. All compensation payable to
Executive hereunder shall be subject to such deductions as the Company is from
time to time required to make pursuant to law, governmental regulation or order.

                            (Signature Page Follows)

                                       15
<PAGE>

      IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first set forth above.

                                SANTARUS, INC.

                                By: /s/ Gerald T. Proehl
                                    --------------------------------------------
                                    Gerald T. Proehl
                                    President and Chief Executive Officer

                                    /s/ C. Christine Simmons
                                ------------------------------------------------
                                C. Christine Simmons<PAGE>

                                                                    EXHIBIT 10.1

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                                                    CONFIDENTIAL

                          TGF-(alpha) / HER-1 VACCINE

            LICENSE, DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT

                                BETWEEN AND AMONG

                                 TARCANTA INC.,
                                 TARCANTA, LTD.,

                                  CIMAB, S.A.,

                              YM BIOSCIENCES, INC.
                                       AND
                                   CIMYM, INC.

                               DATED JULY 13, 2004

                                       1

<PAGE>

                                                                    CONFIDENTIAL

                                TABLE OF CONTENTS

<TABLE>
<S>         <C>
Exhibit A   Licensed Patent Rights
Exhibit B   Transferred Assets
Exhibit C   Form of Quality Agreement
Exhibit D   Patent and Know-How Agreement between CIM and CIMAB Exhibit E
Exhibit E   Patent License Agreement between HEBER BIOTEC, S.A. and CIMAB

</TABLE>

                                       2
<PAGE>

                                                                    CONFIDENTIAL

                          TGF-(alpha) / HER-1 VACCINE

            LICENSE, DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT

      THIS TGF-(alpha) / HER-1 VACCINE LICENSE, DEVELOPMENT, MANUFACTURING AND
SUPPLY AGREEMENT (the "Agreement") is made effective as of the 13th day of July,
2004 (the "Effective Date") by and between CIMAB, S.A., a corporation organized
under the laws of Cuba, having offices at Calle 206, No. 1926, e/ 19 y 21,
Atabey, Playa, Ciudad de La Habana, Cuba ("CIMAB"), TARCANTA , a corporation
organized under the laws of the State of Delaware, United States of America,
having offices at 2110 Rutherford Road, Carlsbad, California 92008 ("TARCANTA"),
TARCANTA, Ltd., a corporation organized under the laws of the Republic of
Ireland, having offices at 30 Herbert Street, Dublin 2, Ireland ("TARCANTA
LTD."), YM BIOSCIENCES, INC., a corporation organized under the laws of Nova
Scotia, Canada, having offices at 5045 Orbitor Drive, Building 11, Suite 400,
Mississauga, Ontario L4W 4Y4, Canada ("YMB"), and CIMYM, Inc., a corporation
organized under the laws of Barbados, having offices at Chelston Park, Building
2, Collymore Rock St., St. Michael, Barbados, West Indies ("CIMYM"). TARCANTA,
TARCANTA LTD., CIMAB, YMB and CIMYM are sometimes referred to herein
individually as a "Party" and collectively as the "Parties."

                                    RECITALS

      1. CIMAB, S.A. is a corporation with independent juridical personality
organized under the laws of Cuba, with offices at Calle 206, No. 1926, e/ 19 y
21, Atabey, Playa, Ciudad de La Habana, Cuba.

      2. Centro de Inmunologia Molecular, located at Calle 216 y 15, Atabey,
Playa, Ciudad de La Habana, 11600, Cuba ("CIM"), and HEBER BIOTEC, located at
Ave. 31 e/ 158 y 190 Cubanacan, Playa, Ciudad de La Habana 10600, Cuba ("HEBER")
have granted CIMAB licenses, with the right to grant the sublicenses to TARCANTA
and TARCANTA LTD. contemplated under this Agreement, of certain patents, patent
applications, other valuable technology and know-how owned or controlled by CIM
and/or HEBER, to wit, certain patents, patent applications, other valuable
technology and know-how relating to certain products, defined below as the
Licensed Products. Copies of such license agreements are attached hereto and
incorporated herein as Exhibits D and E. Neither CIM nor HEBER is a party to
this Agreement, nor are they responsible for the debts, obligations or actions
of CIMAB under this Agreement or arising from or in connection with this
Agreement.

      3. TARCANTA is a corporation with independent juridical personality
organized under the laws of the State of Delaware, United States of America
("U.S."), with offices at 2110 Rutherford Road, Carlsbad, California 92008, U.S.

      4. TARCANTA LTD. is a corporation with independent juridical personality
organized under the laws of the Republic of Ireland, with offices at 30 Herbert
Street, Dublin 2, Ireland 30 Herbert Street, Dublin 2, Ireland 30 Herbert
Street, Dublin 2, Ireland.

                                       1
<PAGE>

                                                                    CONFIDENTIAL

      5. YMB is a corporation with independent juridical personality organized
under the laws of Nova Scotia, Canada, with offices at 5045 Orbitor Drive,
Building 11, Suite 400, Mississauga, Ontario L4W 4Y4, Canada ("YMB").

      6. CIMYM is a corporation with independent juridical personality organized
under the laws of Barbados, with offices at Chelston Park, Building 2, Collymore
Rock St., St. Michael, Barbados, West Indies ("CIMYM").

      7. TARCANTA and TARCANTA LTD. believe that conducting international
clinical trials in countries throughout the Territory, including the Other
Countries, will significantly advance their ability to obtain Regulatory
Approvals of the Licensed Products in the U.S. and throughout the Territory in a
timely manner by increasing the number and diversity of patients that may be
enrolled in clinical trials of the Licensed Products. Accordingly, TARCANTA,
TARCANTA LTD. and CIMAB agree to further develop and TARCANTA and TARCANTA LTD.
agree to conduct clinical trials for the Licensed Products and to obtain
Regulatory Approvals that are necessary in order to market and sell the Licensed
Products in the Territory (as such terms are defined below) in accordance with
the terms and conditions of this Agreement. For the purposes of this Agreement,
all countries in the Territory other than the U.S., Canada and Mexico shall be
referred to herein as the "Other Countries."

      8. TARCANTA and TARCANTA LTD. and TARCANTA LTD. agree, upon receipt of
applicable Regulatory Approvals, to manufacture, market and sell the Licensed
Products in the U.S., Canada and Mexico.

      7. Consistent with normal industry practices in a licensing arrangement of
this nature, and in an effort to advance the potential for making the Licensed
Products available for the treatment of cancer patients in the U.S. and
throughout the Territory, TARCANTA LTD. and TARCANTA LTD. agree, upon receipt of
applicable Regulatory Approvals, to market and sell the Licensed Products
purchased from CIMAB in the Other Countries, in accordance with the terms and
conditions of this Agreement.

      9. In order to ensure an adequate supply of the Licensed Products for
clinical testing and, upon commercialization, for the treatment of patients in
the U.S. and throughout the Territory, TARCANTA and TARCANTA LTD. agree to
purchase the Licensed Products from CIMAB, and CIMAB agrees to manufacture and
sell such Licensed Products to TARCANTA and TARCANTA LTD., in accordance with
the terms and conditions of this Agreement.

      10. CIMAB previously licensed certain rights to the Licensed Products to
CIMYM pursuant to that certain Licensing Agreement between CIMAB and CIMYM dated
as of January 24th, 2001 (the "CIMAB-CIMYM Vaccine Agreement"), and CIMAB and
CIMYM now wish to suspend the CIMAB-CIMYM Vaccine Agreement, and to permit
TARCANTA and TARCANTA LTD. to sublicense directly from CIMAB certain rights to
the Licensed Products under this Agreement.

                                       2
<PAGE>

                                                                    CONFIDENTIAL

      11. Because the Parties believe that a more effective vaccine for the
treatment of some types of cancer may be created by the sequential use or the
combination of the TGF-(alpha) and/or HER-1 Vaccines with an EGF Vaccine
Controlled By CIMAB, simultaneously with the execution of this Agreement,
TARCANTA and TARCANTA LTD. will also enter into a certain EGF Vaccine License,
Development, Manufacturing and Supply Agreement with CIMAB, pursuant to which
TARCANTA and TARCANTA LTD. will further develop, conduct clinical trials,
manufacture and sell the EGF Vaccine (as such term is defined therein) in the
Territory. For the purposes of this Agreement, all countries in the Territory
other than the U.S., Canada and Mexico shall be referred to herein as the "Other
Countries."

      In consideration of the premises and of the mutual covenants and
obligations set forth herein, the Parties hereby agree as set forth below.

                                   ARTICLE 1.

                                   DEFINITIONS

      The following capitalized and italicized terms shall have the following
meanings:

      1.1 "Adjuvant" shall mean any and all compounds, compositions, components
or formulations of components, intended to induce, enhance or modify an
antigen-specific, active response of the Licensed Product in combination with
one or more antigens.

      1.2 "Affiliate" means any individual, corporation, association or other
business entity which directly or indirectly controls, is controlled by or is
under common control with the Party in question. As used in this definition of
"Affiliate," the term "control" means the direct or indirect ownership of more
than fifty percent (50%) of the stock having the right to vote for directors
thereof or the ability to otherwise control the management of the corporation or
other business entity whether through the ownership of voting securities, by
contract, resolution, regulation or otherwise; provided, however, that the term
"Affiliate" shall not include subsidiaries or other entities in which a Party or
its Affiliates owns a majority of the ordinary voting power necessary to elect a
majority of the board of directors or other governing body, but is restricted
from electing such majority by contract or otherwise until the time such
restrictions are no longer in effect.

      1.3 "Applicable Laws" means all laws, statutes, ordinances, codes, rules
and regulations that have been enacted by a Government Authority and are in
force as of the Effective Date or come into force during the term of this
Agreement, in each case to the extent that the same are applicable to the
performance by the Parties of their respective obligations under this Agreement.
For purposes of this Agreement, GCPs, GLPs and cGMPs (as such terms are defined
below) shall be deemed to be within the term "Applicable Laws."

                                       3
<PAGE>

                                                                    CONFIDENTIAL

      1.4 "Barter" means that offsetting mechanism under which TARCANTA and
TARCANTA LTD. discharge certain of their payment obligations hereunder by
placing funds in the Barter Escrow Account against which the value of Barter
Goods purchased by CIMAB shall be accredited according to the provisions set
forth in Section 5.10.3.

      1.5 "Barter Escrow Account" means an escrow account opened with a
reputable bank in London, England, or Ireland, as agent bank, strictly for the
purpose of receiving Barter Payments owed by TARCANTA and TARCANTA LTD. to CIMAB
as provided by Section 5.10.3 herein, and against which CIMAB's purchase of
Bartered Goods shall be debited pursuant to Section 5.10.3. Any bank on the list
of specially designated nationals issued by the U.S. Treasury Department's
Office of Foreign Assets Control, or which is a Cuban national, is not qualified
to be a bank at which the "Barter Escrow Account" may be maintained. The funds
in the Barter Escrow Account may be released only upon confirmation by such bank
and its escrow agent that the goods listed on the purchase order received from
CIMAB conform to the definition of Barter Goods, and upon further confirmation
by such bank and its escrow agent that CIMAB has declared on the purchase order
that said Barter Goods are to be used for public health purposes of the Cuban
people.

      1.6 "Barter Goods" shall mean food, medicines and/or medical supplies to
be exported to Cuba and destined for the public health purposes of the Cuban
people. As used in this Section 1.6, "food" means "agricultural commodities" as
defined by the Trade Sanctions Reform and Export Enhancement Act, P.L. 106-387,
Title IX, and the implementing regulations of the U.S.U.S. government. As used
in this Section 1.6, "medicine" and "medical supplies" have the meaning of
"medicine" and "medical device" in the Trade Sanctions Reform and Export
Enhancement Act, P.L. 106-387, Title IX, and any implementing regulations of the
U.S.U.S. government.

      1.7 "Barter Payments" means payments by TARCANTA, TARCANTA LTD., their
Affiliates or Sublicensees into the "Barter Escrow Account" in accordance with
the provisions set out in Section 5.10.3.

      1.8 "BLA" means a Biologics License Application to the FDA or an
equivalent application to any other Government Authority within the Territory
requesting market approval for a new biological product (or a New Drug
Application (NDA), or equivalent application, in the event that the FDA or other
Government Authority determines that an NDA, rather than a BLA, is the
appropriate mechanism for requesting such approval).

      1.9 "Carrier Protein" means any immunogenic carrier or fusion protein
including, without limitation, P64K.

      1.10 "CIMAB's Licensors" or "its Licensors" means CIM and HEBER.

      1.11 "Combination Product" means any formulated therapeutic cancer vaccine
that includes one or more of the Licensed Products and the EGF Vaccine
sublicensed to

                                       4
<PAGE>

                                                                    CONFIDENTIAL

TARCANTA and TARCANTA LTD. under the EGF Vaccine License, Development,
Manufacturing and Supply Agreement. For the avoidance of doubt, the term
"Combination Product" excludes the combined administration to a patient of such
products separately, provided that they are priced and sold independently.

      1.12 "Commercialization Phase" means the period after the approval by the
U.S. FDA of the first BLA for any Licensed Product filed by TARCANTA, TARCANTA
LTD. or their Affiliates or Sublicensees.

      1.13 "Committee I" shall have the meaning set forth in Article 3.

      1.14 "Committee II " shall have the meaning set forth in Article 4.

      1.15 "Confidential Information" shall have the meaning set forth in
Article 11.

      1.16 "Contract Manufacturer" means any Person contracted by TARCANTA,
TARCANTA LTD., their Affiliates or Sublicensees, or by CIMAB to manufacture,
Finish (as such term is defined herein), or supply the Licensed Products, or any
component or ingredient thereof, in accordance with the terms and conditions of
this Agreement; provided, however, that no assignment of rights to a Contract
Manufacturer hereunder shall relieve CIMAB, TARCANTA or TARCANTA LTD., or their
Affiliates or Sublicensees, of their obligations to fully comply with the terms
and conditions of this Agreement. In the case of TARCANTA, TARCANTA LTD., their
Affiliates or Sublicensees, "Contract Manufacturer" shall not include any entity
that is a Cuban national.

      1.17 "Controlled By" means with respect to any Licensed Know-How, Licensed
Patent Rights, or other intellectual property right that a Party owns, has a
license to, or otherwise uses and has the ability to grant to the other party
access, a license or a sublicense (as applicable) to such Licensed Know-How,
Licensed Patent Rights, or other intellectual property right as provided for in
this Agreement, without violating the terms of any agreement or other
arrangement with any Third Party, including a Third Party Cuban National,
existing at the time such Party would be first required under this Agreement to
grant the other Party such access, license or sublicense.

      1.18 "Cost of Goods Sold" means TARCANTA or TARCANTA LTD.'s documented,
actual costs of manufacture of the Licensed Products, including costs of
packaging, labeling and insurance and transportation. Cost of Goods Sold shall
not include the costs of conducting clinical trials or performing pre-clinical
testing; sales, general and administrative costs; capital expenditures; research
and development costs; or interest expenses.

      1.19 "Cuban national" means, unless otherwise stated, a "national" of Cuba
within the meaning of the Cuban Assets Control Regulations, 31 C.F.R.515.302,
issued by the U.S.U.S. Treasury Department's Office of Foreign Assets Control.

                                       5
<PAGE>

                                                                    CONFIDENTIAL

      1.20 "Delivery Date" shall have the meaning set forth in Article 7.

      1.21 "Delivery Location" shall have the meaning set forth in Article 7.

      1.22 "Development Phase" means the period prior to the approval by the
U.S. FDA of the first BLA filed by TARCANTA or TARCANTA LTD. for any Licensed
Product.

      1.23 "Development Plan" shall have the meaning set forth in Article 3.

      1.24 "Development Work" shall have the meaning set forth in Article 3.

      1.25 "Disclosing Party" shall have the meaning set forth in Article 11.

      1.26 "Dispute Resolution Procedures" means the procedures established by
Article 14.

      1.27 "Effective Date" means the date set forth in the first paragraph of
this Agreement.

      1.28 "Europe" means Austria, Belgium, Denmark, Finland, France, Germany,
Greece, Ireland, Italy, Luxembourg, Portugal, Spain, Sweden, The Netherlands,
United Kingdom, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania,
Malta, Poland, Slovakia, Slovenia, Bulgaria, Romania, Turkey, Norway,
Liechtenstein, San Marino, Monaco, and the Vatican.

      1.29 "FDA" means the U.S. Food and Drug Administration, and any successor
thereto.

      1.30 "FFDCA" means the Federal Food, Drug, and Cosmetic Act, 21 U.S.. Code
321 et seq., as amended from time to time.

      1.31 "Finish" means to fill, package and label the Licensed Products in
their final packaging configuration for sale to an end-user.

      1.32 "Firm Commitment Quantities" shall have the meaning set forth in
Section 7.1.1.

      1.33 "First Commercial Sale" means the first sale of a Licensed Product by
TARCANTA, TARCANTA LTD., or their Affiliates or Sublicensees for use or
consumption of such Licensed Product in a country in the Territory where
Regulatory Approval of such Licensed Product has been obtained. Sale of a
Licensed Product to an Affiliate or a Sublicensee shall not constitute a First
Commercial Sale unless such Affiliate or such Sublicensee is the end user of
such Licensed Product.

      1.34 "Force Majeure" shall have the meaning set forth in Section 15.2.

                                       6
<PAGE>

                                                                    CONFIDENTIAL

      1.35 "GCPs" means good clinical practices equivalent to those applicable
in the U.S. and specifically including the International Committee on
Harmonization Guidelines for Good Clinical Practices.

      1.36 "GLPs" means current good laboratory practices equivalent to those
applicable in the U.S.U.S. and in effect from time to time during the term of
this Agreement.

      1.37 "cGMPs" means current good manufacturing practices equivalent to
those applicable in the U.S. and in effect from time to time during the term of
this Agreement.

      1.38 "Government Authority" means any supranational, national, regional,
state or local government, court, governmental agency, authority, board, bureau,
instrumentality or regulatory body.

      1.39 "Importer" shall have the meaning set forth in Section 7.1.1

      1.40 "Improvement" means any improvement in or modification to an existing
Licensed Product, Licensed Patent Right, or Licensed Know-How including, without
limitation, any new method of treating cancer patients using the Licensed
Products, developed, individually by or on behalf of CIMAB or by or on behalf of
TARCANTA, TARCANTA LTD. or their Affiliates or its Subsidiaries, or jointly by
the any of the Parties and/or their respective Affiliates or Subsidiaries, under
the Development Plan. Any patent rights resulting from any Improvement shall be
included within the definition of Licensed Patent Rights for purposes of this
Agreement. Any Know-How resulting from any Improvement shall be included within
the definition of Know-How for purposes of this Agreement. Notwithstanding
anything in the foregoing to the contrary, neither TARCANTA, TARCANTA LTD. nor
their respective Affiliates or Subsidiaries shall be required to transfer or
license, nor shall they transfer or license, to CIMAB any Know-How unrelated to
the Licensed Product, and neither CIMAB nor its Licensors shall be required to
transfer or license, nor shall they transfer or license, to TARCANTA or TARCANTA
LTD. or their respective Affiliates or Subsidiaries any Know-How unrelated to
the Licensed Products.

      1.41 "IND Submission" means an "Investigational New Drug" application to
the FDA requesting approval to initiate a clinical trial on a new drug or
biological product.

      1.42 "Infringement" shall have the meaning set forth in Article 10.

      1.43 "Know-How" means information, data and proprietary rights of any type
whatsoever (other than the Licensed Patent Rights) in any tangible or intangible
form whatsoever relevant to the development, manufacture and commercialization
of any Licensed Product, including, without limitation, inventions, practices,
methods, techniques, specifications, formulations, formulae, knowledge,
know-how, skill, experience, test data (including pharmacological, biological,
chemical, biochemical, toxicological and clinical test data), analytical and
quality control data, stability data, results of studies, technical drawings and
related copyrights, and other similar information.

                                       7
<PAGE>

                                                                    CONFIDENTIAL

      1.44 "Licensed Know-How" means Know-How Controlled By CIMAB related to any
Licensed Product at any time during the term of this Agreement and the Know-How
Controlled By either Party related to the Improvements at any time during the
term of this Agreement.

      1.45 "Licensed Patent Rights" means (i) the patents and patent
applications listed on Exhibit A attached hereto and incorporated herein by
reference, covering Licensed Products or methods of manufacture or use thereof
owned or Controlled By CIMAB; (ii) all divisional, continuation,
continuation-in-part, reissue, extension, re-examination, renewal, or substitute
applications within the Territory; (iii) all patents and patent applications
within the Territory that result from the Improvements; (iv) all patents that
may issue on any of the patent applications within (i), (ii) or (iii) above; and
(v) all foreign patent applications and patents within the Territory
corresponding to any of the patent applications or patents within (i), (ii),
(iii) or (iv) above. In addition, if within three (3) years of the Effective
Date of this agreement, TARCANTA, TARCANTA LTD. or their respective Affiliates
discover that they require a license to additional patents, patent applications,
technology or Know-How Controlled By CIMAB that are directly related to the
Licensed Products that are required by TARCANTA, TARCANTA LTD. or their
respective Affiliates to accomplish the objectives of this Agreement, such
patents, patent applications, technology or Know-How will automatically be added
to the appropriate list or exhibits attached to this Agreement and by such
addition be included as "Licensed Patent Rights" under this Agreement.

      1.46 "Licensed Product(s)" means any product containing (a) therapeutic
cancer vaccines composed of a TGF-(alpha) carrier fusion protein conjugated to a
Carrier Protein (the "TGF-(alpha) Vaccine"), and/or (b) therapeutic cancer
vaccines composed of HER-1, delivered in a proprietary Th1-inducing delivery
vehicle (the "HER-1 Vaccine"), or any portion, component or derivatives of the
TGF-(alpha) and/or the HER-1 Vaccines, or any combination thereof that are
otherwise co-administered to a patient as a means of treating cancer, and any
Improvements thereto.

      1.47 "Marketing Plan" shall have the meaning set forth in Article 4.

      1.48 "Manufacturing Facilities" means the production plants used by any
Operating Party hereto to manufacture, supply or Finish the Licensed Products,
or any portion, component or derivatives of the Licensed Products, for sale in
the Territory in accordance with the terms of this Agreement.

      1.49 "Net Sales" means the gross amount invoiced by TARCANTA, TARCANTA
LTD., their Affiliates or Sublicensees in connection with sales of the Licensed
Products to any Person in the Territory that is not an Affiliate, subsidiary or
Sublicensee of TARCANTA or TARCANTA LTD., after deduction of all documented
trade, case and quantity credits, discounts, refunds, rebates and administrative
fees, allowances or credits for returns, sales commissions, and prepaid freight,
transportation insurance, sales taxes and other government charges (including,
without limitation, value-added taxes), and less either (a) the documented,

                                       8
<PAGE>

                                                                    CONFIDENTIAL

applicable Cost of Goods Sold for such Licensed Products in the case of Licensed
Products manufactured by or on behalf of TARCANTA or TARCANTA LTD., or (b) the
applicable Transfer Price paid to CIMAB, in the case of Licensed Products
manufactured by on or on behalf of CIMAB.

      1.50 "Operating Parties" means CIMAB, TARCANTA and TARCANTA LTD.

      1.51 "Other Countries" means all countries in the Territory excluding the
U.S., Canada and Mexico.

      1.52 "Party(ies)" means CIMAB, TARCANTA, TARCANTA LTD., YMB and CIMYM.

      1.53 "Payment in Cash" means all payments to CIMAB other than Barter
Payments.

      1.54 "Person" means any person or legal entity.

      1.55 "Purchase Orders" shall have the meaning set forth in Article 7.

      1.56 "Quality Agreement" shall have the meaning set forth in Article 7.

      1.57 "Reasonable Commercial Efforts" means, with respect to the efforts to
be expended by a Party with respect to any objective, reasonable, diligent, good
faith efforts to accomplish such objective as typically made by commercial
businesses in similar circumstances and context to achieve a particular result
in a timely manner and maximize the economic return to the parties from its
commercialization but shall not require a Party to take action that would be
commercially unreasonable under the particular circumstances and context, but
without taking into account alternate opportunities available to such Party.

      1.58 "Receiving Party" shall have the meaning set forth in Article 11.

      1.59 "Regulatory Approval" means, with respect to a jurisdiction or, where
applicable, a multinational jurisdiction, (i) any approvals, licenses,
registrations or authorizations necessary to conduct clinical trials of any
Licensed Product, or for the manufacture, marketing and sale of any Licensed
Product in such jurisdiction, and (ii) where relevant, pricing approvals
necessary to obtain reimbursement from a Government Authority with respect to
such Licensed Product. For the sake of clarity, except as otherwise expressly
provided, "Regulatory Approval" shall not be achieved for any Licensed Product
in a nation or, where applicable, a multinational jurisdiction until any
applicable approvals relating to pricing and reimbursement from a Government
Authority have been obtained in such nation or such jurisdiction. However,
notwithstanding anything in this paragraph to the contrary, for purposes of
determining the "Commercialization Phase" only, "Regulatory Approval" shall mean
only any approvals, licenses, registrations or authorizations for the marketing
and sale of any Licensed Product in a jurisdiction.

                                       9
<PAGE>

                                                                    CONFIDENTIAL

      1.60 "Regulatory Application" means any application necessary and
appropriate to obtain a Regulatory Approval, including, without limitation, all
required documents, data and information concerning, filed or required to be
filed, or otherwise submitted by either Party to a Governmental Authority in
connection with obtaining such Regulatory Approval.

      1.61 "Royalty(ies)" shall have the meaning set forth in Section 5.3.

      1.62 "Specifications" means the specifications for any Licensed Product,
consistent with the stage of development of such Licensed Product, as adopted
and amended by Committee I from time to time.

      1.63 "Sublicensee" means a sublicensee of CIMAB, TARCANTA or TARCANTA
LTD., authorized or permitted in accordance with the terms of this Agreement;
provided, however, that no sublicense or assignment of rights to a Sublicensee
hereunder shall relieve CIMAB, TARCANTA or TARCANTA LTD. of their obligations to
fully comply with the terms and conditions of this Agreement.

      1.64 "Term" shall have the meaning set forth in Section 12.1.1.

      1.65 "Territory" means the U.S., the countries of "Europe" as defined
above, Canada, Japan, Mexico, Australia, New Zealand and any other countries
added by mutual agreement of the Parties in writing.

      1.66 "Third Country" means a country that is not Cuba or the U.S.

      1.67 "Third Party(ies)" means any Person(s) other than CIMAB, Cuban
nationals (except where Cuban nationals are expressly included), TARCANTA,
TARCANTA LTD., YMB, CIMYM or their respective Affiliates.

      1.68 "Transfer Price" shall have the meaning set forth in Section 6.1.2.

      1.69 "Transferred Assets" means the biological materials, documentation
nd other items listed on Exhibit B hereto.

                                    ARTICLE 2

                  SUSPENSION OF CIMAB-CIMYM VACCINE AGREEMENT,

                      GRANT OF RIGHTS AND RELATED COVENANTS

      2.1 Suspension of CIMAB-CIMYM Vaccine Agreement.

            2.1.1 In consideration of the payments to be made to YMB by TARCANTA
and TARCANTA LTD. in accordance with the terms of this Agreement, CIMAB and
CIMYM

                                       10
<PAGE>

                                                                    CONFIDENTIAL

hereby agree that the CIMAB-CIMYM Vaccine Agreement shall be suspended by mutual
agreement of CIMYM and CIMAB as of the Effective Date. Further, CIMAB agrees
that, in the event that this Agreement is terminated in accordance with the
terms hereof by any of the Operating Parties prior to its expiration, or
specifically in the event that YMB fails to receive the consideration provided
for it in the time or times set forth herein, upon the occurrence of such an
event, the CIMAB-CIMYM Vaccine Agreement shall be deemed, as between CIMAB and
CIMYM to have been reinstated and continued in full force and in effect,
unamended except as specifically set forth in Section 2.1.2, below, without any
further action of the Parties, and this Agreement and any sublicense granted
pursuant to the terms of this Agreement shall be terminated and of no further
force and effect.

            2.1.2 In the event that, during the time that this Agreement is in
effect, CIMAB grants a sublicense to a Third Party for any country that is not
included in the definition of the Territory covered by this Agreement, but that
is included in the definition of "territory" included in the CIMAB-CIMYM
Agreement, upon the reinstatement of the CIMAB-CIMYM Agreement in the event that
this Agreement is terminated, any such country shall be automatically excluded
from the definition of the "territory" thereunder and CIMYM shall have no rights
with respect to such country.

            2.1.3 In consideration for CIMYM and YMB's agreement to suspend the
CIMAB-CIMYM Vaccine Agreement, and to timely perform the responsibilities set
forth in Section 3.5.3, below, TARCANTA and/or TARCANTA LTD. agree to pay to YMB
a total of [***], payable as follows: [***] payable on September 30, 2004; [***]
payable on December 31, 2004, [***] payable on September 30, 2005, and [***]
payable on December 31, 2005.

            2.2 Grant of Sublicenses by CIMAB to TARCANTA and TARCANTA LTD.

            2.2.1 Licensed Products - U.S., Canada and Mexico. Subject to the
terms and conditions of this Agreement, CIMAB hereby grants to TARCANTA and
TARCANTA LTD. an exclusive sublicense under the Licensed Patent Rights, the
Licensed Know-How, and the Improvements to make, have made, use, offer for sale,
market and sell the Licensed Products in the U.S., Canada and Mexico.

            2.2.2 Notwithstanding the foregoing Section 2.2.1, TARCANTA and
TARCANTA LTD.'s rights under this Agreement to any Adjuvant and to any Carrier
Protein with respect to the U.S., Canada and Mexico, shall be limited to making,
having made, using, offering for sale, marketing and selling such Adjuvant and
Carrier Protein in connection with the Licensed Products or any other
therapeutic cancer vaccines or therapeutic cancer products licensed by CIMAB to
TARCANTA or TARCANTA LTD. or any of their Affiliates or Sublicensees.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       11
<PAGE>

                                                                    CONFIDENTIAL

            2.2.3 Also notwithstanding the foregoing Section 2.2.1, CIMAB shall
have the right to grant a sublicense to the Government of Mexico or to a
government-owned instrumentality designated by the Government of Mexico to
purchase from CIMAB and provide the Licensed Products for use only by healthcare
facilities owned, controlled and managed by said government within Mexico for
public health purposes, subject to the advance approval by TARCANTA of the terms
and conditions of any such sublicense agreement, which approval shall not be
unreasonably withheld, and provided that CIMAB shall use its best efforts to
ensure that any Licensed Product provided by CIMAB or its Licensors to the
Government of Mexico shall not subsequently be shipped to any of the countries
within the Territory.

            2.2.4 Licensed Products - Other Countries. Subject to the terms and
conditions of this Agreement, CIMAB hereby grants to TARCANTA LTD. and TARCANTA
an exclusive sublicense under the Licensed Patent Rights, the Licensed Know-How,
and the Improvements to use, offer for sale, market, sell, and import the
Licensed Products in the Other Countries.

            2.2.5 Notwithstanding the foregoing Section 2.2.4, TARCANTA and
TARCANTA LTD.'s rights under this Agreement to any Adjuvant and to any Carrier
Protein with respect to any of the Other Countries, shall be limited to using,
offering for sale, marketing selling and importing such Adjuvant and Carrier
Protein in connection with the Licensed Products or any other therapeutic cancer
vaccines or therapeutic cancer products licensed by CIMAB to TARCANTA or
TARCANTA LTD. or any of their Affiliates or Sublicensees.

      2.3 Rights to Sublicense. TARCANTA and/or TARCANTA LTD. may sublicense
their rights to use, offer for sale, market, sell and import the Licensed
Products anywhere in the Territory to a Third Party, provided, however that (i)
TARCANTA and/or TARCANTA LTD. shall amend the Marketing Plan developed, from
time to time, by TARCANTA and/or TARCANTA LTD., to include the anticipated
sublicense arrangement, and discuss same with Committee II in accordance with
Article 4 of this Agreement, (ii) CIMAB retains the exclusive right to
manufacture the Licensed Products for the Other Countries, (iii) the applicable
terms of the Sublicense Agreement (with the exception of the portion of the
Royalties payable to CIMAB as a result of any such Sublicense Agreement in
accordance with Section 5.6 of this Agreement), shall not be less favorable to
CIMAB, in the aggregate, than the applicable terms of this Agreement, and (iv)
that no such assignment of rights to a Sublicensee hereunder shall relieve
TARCANTA or TARCANTA LTD. of their obligations to fully comply with the terms
and conditions of this Agreement.

      2.4 It is understood and agreed that neither TARCANTA nor TARCANTA LTD.
shall be required to undertake, and TARCANTA and TARCANTA LTD. shall not
undertake, to sell any CIMAB product unrelated to the Licensed Products. It is
understood and agreed that neither TARCANTA nor TARCANTA LTD. shall be required
to transfer, and neither TARCANTA nor TARCANTA LTD. (including their officers,
directors, employees and agents) will transfer to CIMAB, any technology or
know-how unrelated to the Licensed Products.

                                       12
<PAGE>

                                                                    CONFIDENTIAL

      2.5 Covenant To Take No Action. Subject to the terms and conditions of
this Agreement, CIMAB hereby represents, warrants and agrees that if any of
CIMAB's, its Licensors' intellectual property rights are required to make, have
made, use, offer for sale, sell and import Licensed Products anywhere in the
Territory, neither CIMAB nor its Licensors shall take any action of any nature
whatsoever during the term of this Agreement under such intellectual property
rights which would prevent or interfere with such activities by TARCANTA,
TARCANTA LTD. and their respective Affiliates and Sublicensees.

      2.6 Non-Competition. Neither TARCANTA, TARCANTA LTD. nor their respective
Affiliates shall enter into other agreements with Third Parties to develop
and/or market any molecularly defined therapeutic cancer vaccines that include
substantially the same human epidermal growth factor receptor sequences or human
epidermal growth factor receptor ligand sequences during the Term of this
Agreement.

      2.7 Right of First Refusal. TARCANTA and TARCANTA LTD. shall have a right
of first refusal to negotiate in good faith and in a timely manner with CIMAB
for the acquisition of other EGF-based therapeutic cancer vaccines Controlled By
CIMAB during the Term of this Agreement.

                                    ARTICLE 3

                                   DEVELOPMENT

      3.1 Development Plan. In an effort to develop the most efficacious version
of the Licensed Products for the treatment of cancer patients in the U.S. and
throughout the Territory, the Operating Parties agree to coordinate efforts to
improve the manufacturing, quality control and quality assurance processes and
methods for the Licensed Products, as well as to cooperate in the design and
development of all pre-clinical and clinical trial testing protocols required to
obtain Regulatory Approvals for the Licensed Products. Such further development
of the Licensed Products ("Development Work") will be conducted by the Operating
Parties pursuant to a mutually agreed development plan to be established by the
Operating Parties within ninety (90) days after the Effective Date (as such plan
is in effect from time to time, the "Development Plan"), in accordance with the
terms and conditions set forth below.

      3.2 Committee I. Within twenty (20) business days after the Effective
Date, TARCANTA and TARCANTA LTD. shall appoint three (3) individuals and CIMAB
shall appoint three (3) individuals to serve as its representatives on Committee
I. Each of the Operating Parties shall have the right to change any or all of
its representatives on Committee I upon written notice to the other Operating
Parties. Committee I may appoint individuals to serve as representatives on
subcommittees to assist Committee I with respect to any particular area required
for development of the Licensed Products under the Development Plan, including,
product manufacturing, process development, qualification and validation of
Manufacturing Facilities necessary for the manufacture and supply of the
Licensed Products, research, quality control and assurance, pre-clinical studies
design, implementation and evaluation, clinical

                                       13
<PAGE>

                                                                    CONFIDENTIAL

protocols design, implementation and evaluation, and regulatory filings directly
related to the Licensed Products. Committee I shall:

      (a) Elaborate written plans for the transfer to TARCANTA or TARCANTA LTD.,
as designated by TARCANTA, of the Transferred Assets and all related materials
and documentation;

      (b) Prepare and approve the Development Plan, including, without
limitation, go/no-go criteria, timelines and responsibilities;

      (c) Monitor and make recommendations regarding the performance of the
Operating Parties under the Development Plan and the conduct of the Development
Work, including, without limitation, the design of clinical trial protocols and
elaboration of quality controls;

      (d) Prepare and approve modifications to the Development Plan;

      (e) Adopt Specifications for the Licensed Products, taking into account
any Applicable Laws;

      (f) Comment and advise on each of the Operating Party's plans for
obtaining Regulatory Approvals relating to the Licensed Products;

      (g) Develop adverse event reporting criteria and procedures in accordance
with Applicable Laws; and

      (h) Review any and all proposed publications or communications relating to
the Development Plan, and activities relating to any Improvement, if applicable,
and the results therefrom, and any and all proposed filings of patent
applications in connection therewith.

      3.3 Committee I shall meet not less frequently than twice per calendar
year during the Development Period, on such dates and at such times and
locations as agreed to by the Operating Parties. In the event that
representatives of the Operating Parties disagree upon any decision to be made
with respect to the Development Plan, the decision shall be referred to their
chief executive officers for resolution. In the event that the chief executive
officers are not able to reach a timely resolution to the matter in question,
TARCANTA and TARCANTA LTD. will have the right to make a final decision with
respect to all activities that impact the development of the Licensed Products
for eventual commercialization within the Territory, provided, however, that if
the chief executive officers of the Operating Parties are unable to reach timely
resolution on decisions that require a material expenditure of funds by CIMAB,
the disagreement shall be referred to the Dispute Resolution procedure detailed
in this Agreement. Members of Committee I may attend a meeting of Committee I
either in person, by telephone, or by videoconference, but not by proxy. In the
event any of CIMAB's representatives on Committee I are not granted a visa to
attend a meeting scheduled to be held in the U.S., the meeting shall be held in
a third country or, upon mutual agreement of CIMAB, TARCANTA and TARCANTA LTD.,
in Cuba.

                                       14
<PAGE>

                                                                    CONFIDENTIAL

      3.4 It is understood and agreed that neither TARCANTA nor TARCANTA LTD.
shall have any obligation to transfer to CIMAB, and shall not transfer, directly
or indirectly, to CIMAB or to any other Cuban national, any technology unrelated
to the Licensed Products. It is further understood and agreed that no officer,
director, employee or agent of TARCANTA or TARCANTA LTD. (whether he or she is a
citizen or resident of the U.S. or of any other nationality) shall engage in
technology transfer activity that is unrelated to the research and development
of the Licensed Products.

      3.5 Responsibilities of the Parties.

            3.5.1 Without limitation, TARCANTA and TARCANTA LTD. and their
respective its Affiliates and Sublicensees shall use Reasonable Commercial
Efforts to:

      (a) Submit all Regulatory Applications relating to Licensed Products to
jurisdictions within the Territory,

      (b) Obtain and maintain Regulatory Approvals for the Licensed Products in
the Territory.

      (c) Perform the work to be performed by TARCANTA and TARCANTA LTD. under
the Development Plan;

      (d) Conduct clinical trials necessary to obtain Regulatory Approvals
required to market and sell Licensed Products in the Territory;

      (e) Correspond with all Government Authorities in the Territory with
respect to the Licensed Products;

      (f) Market, sell, and distribute Licensed Product in the Territory;

      (g) Manufacture Licensed Product for sale and distribution in the U.S.,
Canada and Mexico, in accordance with Applicable Law; and

      (h) Disclose and communicate Improvements to CIMAB in a timely manner.

            3.5.2 Without limitation, CIMAB shall use Reasonable Commercial
Efforts to:

      (a) Assist TARCANTA and TARCANTA LTD. in their submission of Regulatory
Applications relating to Licensed Products to jurisdictions within the Territory

      (b) Perform the work to be performed by CIMAB under the Development Plan;

                                       15
<PAGE>

                                                                    CONFIDENTIAL

      (c) Obtain and maintain Regulatory Approvals required to manufacture
Licensed Products for supply to TARCANTA LTD., TARCANTA, and their Affiliates
and Sublicensees for sale in the Other Countries under this Agreement;

      (d) Disclose and communicate the Licensed Know-How to TARCANTA and
TARCANTA LTD. in a timely manner;

      (e) disclose and communicate Improvements to TARCANTA and TARCANTA LTD. in
a timely manner; and

      (f) Manufacture the Licensed Products for sale and distribution by
TARCANTA LTD., NEWNCVX-DE, their Affiliates and Sublicensees in the Other
Countries, in accordance with this Agreement.

            3.5.3 Without limitation, YMB and CIMYM shall use Reasonable
Commercial Efforts to:

            (a) Within sixty (60) days following the Effective Date, provide the
Operating Parties with copies of all written data, documentation, information,
correspondence, reports, test results, summaries, analyses and opinions with
respect to: (i) pre-clinical testing and clinical trials (including without
limitation copies of clinical report forms); (ii) the prosecution of patent
applications; and (iii) Regulatory Applications, developed by or on behalf of
CIMYM and/or YMB in relation to the Licensed Products and the EGF Vaccine
licensed to CIMYM under the CIMAB-CIMYM Vaccine Agreement prior to the Effective
Date.

            3.5.4 As part of TARCANTA and TARCANTA LTD.'s efforts to obtain any
Regulatory Approvals in the Territory, TARCANTA and TARCANTA LTD. may, during
the Term of this Agreement, use any data generated by CIMAB, CIMYM, YMB and
their respective Affiliates and Sublicensees with respect to the Licensed
Products and the EGF Vaccine without additional cost to TARCANTA or TARCANTA
LTD.

            3.5.5 As part of CIMAB's efforts to obtain any Regulatory Approvals
outside the Territory, CIMAB may, during the Term of this Agreement, use outside
the Territory any data generated by TARCANTA, TARCANTA LTD., CIMYM, YMB and
their respective Affiliates and Sublicensees with respect to the Licensed
Products and the EGF Vaccine without additional cost to CIMAB.

      3.6 Cooperation Regarding Regulatory Applications. In order to expedite
the receipt of Regulatory Approvals for the Licensed Products throughout the
Territory, and to ensure that all pertinent information regarding the safety and
efficacy of the Licensed Products are timely communicated between the Operating
Parties, each Operating Party shall, at least sixty (60) days in advance of such
filings or submissions, inform the other Operating Parties of its intent to file
Regulatory Applications to market and sell Licensed Products. The other
Operating Parties will cooperate with the Operating Party that files or
otherwise submits the Regulatory Application as such Operating Party reasonably
requests in obtaining such Regulatory Approvals. In the event that any of the
consultations or disclosures required under this Section 3.6 conflict with an

                                       16
<PAGE>

                                                                    CONFIDENTIAL

Operating Party's confidentiality or non-disclosure obligations to a Third
Party, the Operating Party with the conflict shall use its best efforts to make
such information available to the other Operating Parties, including requesting
the Third Party agree to enter into a confidentiality agreement with the other
Operating Parties. Notwithstanding anything in this Agreement to the contrary,
each Operating Party shall provide the other Operating Parties with complete
information regarding (i) the results of any pre-clinical testing of the
Licensed Products that indicates any potential for teratogenicity, mutagenicity
or toxicity in humans; (ii) adverse events or serious adverse events associated
with the administration of the Licensed Products to patients, (iii) all
protocols, summaries of all data and the results of statistical analysis of such
data with respect to the results of any interim or final analyses of all
clinical trials performed using the Licensed Products; and (iv) any
correspondence with any Government Authority, relating to any such Regulatory
Approval, to the suspension or termination of any clinical trials regarding the
Licensed Product, or the suspension or termination of any right to market the
Licensed Products, once such approvals have been obtained.

      3.7 Maintenance of Regulatory Approvals. The Operating Party that owns a
Regulatory Approval shall be responsible for filing all reports required to be
filed under Applicable Laws in order to maintain any Regulatory Approvals for
manufacturing, marketing, and sale of Licensed Products in the Territory,
including, without limitation, adverse drug experience reports. Each Operating
Party shall cooperate with the other Operating Parties in preparing and filing
all such reports and, upon the filing Operating Parties' request, provide the
filing Operating Party with any information in the non-filing Operating Party's
control which the filing Operating Party deems to be relevant to any such
report. Notwithstanding the foregoing, to the extent that any Operating Party
has or receives any information regarding any adverse drug experience which may
be related to the use of any Licensed Product, that Operating Party shall
promptly provide the other Operating Parties with all such information. Promptly
after the Effective Date, the Operating Parties shall, as part of the
Development Plan, determine the procedures to be followed with respect to
reporting adverse drug experiences, such procedures to be consistent with each
of the Operating Parties' obligations under Applicable Laws.

      3.8 Improvements. In an effort to develop the most efficacious version of
the Licensed Products for the treatment of cancer patients in the U.S. and
throughout the Territory, each Operating Party shall disclose in a timely manner
to Committee I and to the other Operating Parties all Improvements that such
Operating Party and its Affiliates, or, in the case of CIMAB, its Licensors,
invents or develops, individually, or jointly, during the term of this
Agreement. Committee I shall determine whether to incorporate an Improvement
into the Development Plan. If Committee I incorporates an Improvement into the
Development Plan, Committee I shall also recommend whether such Improvement
shall occur in lieu of or in addition to the then-current activities underway
pursuant to the Development Plan.

      3.9 Maintenance of Records. Each Operating Party shall keep and maintain,
and shall cause its Affiliates and Sublicensees, to keep and maintain, accurate
and complete records of all Development Work and all results of any trials,
studies and other investigations conducted under this Agreement by or on behalf
of such Operating Party for the period of time retention of such records is
required under all Applicable Laws. For so long as a Operating Party is
conducting

                                       17
<PAGE>

                                                                    CONFIDENTIAL

Development Work hereunder, such Operating Party shall prepare and submit to
Committee I, on a semi-annual basis, written progress reports summarizing the
current status and progress of the Development Work. Each Operating Party shall
have access, on reasonable notice, to all records required to be kept and
maintained under this section 3.9.

      3.10 Inspection. Each Operating Party, or such Operating Party's
authorized representatives, at the Operating Party's own expense, may visit the
facilities of the other Operating Parties or the other Operating Parties'
Affiliates and Sublicensees where Development Work is being performed during
normal business hours upon reasonable notice without undue interruption to
normal business operations. In the event an Operating Party's representatives,
or any of them, are not able to obtain visas, the Operating Party may retain and
appoint other Persons reasonably acceptably to the Operating Party being
inspected, including without limitation nationals of the country where the
facility is located, to carry out such inspections, provided, however, that all
such Persons performing such inspections shall be bound by a non-disclosure and
confidentiality agreement to the Operating Party being inspected. A report
detailing the results of all such inspections shall be provided to the chief
executive officers of each of the Parties promptly following any such
inspection.

                                    ARTICLE 4

                                    MARKETING

      4.1 Marketing. Within 180 days after the Effective Date, TARCANTA and
TARCANTA LTD., shall prepare a preliminary plan detailing TARCANTA and TARCANTA
LTD.'s plans for marketing the Licensed Products within the Territory, including
any strategy to grant sublicenses (as such plan is in effect from time to time,
the "Marketing Plan").

      4.2 Committee II. Within ninety (90) days after the Effective Date,
TARCANTA and TARCANTA LTD. shall appoint two (2) individuals and CIMAB shall
appoint two (2) individuals to serve as its representatives on Committee II.
Each Operating Party shall have the right to change any or all of its
representatives on Committee II upon written notice to the other Operating
Parties. Committee II may appoint individuals to serve as representatives on
subcommittees to assist Committee II with respect to any particular area, and
members of Committee I may attend all meetings of Committee II.

            4.2.1 Committee II shall meet not less frequently than twice per
calendar year following its organization, on such dates and at such times and
locations as agreed to by the Operating Parties. Consistent with industry
practices for a licensing agreement of this nature, Committee II shall review
the Marketing Plan for the Licensed Products. In the event any of CIMAB's
representatives are not granted visas to attend a meeting scheduled to be held
in the U.S., the meeting shall be held in a third-country or, upon mutual
agreement, in Cuba. In the event that any Operating Party disagrees with the
Marketing Plan for the Licensed Products, the

                                       18
<PAGE>

                                                                    CONFIDENTIAL

decision shall be referred to the chief executive officers of the Parties for
resolution. In the event that the chief executive officers of the Parties are
not able to reach a timely resolution of the matter in question, TARCANTA and
TARCANTA LTD. will have the right to make a final decision with respect to all
activities that impact the marketing of the Licensed Product within the
Territory, provided, however, that if the chief executive officers of the
Parties are unable to reach a timely resolution on a decision that requires a
material expenditure of funds by CIMAB, the disagreement shall be referred to
the Dispute Resolution procedure detailed in this Agreement. Members of
Committee II may attend a meeting of Committee II either in person, by
telephone, or by videoconference, but not by proxy.

                                    ARTICLE 5

                             CONSIDERATION AND COSTS

      5.1 Development Phase Payments (Technology Transfer Fees and Development
Phase Milestone Fees). In consideration of CIMAB's efforts in developing the
Licensed Products prior to the Effective Date, the transfer of the Transferred
Assets to be made by CIMAB to TARCANTA or TARCANTA LTD. in accordance herewith,
and in consideration of the rights granted to TARCANTA and/or TARCANTA LTD.
hereunder, TARCANTA and/or TARCANTA LTD. shall be responsible for payment of the
following Technology Transfer Fees and Development Phase Milestone Fees in
accordance with the following terms and conditions:

      5.1.1 Technology Transfer Fees and Development Phase Milestone Fees.
TARCANTA and/or TARCANTA LTD. shall, upon the satisfactory completion of the
milestones listed next to each particular milestone payment, make payments in
the total amounts specified for each such milestone in this Section 5.1.1. Once
paid, such payments are non-refundable. With respect to the milestone payments
listed below: (a) sixty-five percent (65%) shall be paid to CIMAB, 100% into the
Barter Escrow Account, and (b) thirty-five percent (35%) shall be paid to YMB in
cash, within thirty (30) days following the successful completion of the
indicated Development Phase event triggering TARCANTA and/or TARCANTA LTD.'s
obligation to make the respective payment to CIMAB and YMB:

<TABLE>
<CAPTION>
                                                                MILESTONE
                       MILESTONE                              PAYMENT (US$)
---------------------------------------------------------------------------
<S>                                                           <C>
               TECHNOLOGY TRANSFER FEES
Upon the execution of this Agreement by all Parties.              [***]

Upon the transfer by CIMAB and acceptance by TARCANTA             [***]
and/or TARCANTA LTD. of all documentation related to
the Transferred Assets, which acceptance may not
be unreasonably withheld.

Upon the transfer by CIMAB and acceptance by TARCANTA             [***]
and/or TARCANTA LTD. of the biological materials
comprising the Transferred Assets, which transfer
and acceptance will occur when requested by TARCANTA
and/or TARCANTA LTD. at any time

</TABLE>

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       19
<PAGE>

                                                                    CONFIDENTIAL

<TABLE>
<S>                                                           <C>
within one (1) year following the acceptance by TARCANTA
and/or TARCANTA LTD. of all documentation related to the
Transferred Assets, which acceptance may not be
unreasonably withheld.

DEVELOPMENT PHASE MILESTONE FEES

Upon the approval by the FDA of the first IND                     [***]
Submission for a Phase 2 clinical trial of the Licensed
Products.

Upon the completion by TARCANTA and/or TARCANTA LTD. of           [***]
the first Phase 2 clinical trial of the Licensed
Products, provided that such Phase 2  clinical
trial evidences, to TARCANTA and/or TARCANTA LTD.'s
reasonable satisfaction, anti-tumor effects in advanced
cancer patients, as measured by: (i) objective evidence
of tumor reduction; and/or (ii) a statistically
significant increase in survival times compared with
historical control of patients with the same tumor
localization and clinical stage.

Upon the submission to the FDA by TARCANTA and/or                 [***]
TARCANTA LTD. of the first BLA for the Licensed
Products.
</TABLE>

      5.2 Commercialization Phase Payments. TARCANTA and/or TARCANTA LTD. shall,
upon the satisfactory completion of the milestones listed next to each
particular milestone, make payments in the total amounts specified for each such
milestone in this Section 5.2. Once paid, said payments are non-refundable. With
respect to the milestone payments listed below: (a) sixty-five percent (65%)
shall be paid to CIMAB, 50% into the Barter Escrow Account and 50% Payment in
Cash, and (b) thirty-five percent (35%) shall be paid to YMB in cash, within
thirty (30) days following the successful completion of the indicated
Development Phase event triggering TARCANTA and/or TARCANTA LTD.'s obligation to
make the respective payment to CIMAB and YMB:

<TABLE>
<CAPTION>
                                                                MILESTONE
                       MILESTONE                              PAYMENT (US$)
---------------------------------------------------------------------------
<S>                                                           <C>
Upon the approval by the FDA of the first BLA submitted           [***]
by TARCANTA and/or TARCANTA LTD. for the Licensed
Products.

Upon the approval by FDA of any subsequent BLA submitted          [***]
by TARCANTA and/or TARCANTA LTD. for the Licensed
Products.

Upon the approval by the Governmental Authority of the            [***]
European Union (EU) of the first license application to
market the Licensed Products  submitted by TARCANTA
and/or TARCANTA LTD. in the EU.

Upon the approval by the Governmental Authority of Japan          [***]
of the first license application to market the Licensed
Products submitted by TARCANTA  and/or TARCANTA
LTD. in Japan.

At the first time such time as sales by TARCANTA,                 [***]
TARCANTA LTD. and their respective Affiliates of the
Licensed Products in the Territory equal  a total
of [***].
</TABLE>

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       20
<PAGE>

                                                                    CONFIDENTIAL

      5.3 Milestone Payments for Combination Products. In the event that
TARCANTA or TARCANTA LTD. develops any Combination Products, the Milestone
Payments for such Combination Products shall be as follows:

      (a) In the event that TARCANTA and/or TARCANTA LTD. have already paid a
particular Milestone Payment to CIMAB in relation to the development of the EGF
Vaccine under the EGF Vaccine Agreement, the Milestone Payments for the
achievement of the corresponding Milestone in relation to the development of any
Combination Product shall be those specified for the Licensed Products under
this Agreement. In this event, the percentage of any such Milestone Payments
made with respect to the Combination Products (a) to CIMAB shall be sixty-five
percent (65%) of the applicable Milestone Payment, payable 100% into the Barter
Escrow Account for any sales occurring during the Development Phase, and 50%
into the Barter Escrow Account and 50% in Payment in Cash for any sales
occurring during the Commercialization Phase, and (b) to YMB shall be
thirty-five percent (35%) of the applicable Milestone Payment, payable in cash.

      (b) In the event, however, that TARCANTA and/or TARCANTA LTD. have not
already paid a particular Milestone Payment to CIMAB in relation to the
development of the EGF Vaccine under the EGF Vaccine Agreement, the Milestone
Payments for the achievement of the corresponding Milestone in relation to the
development of any Combination Product shall be those specified for the Licensed
Products under the EGF Vaccine Agreement. In this event, YMB shall receive
thirty-five percent (35%) of the corresponding amount of the Milestone Payment
it would have received under this Agreement, payable in cash, and CIMAB shall
receive the balance of the Milestone Payment, payable 100% into the Barter
Escrow Account for any sales occurring during the Development Phase, and 50%
into the Barter Escrow Account and 50% in Payment in Cash for any sales
occurring during the Commercialization Phase.

      (c) Furthermore, if any milestone payments have already paid by TARCANTA
or TARCANTA LTD. upon the execution of this Agreement, upon the acceptance of
the documentation and the biological materials that comprise the Transferred
Assets, such milestones shall not be payable again in connection with the
development of any Combination Products.

      (d) The percentage of any milestone payments made with respect to the
Combination Products (a) to CIMAB shall be sixty-five percent (65%), payable
100% into the Barter Escrow Account for any sales occurring during the
Development Phase, and 50% into the Barter Escrow Account and 50% in Payment in
Cash for any sales occurring during the Commercialization Phase, and (b) to YMB
shall be thirty-five percent (35%), payable in cash.

      5.4 Royalty Payments. TARCANTA and TARCANTA LTD. shall pay a royalty
payment of [***] of Net Sales from sales of the Licensed Products
("Royalty(ies)"). With respect to such Royalties: (a) sixty-five percent (65%)
shall be paid to CIMAB, 100% into the Barter Escrow Account for any sales
occurring during the Development Phase, and 100%

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       21
<PAGE>

                                                                    CONFIDENTIAL

into the Barter Escrow Account, 50% of each such payment to be made for the
purchase of Barter Goods and 50% to be made for Payment in Cash for any sales
occurring during the Commercialization Phase, and (b) thirty-five percent (35%)
shall be paid to YMB in cash.

            5.4.1 Royalty Payments for Combination Products. Notwithstanding
anything in this Agreement or the EGF Vaccine Agreement to the contrary,
TARCANTA and TARCANTA LTD. shall pay a royalty payment of [***] of the Net Sales
of any Combination Products. With respect to royalty payments on Combination
Products, the percentage of such royalty payments payable to CIMAB, as opposed
to YMB, shall be based upon the proportion of the Net Sales of the Combination
Product (NS) attributable to the Licensed Product based on comparing the
manufacturing cost of the Licensed Product (ML) with the manufacturing cost of
the Combination Product (MC), as in the following formula:

      - NS of Licensed Product = (ML/MC) x NS of Combination Product,

                  Amount payable to CIMAB = NS of Licensed Product,

                  Amount payable to YMB = NS of Combination Product - NS of
                  Licensed Product.

      - By way of example, in the event that the ML is $[***], and the MC is
        $[***], and the Net Sales of the Combination Product are $[***], CIMAB
        shall receive $[***], and YMB shall receive $[***].

                  Any such payments shall be paid to CIMAB, 100% into the Barter
Escrow Account for any sales occurring during the Development Phase, and 50%
into the Barter Escrow Account and 50% in Payment in Cash for any sales
occurring during the Commercialization Phase, and to YMB in cash. In the event
of any dispute with respect to this formula between YMB and CIMAB, TARCANTA and
TARCANTA LTD. shall be entitled to withhold payment of all such royalties until
YMB and CIMAB have provided TARCANTA and TARCANTA LTD. with a writing, signed by
YMB and CIMAB, certifying their agreement to the formula to be used by TARCANTA
and TARCANTA LTD. to allocate such payments between them.

      5.5 Option to Modify YMB's Milestone Fee and Royalty Percentage. At any
time prior to September 30, 2005, TARCANTA and TARCANTA LTD. shall have the
option, in their sole and absolute discretion, to pay to YMB a total of One
Million Dollars (U.S. $1,000,000' the "Additional Payment") in order to effect a
decrease in certain amounts owed to YMB under this Agreement. Upon the receipt
of the Additional Payment, the following amounts owed to YMB under this
Agreement shall be decreased from thirty-five percent (35%) to twenty-five
percent (25%) of the total amount owed by TARCANTA and/or TARCANTA LTD. to CIMAB
and YMB: (a) the percentage of the Technology Transfer Fees and Development
Phase Milestone Fees owed to YMB under Section 5.1.1, (b) the percentage of the
Commercialization Phase Payments owed to YMB under Section 5.2, (c) the
percentage of the milestones owed to YMB for any Combination Product under
Section 5.3, (d) the percentage of any Royalties owed to YMB for sales of any
Licensed Products under Section 5.4., and (e) the percentage of any

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       22
<PAGE>

                                                                    CONFIDENTIAL

sublicensing payments owed to YMB under Section 5.7, below. An equivalent
reduction shall be made to any Royalties owed to YMB for sales of any
Combination Products.

      5.6 Regulatory Approval Costs. TARCANTA and TARCANTA LTD. shall be
responsible for all costs associated with preparing and filing Regulatory
Applications, and obtaining and maintaining Regulatory Approvals for Licensed
Products in the Territory.

      5.7 Clinical Studies Costs. TARCANTA and TARCANTA LTD. shall be
responsible for all costs associated with the clinical studies related to
Licensed Products that are undertaken by TARCANTA, TARCANTA LTD. and their
respective Affiliates and Sublicensees in accordance with this Agreement.

      5.8 Sublicensing. If TARCANTA or TARCANTA LTD. elects to grant a
sublicense to any Third Party to market or sell Licensed Products anywhere in
the Territory pursuant to Section 2.2, TARCANTA or TARCANTA LTD., depending on
which had granted the sublicense shall, in addition to all other payments
provided for in this Agreement, pay to CIMAB and YMB, within thirty (30) days of
receipt, the amounts listed below. With respect to all such payments: (a)
sixty-five percent (65%) shall be paid to CIMAB, 100% into the Barter Escrow
Account for all such payments during the Development Phase, and 100% into the
Barter Escrow Account, 50% in of each such payment to be made for the purchase
of Barter Goods, and 50% to be made for Payment in Cash, for all such payments
during the Commercialization Phase, and (b) thirty-five percent (35%) shall be
paid to YMB in cash:

            (a) If the sublicense is executed before TARCANTA or TARCANTA LTD.
has initiated any Phase 2 Clinical Trial with a Licensed Product in the
Territory, a [***] portion of any royalty payments, license fees, milestone
payments or other monetary payments received by TARCANTA or TARCANTA LTD. as a
result of such agreement with a Third Party, but excluding any research support,
equity or other non-monetary payments or consideration received by TARCANTA or
TARCANTA LTD.

            (b) If the sublicense is executed after TARCANTA or TARCANTA LTD.
has initiated any Phase 2 Clinical Trial with a Licensed Product in the
Territory, a [***] portion of any royalty payments, license fees, milestone
payments or other monetary payments received by TARCANTA or TARCANTA LTD. as a
result of such agreement with a Third Party, but excluding any research support,
equity or other non-monetary payments or consideration received by TARCANTA or
TARCANTA LTD.

      5.9 Securing Payments Under Article 5. TARCANTA and/or TARCANTA LTD. shall
periodically transfer funds owed to CIMAB under this Agreement in advance into
an escrow account in a reputable bank in London or Ireland (the "Holding
Account"), and CIMAB shall have no accrued interest in such funds at the time of
such transfer. At such time as the milestone is achieved, and CIMAB shall have
an interest in such funds, the funds shall be promptly transferred into the
Barter Escrow Account for the making of Barter Payments and/or

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       23
<PAGE>

                                                                    CONFIDENTIAL

Payments in Cash directly to CIMAB in cash as prescribed hereunder. Funds from
the Holding Account shall be paid into the Barter Escrow Account to be made as
payment for the purchase of Barter Goods during the Development Phase, and to be
made 50% for the purchase of Barter Goods and 50% in Payments in Cash, during
the Commercialization Phase.

            5.9.1 TARCANTA and TARCANTA LTD. shall appoint Citibank
International plc of London, England ("Escrowee"), which is not a Cuban
national, to act as Escrowee of the Holding Account under an escrow agreement
that obligates the Escrowee to hold such funds transferred, and to be
transferred, by TARCANTA and/or TARCANTA LTD., in the Holding Account in
accordance with the terms of said escrow agreement, and to draw upon the Holding
Account to make payments into the Barter Escrow Account or to CIMAB in Payments
in Cash upon either of the following events: (i) TARCANTA or TARCANTA LTD.
notifying the Escrowee of the occurrence of the events triggering TARCANTA or
TARCANTA LTD.'s obligation to make milestone payments, or Royalty payments under
this Article 5 and the amounts thereof, or (ii) in the case where the
achievement of milestones may be unequivocably verified by a press release
disclosed in a public filing by TARCANTA or its Affiliates under the Securities
Laws of the U.S., by CIMAB providing the Escrowee with a copy of said press
release, and upon Escrowee's confirmation of the authenticity of said press
release by confirming same in the filings for TARCANTA or its Affiliates on the
U.S. Securities and Exchange Commission's internet site. TARCANTA or TARCANTA
LTD. may require immediate return of all escrowed funds to TARCANTA and/or
TARCANTA LTD. in the event that the Agreement is terminated. TARCANTA and
TARCANTA LTD. further agree to provide a true copy of said escrow agreement to
CIMAB for its review and approval prior to the execution of same, provided that
such approval shall not be unreasonably withheld.

            5.9.1 As to each payment to be made by the Escrowee, TARCANTA or
TARCANTA LTD. shall advise the Escrowee as to whether the payment is required to
be made under this Agreement by payment for Barter Goods, or by Payment in Cash
to CIMAB, and the Escrowee shall act accordingly.

            5.9.2 The Escrowee and TARCANTA or TARCANTA LTD. shall each notify
CIMAB in writing of the transfer and receipt, respectively, of transfers to the
Holding Account and the amounts thereof.

            5.9.3 TARCANTA and TARCANTA LTD. shall maintain the Holding
Agreement in effect during the term of this Agreement.

            5.9.4 TARCANTA and TARCANTA LTD. shall be entitled to receive any
interest earned on the Holding Account as it is earned.

            5.9.5 TARCANTA and TARCANTA LTD. shall transfer funds to the Holding
Account according to the following schedule, provided, however, that CIMAB shall
have no

                                       24
<PAGE>

                                                                    CONFIDENTIAL

right or interest in these funds until the milestone is achieved and the funds
are transferred into the Barter Escrow Account, or paid in cash, as provided for
in this Agreement:

<TABLE>
<CAPTION>
                       EVENT                                   PAYMENT (US$)                 TIMING OF HOLDING ACCOUNT DEPOSIT
<S>                                                            <C>                        <C>
Upon the execution of this Agreement by all Parties.              [***]                   Not applicable.

Upon the transfer by CIMAB and acceptance by TARCANTA             [***]                   Within 30 days after
and/or TARCANTA LTD. of all documentation related to the                                  the Effective Date.
Transferred Assets, which acceptance may not be
unreasonably withheld.

Upon the transfer by CIMAB and acceptance by TARCANTA             [***]                   Within 30 days after
and/or TARCANTA LTD. of the biological materials                                          the Effective Date.
comprising the Transferred Assets, which acceptance may
not be unreasonably withheld.

Upon the approval by the FDA of the first IND Submission          [***]                   Upon the filing of the
by TARCANTA and/or TARCANTA LTD. for a Phase 2 clinical                                   first IND for the Licensed
trial of the Licensed Products.                                                           Products with FDA by TARCANTA and/or
                                                                                          TARCANTA LTD.

Upon the completion by TARCANTA and/or TARCANTA LTD. of           [***]                   Upon the initiation of the first
the first Phase 2 clinical trial of the Licensed                                          Phase 2 clinical trial for the
Products, provided that such Phase 2 clinical trial                                       Licensed Products by TARCANTA and/or
evidences, to TARCANTA and TARCANTA LTD.'s reasonable                                     TARCANTA LTD.
satisfaction, anti-tumor effects in advanced cancer
patients, as measured by: (i) objective evidence of
tumor reduction; and/or (ii) a statistically significant
increase in survival times compared with historical
control of patients with the same tumor localization and
clinical stage.

Upon the submission by TARCANTA and/or TARCANTA LTD. to           [***]                   Upon the initiation by TARCANTA
the FDA of the first BLA for the Licensed Products.                                       and/or TARCANTA LTD. of the first
                                                                                          Phase 3 (pivotal) clinical trial of
                                                                                          the Licensed Products.

Upon the approval by the FDA of the first BLA submitted           [***]                   Upon filing by TARCANTA and/or
by TARCANTA and/or TARCANTA LTD. for the Licensed                                         TARCANTA LTD. of the first BLA for
Products.                                                                                 the Licensed Products with FDA

Upon the approval by FDA of any subsequent                        [***]                   Upon filing by TARCANTA
</TABLE>

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       25
<PAGE>

                                                                    CONFIDENTIAL

<TABLE>
<S>                                                               <C>                     <C>
BLA submitted by TARCANTA and/or TARCANTA LTD.                                            of each such subsequent BLA for the
for the Licensed Products.                                                                Licensed Products with FDA (if any).

Upon the approval by the Governmental Authority of the            [***]                   Upon filing by TARCANTA and/or
European Union (EU) of the first license application                                      TARCANTA LTD. of the first market
submitted by TARCANTA and/or TARCANTA LTD. to market the                                  application for the Licensed
Licensed Products in the EU.                                                              Products in the EU

Upon the approval by the Governmental Authority of Japan          [***]                   Upon filing by TARCANTA and/or
of the first license application to market the Licensed                                   TARCANTA LTD. of the first market
Products submitted by TARCANTA and/or TARCANTA LTD. in                                    application for the Licensed
Japan.                                                                                    Products in Japan

At the first time sales by TARCANTA, TARCANTA LTD. and            [***]                   Not applicable.
their Affiliates of the Licensed Products in the
Territory equal a total of [***].

Royalties for Other Countries.                                    [***]                   As marketing approval is received
                                                                                          by TARCANTA and/or TARCANTA LTD.
                                                                                          for each of the Other Countries,
                                                                                          a balance of approximately 3 months
                                                                                          estimated Royalties shall be
                                                                                          maintained in the Escrow Account.
</TABLE>

      5.9.6 Notwithstanding any other provision of this Agreement to the
contrary, if CIMAB does not receive timely payment of its sixty-five percent
(65%) portion of the initial [***] Technology Transfer Fee payable upon the
execution of this Agreement by all Parties (which is payable to CIMAB 100% in
Barter), CIMAB may terminate this Agreement. TARCANTA and/or TARCANTA LTD.'s
failure to make any of the deposits into the Holding Account in the amounts and
at the times required by the schedule set out in Section 5.7.5 shall be subject
to CIMAB's rights and remedies as set forth in Section 12.3.

            5.9.7 TARCANTA and/or TARCANTA LTD.'s transfer of funds to the
Holding Account as required by this Agreement or otherwise shall not constitute
payment to CIMAB or discharge of any of TARCANTA and/or TARCANTA LTD.'s
obligations under this Agreement to make payment to CIMAB (whether by payments
for Barter Goods or for Payments in Cash). The failure of the Escrowee to make
payments for Barter Goods or to CIMAB for Payment in Cash, shall not constitute
any excuse for TARCANTA or TARCANTA LTD.'s failure to make the payments required
by this Agreement.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       26
<PAGE>

                                                                    CONFIDENTIAL

      5.10 Taxes and Withholding All payments under this Agreement will be made
without any deduction or withholding for or on account of any tax unless such
deduction or withholding is required by Applicable Laws. If the paying Operating
Party is so required to deduct or withhold, such Operating Party will (i)
promptly notify the other Operating Party of such requirement, (ii) pay to the
relevant authorities the full amount required to be deducted or withheld
promptly upon the earlier of determining that such deduction or withholding is
required or receiving notice that such amount has been assessed against the
other Operating Party, (iii) promptly forward to the other Operating Party an
official receipt (or certified copy) or other documentation reasonably
acceptable to the other Operating Party evidencing such payment to such
authorities.

      5.11 Currency. All payments and calculations hereunder shall be in Euros
in an amount equivalent to the amount due in U.S. dollars at the exchange rate
offered by the Bank of America on the date upon which payment is due, provided,
however, that in the event that CIMAB is prevented from receiving payment in
Euros by Applicable Laws, CIMAB may, during the period when such laws are in
effect, designate that all subsequent payments shall be in another currency
designated by CIMAB, provided further, however, that such other currency shall
not be any currency of Cuba. As applicable, Net Sales and expenses incurred by
either Operating Party shall be translated into U.S. dollars in accordance with
TARCANTA's customary and usual translation procedures, consistently applied.,
provided, however, that Net Sales received by TARCANTA or TARCANTA LTD. in Euros
shall not be translated into U.S. dollars, but shall be paid as a percentage of
Euros received in accordance with the terms of this Agreement.

      5.12 Payments

            5.12.1. Payments in Cash. TARCANTA and/or TARCANTA LTD. shall direct
the Escrowee to make the Payments in Cash from the Barter Escrow Account to
CIMAB by wire transfer of immediately available funds to an account at a bank in
a Third Country reasonably designated by CIMAB from time to time in writing, and
payments in cash to YMB by wire transfer of immediately available funds to an
account at a bank in a Third Country reasonably designated by YMB from time to
time in writing. TARCANTA LTD. shall so direct the Escrowee promptly upon the
Barter Escrow Account receiving funds to be used for Payments in Cash.

            5.12.2. If any sum due and payable under this Agreement shall not
have been paid or, as applicable, deposited in the Holding Account or the Barter
Escrow Account, on or before the applicable due date, compound interest shall
accrue on the unpaid amount at the rate of one percent (1%) per month or, if
less, the maximum rate permitted under applicable law from the payment due date,
until the actual date of payment without prejudice to any other claim or remedy
available to the non-paying Party.

                                       27
<PAGE>

                                                                    CONFIDENTIAL

      5.12.3 Payments into Barter Escrow Account. Where this Agreement provides
for payments into the Barter Escrow Account, TARCANTA and/or TARCANTA LTD. shall
be responsible for all amounts due for payment into the Barter Escrow Account
when due under this Agreement, which shall be accomplished by either direct
payment by TARCANTA or TARCANTA LTD. into the Barter Escrow Account or by
payment of the amount due into the Barter Escrow Account by the Holding Account
escrowee. The funds in the Barter Escrow Account shall only be used to carry out
CIMAB's purchase of Barter Goods from U.S. sources or to make Payment in Cash to
CIMAB, in accordance with the terms of this Agreement. Whenever CIMAB intends to
purchase Barter Goods using the funds deposited in the Barter Escrow Account,
CIMAB shall provide the escrow agent at the bank at which the Barter Escrow
Account is maintained and TARCANTA LTD. with a purchase order to a Third Party
supplier of Barter Goods that identifies the Barter Goods being purchased. Upon
confirmation by TARCANTA LTD. to the bank and its escrow agent that the goods
listed on the purchase order conform to the definition of Barter Goods, and upon
further confirmation by the bank and its escrow agent that CIMAB has declared on
such purchase order that said Barter Goods are to be used for public health
purposes of the Cuban people, the bank and its escrow agent shall pay the Third
Party supplier in accordance with its invoice for the sale of the items
identified on the purchase order by transfer of funds, or honoring the
presentation of drafts, to or at the order of the Third Party supplier. Prior to
the initial payments into the Barter Escrow Account, TARCANTA or TARCANTA LTD.
shall determine that the bank at which the Barter Escrow Account is maintained
has obligated itself to act in accordance with the foregoing procedures
concerning use of the funds in the Barter Escrow Account, and shall be entitled
to determine from time to time that this obligation remains in effect. The
Barter Escrow Account shall be opened and maintained at Citibank International
plc, London, England, or such other bank as may be mutually agreeable to the
Operating Parties, and TARCANTA and/or TARCANTA LTD. will pay the fees required
to establish and maintain the Barter Escrow Account, including fees payable for
the services of the escrow agent. CIMAB will be entitled to all interest on the
funds deposited into the Barter Escrow Account, which interest shall also be
payable in Bartered Goods. CIMAB shall be entitled to request that TARCANTA and
TARCANTA LTD. transfer the Barter Escrow Account to another first class bank
that is not a Cuban national, provided, however, that (a) such bank is a
financial institution that is a U.S. bank, a foreign subsidiary or branch of a
U.S. bank, or a bank that is owned or controlled by a U.S. bank, (b) TARCANTA or
TARCANTA LTD. determines that the successor bank has obligated itself to operate
the account as set forth herein, and (c) such transfer shall not cause TARCANTA
or TARCANTA LTD. to pay additional taxes in connection with the transfer of
funds to, or the maintenance of, such account. Use of the funds in the Barter
Escrow Account for the purchase of Barter Goods under this Section 5.12.3 shall
include the purchase of Barter Goods, as well as for shipping and insurance
costs for delivery of said goods to CIMAB in Cuba. The escrow agent of the bank
shall be appointed by the bank with the consent of CIMAB, TARCANTA and TARCANTA
LTD., and shall be a national of any country in the European Union.

            5.12.4 Immediately upon U.S. law, and/or the U.S. Treasury
Department's Office of Foreign Assets Control, permitting payments required by
this Agreement to be made into the Barter Escrow Account to be made instead in
Cash to CIMAB, all payments required by this Agreement to be made into the
Barter Escrow Account shall instead be made in Cash directly to

                                       28
<PAGE>

                                                                    CONFIDENTIAL

CIMAB. Immediately upon U.S. law, or the U.S. Treasury Department's Office of
Foreign Assets Control, removing any restrictions on Cuban nationals engaging in
the transactions that, under the express terms of this Agreement, Cuban
nationals are disqualified from undertaking, such disqualifications shall be
deemed to have been eliminated from this Agreement.

            5.12.5 In the event that U.S. law, or the decisions or orders of
U.S. government authorities, prevents CIMAB from actually receiving any of the
payments required to be paid to CIMAB under this Agreement, or prevents payment
into the Holding Account or the Barter Escrow Account, as required under this
Agreement, including without limitation payments required under this Article 5,
Article 6 and Article 7, or prevents the purchase of Bartered Goods by use of
funds in the Barter Escrow Account, or in the event of any change in United
States law or administrative practice that makes it impermissible for Cuban
nationals, or CIMAB, to purchase and import into Cuba Bartered Goods (which
circumstances hereafter in this Section 5.10.4 are described for convenience as
"the Event") CIMAB may, in its reasonable discretion, exercise the following
options:

      (a) Upon occurrence of the Event, CIMAB may immediately suspend
fulfillment of any orders for the Licensed Products under this Agreement for the
Territory until such time as it is able to receive all payments required by this
Agreement. If CIMAB exercises this option, TARCANTA and TARCANTA LTD. will have
the right to manufacture additional quantities of Licensed Products to make up
for any shortfall.

      (b) If, after six months of its occurrence, the Event continues in effect,
CIMAB and YMB shall be entitled to Royalties on account of sales of the Licensed
Products in the Other Countries at the rate of [***] of Net Sales, with
sixty-five percent (65%) of such Royalties payable to CIMAB and thirty-five
percent (35%) payable to YMB.

      (c) In addition, between six (6) months and one (1) year following the
occurrence of the Event, TARCANTA or TARCANTA LTD. may transfer its rights and
obligations under this Agreement with respect to the Other Countries and Mexico
to a Third Party to be designated by TARCANTA or TARCANTA LTD. and approved by
CIMAB, such approval will be subject to the same provisions set forth in Section
2.2.

      (d) In addition, if, after one (1) year of the occurrence of the Event,
the Event prevents actual receipt outside the U.S. in the bank in a Third
Country designated pursuant to Section 5.12.1, or to the Barter Escrow Account,
as applicable, of payment of Royalties for Licensed Products from the Other
Countries, or prevents the purchase of Bartered Goods by use of funds in the
Barter Escrow Account, or prevents Cuban nationals or CIMAB from purchasing and
importing into Cuba Bartered Goods, (i) TARCANTA and TARCANTA LTD. shall retain
all rights and obligations granted under this Agreement with respect to the U.S.
and Canada, (ii) CIMAB may terminate all licenses to TARCANTA and TARCANTA LTD.
under the Licensed Patent Rights, the Licensed Know-How, and the Improvements to
make, have made, use, offer for sale, market, sell, and import the Licensed
Product in the Other Countries and Mexico, and all other rights under this
Agreement associated with the using, offering for sale, marketing, selling and
importing in the Other Countries and Mexico granted by, under or pursuant to
this

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       29
<PAGE>

                                                                    CONFIDENTIAL

Agreement, and (iii) upon any such termination by CIMAB the CIMAB-CIMYM
Vaccine Agreement shall be deemed, as between CIMAB and CIMYM to have been
reinstated, unamended except as set forth in Section 2.1.2, above, and in full
force and effect as to all countries covered by said agreement except the U.S.
and Canada, without any further action by the parties thereto. Upon such
termination, all Regulatory Approvals and Regulatory Applications for the Other
Countries and Mexico shall be transferred, and shall be deemed transferred to,
CIMAB, as well as all data comprising preclinical and clinical studies performed
by TARCANTA, TARCANTA LTD. or their Affiliates in the Other Countries, to the
extent that the disclosure of any clinical study information is permitted under
Applicable Laws protecting the privacy of patients participating in such studies
and to the extent permitted under License number CU-73444 issued by the U.S.
Department of Treasury to CancerVax Corporation, or any subsequent modification
thereof. TARCANTA LTD. and TARCANTA shall provide all documents, and all
cooperation, as may be necessary to effectuate said transfers in a period of 3
months from the date of receiving the Notice of Termination as prescribed below.
A Notice of Termination pursuant to this paragraph, issued by CIMAB, shall be
deemed full and sufficient proof of termination by all Third Parties, who shall
be entitled fully to rely upon same.

      (e) CIMAB's termination of the license granted to TARCANTA LTD. and
TARCANTA with respect to the Other Countries and Mexico shall constitute
termination of any sublicense granted by TARCANTA LTD. and TARCANTA with respect
to the Other Countries and Mexico pursuant to the terminating license.

            5.12.6 In the event that the Event abates, any modifications in the
Royalty rates pursuant to Section 5.10.4 and the options exercised by CIMAB in
accordance with Section 5.10.4, if any, shall remain in effect until the
following condition has been satisfied: that CIMAB has received an amount equal
to the amount it would have received had the Event not occurred, together with
(a) compound interest thereon at the rate of one percent (1%) per month, or such
lesser amount as required under Applicable Law, and upon satisfaction of the
aforesaid condition, at TARCANTA LTD. or TARCANTA's option, the status quo ante
shall be restored, and this Agreement shall continue in effect according to its
terms until expiration of its term as stated in Section 12 without any tolling
of the Term or its earlier termination with respect to the rights of TARCANTA
LTD. and TARCANTA in the Other Countries and Mexico pursuant to this Agreement.
TARCANTA LTD. and TARCANTA shall exercise their option to restore the status quo
ante within 90 days of the "condition" specified in the first sentence of this
Section 5.10.5 being satisfied. The Operating Parties shall agree when the
condition set forth in the first sentence of this Section 5.10.5 shall have been
satisfied; pending the resolution of any dispute, pursuant to the Dispute
Resolution provisions or agreement, the condition set forth in the first
sentence of this paragraph shall be deemed not to have been satisfied.

            5.12.7 In the event that any order of any U.S. court asserting
competent jurisdiction (including without limitation, its federal and state
courts asserting such jurisdiction), issued on account of claims, judgments or
disputes that do not arise out of CIMAB's own activities, prevents CIMAB from
receiving Payments in Cash, or prevents payments into the Holding Account or
payments into the Barter Escrow Account under this Agreement, or prevents the
purchase of Barter Goods by use of the funds in the Barter Escrow Account, or
prevents

                                       30
<PAGE>

                                                                    CONFIDENTIAL

CIMAB from purchasing and importing into Cuba Barter Goods, which circumstances
hereafter in this Section 5.12.6 are described for convenience as "the Event",
then, CIMAB may, in its reasonable discretion, exercise the following options:

      (a) Upon the occurrence of the Event, CIMAB may immediately suspend
fulfillment of any of its obligations under this Agreement to supply the
Licensed Products for the Other Countries with respect to any jurisdiction in
which the aforesaid Court order is enforceable (hereafter, "affected
jurisdiction"). If CIMAB exercises this option, TARCANTA and TARCANTA LTD. will
have the right to manufacture additional quantities of Licensed Products to make
up for any shortfalls.

      (b) During the pendency of any litigation with respect to the aforesaid
court order, CIMAB and YMB shall be entitled to a royalty of [***] of Net Sales
from sales of the Licensed Products in the Other Countries, with sixty-five
percent (65%) of such Royalties payable to CIMAB and thirty-five percent (35%)
payable to YMB, except that this subparagraph (b) shall be inapplicable to
Royalties whose payment to CIMAB is prevented by the aforesaid Court order. In
the event that the litigation results in the withdrawal or termination of any
such order, and any funds that had not been paid to CIMAB as a result of said
Court order or decision are paid to CIMAB, TARCANTA and/or TARCANTA LTD. shall
be entitled to recover the additional amount paid to CIMAB and YMB under this
subparagraph, which recovery shall be taken first from any past due payments
released to CIMAB upon termination of the Court order and, if not sufficient, by
reduction of the Royalties payable to CIMAB and YMB by twenty-five percent
(25%), until the amount has been recovered.

      (c) If litigation, if any, is unsuccessful in terminating the Court order,
then, upon the final decision in such litigation:

            (i) CIMAB and YMB shall be entitled to a royalty of [***] of Net
Sales from sales of the Licensed Products in the Other Countries, with
sixty-five percent (65%) of such Royalties payable to CIMAB and thirty-five
percent (35%) payable to YMB, except that this subparagraph (c)(i) shall be
inapplicable to Royalties whose payment to CIMAB is prevented by the aforesaid
Court order;

            (ii) TARCANTA or TARCANTA LTD. may transfer the rights and
obligations under this Agreement in the Other Countries in affected jurisdiction
to a Third Party to be designated by TARCANTA or TARCANTA LTD. and approved by
CIMAB, with such approval subject to the same provisions set forth in Article
2.2.

            (iii) In addition, if, after one (1) year of its occurrence, the
Event prevents actual receipt of Payments in Cash outside of the U.S. in the
bank in a Third Country designated pursuant to Section 5.12.1, or payment into
to the Holding Account or payment into the Barter Escrow Account, of the payment
of Royalties with respect to the Other Countries due on account of sales of the
Licensed Products in any jurisdiction affected thereby, or prevents the purchase
of Barter Goods by use of the funds in the Barter Escrow Account, or prevents
CIMAB from purchasing and importing in to Cuba Bartered Goods TARCANTA and
TARCANTA LTD. shall

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       31
<PAGE>

                                                                    CONFIDENTIAL

retain all rights and obligations granted under this Agreement with respect to
the U.S. and Canada, but CIMAB may terminate the license under the Licensed
Patent Rights, the Licensed Know-How, and the Improvements to use, offer for
sale, market, sell, and import the Licensed Product in the Other Countries and
Mexico in the affected jurisdiction, granted by, under or pursuant to this
Agreement. Upon such termination, all Regulatory Approvals and Regulatory
Applications in the Other Countries and Mexico in the affected jurisdiction
shall be transferred, and shall be deemed transferred to, CIMAB, as well as all
data comprising preclinical and clinical studies performed by TARCANTA, TARCANTA
LTD. or their Affiliates in the Other Countries, to the extent that the
disclosure of any clinical study information is permitted under Applicable Laws
protecting the privacy of patients participating in such studies. TARCANTA
and/or TARCANTA LTD. shall provide all documents, and all cooperation, as may be
necessary to effectuate said transfers in a period of 3 months from the date of
receiving the Notice of Termination as prescribed below. A Notice of Termination
pursuant to this paragraph, issued by CIMAB, shall be deemed full and sufficient
proof of termination by all Third Parties, who shall be entitled fully to rely
upon same.

            (iv) CIMAB's termination of the license granted to TARCANTA and
TARCANTA LTD. with respect to the Other Countries and Mexico shall constitute
termination of any sublicense granted by TARCANTA LTD. and TARCANTA with respect
to the Other Countries and Mexico pursuant to the terminating license and, upon
any such termination by CIMAB, the CIMAB-CIMYM Vaccine Agreement shall be
deemed, as between CIMAB and CIMYM to have been reinstated, unamended except as
set forth in Section 2.1.2, above, and in full force and effect as to all
countries covered by said agreement except the U.S. and Canada, without any
further action by the parties thereto.

      (d) In the event that, after the unsuccessful conclusion of the aforesaid
litigation, the Court order is vacated, extinguished, or expires, by reason of
satisfaction of the underlying judgment or claim or otherwise, any modifications
in Royalty rates pursuant to 5.12.7, and the options exercised by CIMAB in
accordance with 5.12.7, if any, shall remain in effect until CIMAB has received
an amount equal to the amount it would have received but for said Court order
(the "condition"). In the event the aforesaid condition is satisfied, at
TARCANTA LTD. and TARCANTA's option, the status quo ante shall be restored, and
this Agreement shall continue in effect according to its terms until expiration
of its Term as stated in Section 12 without any tolling or its earlier
termination, pursuant to this Agreement. TARCANTA LTD. and NEWNCVX-DE shall
exercise their option to restore the status quo ante within 90 days of the
"condition" specified in the first sentence of this paragraph being satisfied.
The Parties shall agree when the condition set forth in the first sentence of
this paragraph shall have been satisfied; pending the resolution of any dispute,
pursuant to the Dispute Resolution procedures, or otherwise the condition shall
be deemed not to have been satisfied.

            5.12.8 Notwithstanding the provisions of Section 5.12.7, in the
event that any Party, in good faith, believes that the Court order referenced in
Section 5.12.7 was issued by a Court lacking competent jurisdiction, both
parties will commit to join in litigation to overturn the court order as quickly
as possible and, CIMAB shall not be entitled to implement any of it's remedies
under Section 5.12.7 (b) and 5.12.7(c) for a period of six-months from the date
on

                                       32
<PAGE>

                                                                    CONFIDENTIAL

which the Court order was issued, and all Parties agree to join in litigation
and use their best efforts to seek a withdrawal of the Court order.

            5.12.9 In the event that any order of any court of the U.S. that
lacks competent jurisdiction, including without limitation, any U.S. federal and
state courts, issued on account of claims, judgments or disputes that do not
arise out of CIMAB's own activities, prevents actual receipt of Payments in Cash
outside of the U.S. in a bank in a Third Country designated pursuant to Section
5.12.1, or prevents payment into the Holding Account or the Barter Escrow
Account, required under this Agreement, or prevents the purchase of Barter Goods
by use of the funds in the Barter Escrow Account, or prevents CIMAB from
purchasing and importing into Cuba Barter Goods, then the Parties agree to use
Reasonable Commercial Efforts to secure the elimination of any such order as
quickly as possible.

            5.12.10 Notwithstanding any of the other provisions of Section 5.12,
in the event that U.S. law, or the decisions or orders of U.S. government
authorities, or any order of any U.S. court, prevents CIMAB from actually
receiving any of the payments required to be paid to CIMAB under this Agreement,
the obligations of TARCANTA and TARCANTA LTD. to make any payments to YMB in
accordance with the terms of this Agreement shall remain in full force and
effect.

      5.13 Books of Account. TARCANTA and TARCANTA LTD. shall keep and maintain
accurate and complete records and books of account in sufficient detail and form
so as to enable verification of the payments due to CIMAB under this Agreement.

      5.14 Audit Rights. TARCANTA and TARCANTA LTD. shall maintain records and
books of account relating to the Licensed Product for a period of not less than
seven (7) years following the year to which the records pertain. TARCANTA and
TARCANTA LTD. shall permit such records and books of account to be examined only
by independent certified public accountants selected by CIMAB who are qualified
in the application of U.S. generally accepted accounting principles ("GAAP"),
including without limitation independent certified public accountants who are
Cuban nationals. No more than one (1) such audit may be conducted by or on
behalf of CIMAB in any calendar year. All audits shall be conducted during
TARCANTA and TARCANTA LTD.'s normal business hours and only after reasonable
written prior notice. Without limitation, thirty (30) days prior written notice
shall be deemed reasonable notice. If the audit shows that TARCANTA or TARCANTA
LTD. owes a payment (including reimbursement of any previously overpaid amount)
to CIMAB under this Agreement, TARCANTA or TARCANTA LTD., as applicable, shall
promptly make such payment. The cost of such examination shall be borne by
CIMAB, unless such audit reveals that TARCANTA or TARCANTA LTD. underpaid CIMAB
by more than ten percent (10%), then TARCANTA or TARCANTA LTD. shall bear the
cost of such audit.

      5.15 Reports. Beginning after TARCANTA or TARCANTA LTD. has received a
Regulatory Approval to market the Licensed Product in the Territory, TARCANTA
and TARCANTA LTD. shall provide CIMAB with a report detailing all sales
activities for the

                                       33
<PAGE>

Licensed Products in the Territory during the preceding calendar quarter. Such
reports shall be provided to CIMAB within forty-five (45) days following the end
of each calendar quarter.

                                    ARTICLE 6

                   SUPPLY COMMITMENTS AND MANUFACTURING RIGHTS

      6.1 Supply Commitment

            6.1.1 Supply Commitment. CIMAB shall, at no additional cost to
TARCANTA or TARCANTA LTD., manufacture and supply all quantities of the Licensed
Products required by TARCANTA and TARCANTA LTD. for: (a) Phase 2 clinical trials
for all countries within the Territory; and (b) Phase 3 clinical trials in the
Other Countries. In order to ensure an adequate supply of Licensed Products to
complete the necessary clinical testing and, following the receipt of Regulatory
Approvals, for the uninterrupted supply of the Licensed Products to treat
patients in the U.S. and throughout the Territory, CIMAB agrees to manufacture
and supply, and TARCANTA and TARCANTA LTD. shall purchase from CIMAB, all
quantities of the Licensed Products required by TARCANTA, TARCANTA LTD. and
their Affiliates and Sublicensees for commercial sale in the Other Countries, at
a cost equal to the Transfer Price (as such term is defined below).

            6.1.2 Transfer Price. The Transfer Price for the Licensed Products
shall be [***] of any Net Sales, without deduction of the Cost of Goods Sold,
from the sale of the Licensed Products supplied by CIMAB. Should any purchases
of Licensed Products from CIMAB occur during the Development Phase, payment will
be 100% in Barter, whereas any such purchases during the Commercialization Phase
will be 50% in Barter and 50% in Payment in Cash. Royalties owed to CIMAB for
sale by TARCANTA and/or TARCANTA LTD. of Licensed Products during the
Development Phase shall be paid 100% in Barter.

            6.1.3 Failure to Supply by CIMAB. In the event that CIMAB is unable
to fully support TARCANTA LTD. and TARCANTA's quantity requirements for the
Licensed Products for the Other Countries, or in the event that CIMAB fails to
manufacture the Licensed Products in compliance with the Applicable Laws,
TARCANTA and TARCANTA LTD. shall have the right to manufacture the Licensed
Products to meet its quantity requirements or Applicable Law requirements, but
only to the extent that CIMAB is unable to satisfy TARCANTA LTD. and TARCANTA's
quantity requirements or requirements for Licensed Products in compliance with
Applicable Laws for the Other Countries. Once CIMAB demonstrates to TARCANTA and
TARCANTA LTD.'s reasonable satisfaction that it is able to fully support the
quantity requirements and to fully comply with the Applicable Laws, TARCANTA AND
TARCANTA LTD. shall increase its purchase of the Licensed Products to the extent
of CIMAB's ability to supply the Licensed Products. To the extent that TARCANTA
or TARCANTA LTD. supplies the Licensed Products for sale in the Other Countries
because CIMAB has not been able to manufacture sufficient quantities, or because
CIMAB has not complied with the Applicable

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       34
<PAGE>

                                                                    CONFIDENTIAL

Laws, the Royalty payable to CIMAB on such Licensed Products shall be increased
from [***] to [***] of Net Sales from the sale of such Licensed Products in the
Other Countries.

            6.1.4 Failure to Supply by TARCANTA and TARCANTA LTD. In the event
that TARCANTA or TARCANTA LTD. is unable to fully support quantity requirements
for the Licensed Product for the U.S., Canada and Mexico, or in the event that
TARCANTA or TARCANTA LTD. fails to manufacture the Licensed Product in
compliance with the Applicable Laws, and provided that CIMAB and its Contract
Manufacturer, if any, has been approved as a supplier under any BLA or other
Regulatory Approval relevant to such countries, CIMAB or its Contract
Manufacturer shall have the right to manufacture and TARCANTA and TARCANTA LTD.
shall have the obligation to purchase from CIMAB or its Contract Manufacturer,
the Licensed Products to meet quantity requirements or Applicable Law
requirements, but only to the extent that TARCANTA or TARCANTA LTD. is unable to
satisfy quantity requirements or Applicable Law requirements. Notwithstanding
the foregoing, neither TARCANTA nor TARCANTA LTD. shall be under any obligation
to bear any costs whatsoever associated with CIMAB or its Contract Manufacturer
becoming an approved supplier under any BLA or other Regulatory Approval
relevant to the U.S., Canada or Mexico. Once TARCANTA or TARCANTA LTD.
demonstrates that it is able to fully support the quantity requirements and to
fully comply with the Applicable Laws, TARCANTA or TARCANTA LTD. shall resume
supplying the Licensed Products to U.S., Canada and Mexico.

      6.2. Transfer of Transferred Assets and Licensed Know-How. CIMAB shall
transfer to TARCANTA or TARCANTA LTD. all rights, title and interest in and to
all of the Transferred Assets and Licensed Know-How owned or Controlled By CIMAB
that may be required by TARCANTA and TARCANTA LTD. to manufacture the Licensed
Products in accordance with the terms of this Agreement. All documentation and
information comprising the Transferred Assets and Licensed Know-How shall be
provided to TARCANTA or TARCANTA LTD. according to the technology transfer
protocol agreed upon by the Parties as part of the Development Plan. If
additional documentation related to the testing, manufacture or development of
the Licensed Product is developed by CIMAB or its Licensors during the term of
the Agreement, such additional information shall also be transferred promptly to
TARCANTA, TARCANTA LTD. and their Affiliates in a timely manner.

            6.2.1 Transfer of Transferred Assets and Licensed Know-How Related
to the Adjuvants. [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       35
<PAGE>

                                                                    CONFIDENTIAL

      6.3 Engagement of Contract Manufacturers. TARCANTA and TARCANTA LTD., on
the one hand, and CIMAB, on the other hand, each for its own account, may
contract with one or more Contract Manufacturers to Finish, manufacture and
supply Licensed Products to TARCANTA and TARCANTA LTD. and their Sublicensees,
if any, in accordance with the terms of this Agreement, provided, however, that
no assignment of rights to a Contract Manufacturer hereunder shall relieve
CIMAB, TARCANTA or TARCANTA LTD. of complying fully with their obligations under
this Agreement. TARCANTA, TARCANTA LTD. and CIMAB agree that all agreements
engaging a Contract Manufacturer shall provide, including, without limitation,
that the Contract Manufacturer will comply with (i) all Applicable Laws and all
specifications and manufacturing and quality control procedures for the
manufacture and quality assurance of the Licensed Products reasonably
established by TARCANTA and TARCANTA LTD., and (ii) the Confidentiality
provisions of this Agreement. Notwithstanding the foregoing, neither TARCANTA
nor TARCANTA LTD. shall be under any obligation to bear any costs whatsoever
associated with a Contract Manufacturer contracted by CIMAB becoming an approved
supplier under any BLA or other Regulatory Approval relevant to the Territory.

                                    ARTICLE 7

                              PURCHASING PROCEDURES

      7.1. Purchasing Procedures

                                       36
<PAGE>

                                                                    CONFIDENTIAL

            7.1.1 In order to afford CIMAB time to produce sufficient quantities
of the Licensed Product as required to treat cancer patients in the Other
Countries, TARCANTA, TARCANTA LTD. or their Sublicensees, if any, (hereafter.
"Importer" in this Article 7) shall, at least one hundred eighty (180) days
prior to the planned first commercial sale within the Other Countries, and
quarterly thereafter, TARCANTA LTD. or Sublicensee, if any, (hereafter
"Importer" in this Article) will provide CIMAB with a twelve (12) month rolling
forecast of its projected orders for Licensed Products in the Other Countries.
The Importer will guarantee the purchase of seventy-five percent (75%) of the
quantity specified for the first ninety (90) days of each such forecast (the
"Firm Commitment Quantities").

            7.1.2. CIMAB or its Contract Manufacturer, if any, shall notify the
Importer of its acceptance or rejection of a Purchase Order within ten (10)
business days after CIMAB's receipt of the Purchase Order. CIMAB shall promptly
notify the Importer in writing if CIMAB believes, or has reason to believe, that
CIMAB will be unable to supply the Importer with at least the Firm Commitment
Quantities of Licensed Products. CIMAB shall use Reasonable Commercial Efforts
to manufacture one hundred twenty-five percent (125%) of the Importer's rolling
six (6) month forecasted amounts.

            7.1.3. Purchase Order. The Importer shall submit to CIMAB purchase
orders for the Licensed Product ("Purchase Orders"), consistent with the
Importer's forecasts, at least forty-five (45) days before the Delivery Date set
forth in the forecast. Each Purchase Order shall specify:

            (a) the Licensed Products to be delivered and its planned use, i.e.,
whether the Importer intends to use the Licensed Products for clinical trials or
commercial sale;

            (b) the quantity of each Licensed Product to be delivered, whether
the Licensed Products being ordered shall be provided in bulk packaging or
final, end-user packaging configuration, and the specific labeling required to
be affixed to the Licensed Product;

            (c) the Importer's required date of delivery of such Licensed
Products (the "Delivery Date"), provided, however, that in no event shall the
Delivery Date be sooner than thirty (30) days after CIMAB receives the Purchase
Order;

            (d) the location to which such Licensed Products are to be delivered
(the "Delivery Location(s)"); and

            (e) the name, address and phone number of the person to receive the
notice of receipt.

      7.2 Payment, Delivery and Title. CIMAB shall deliver the Licensed Products
to the Importer at the Delivery Location in the quantities and at the Delivery
Dates set forth in any Purchase Order and the acceptance notice related thereto.
Subject to the provisions of Section 7.6, all Licensed Product delivered to the
Importer shall be non-returnable. Title and risk of loss in the Licensed
Products shall transfer to the Importer upon delivery of the Licensed Products
to

                                       37
<PAGE>

                                                                    CONFIDENTIAL

a carrier outside of Cuba specified by the Importer for delivery to the
Delivery Location. Payment by the Importer to CIMAB for the Licensed Products
shall be net 30 days following delivery to the Delivery Location, and shall be
payable 100% in Barter during the Development Phase, and 50% in Barter and 50%
in Payment in Cash during the Commercialization Phase.

      7.3. Packaging. CIMAB shall deliver the Licensed Product to the Importer
in packaging specified by the Importer.

      7.4. Shipping by CIMAB. At the instruction of the Importer as set forth in
a Purchase Order, CIMAB shall arrange, in coordination with the Importer, for
shipment to the Delivery Location, and all expenses related thereto shall be
borne by the Importer. CIMAB shall deliver monthly invoices to Importer for the
costs and fees in connection with the shipment of the Licensed Products to
Importer.

      7.5 Standard Terms. It is understood that, for convenience, use is
permitted of standard pre-printed forms of the Purchase Orders, acknowledgement
or acceptances, or invoices in the performance of obligations hereunder;
provided that any terms, conditions or provisions in such pre-printed forms
which are inconsistent with or which modify or supplement this Agreement shall
be null and void.

      7.6. Order Non-Conformance.

            7.6.1 In the event the Importer disputes the quantity of a Licensed
Product in any shipment of any Licensed Product supplied to the Importer
pursuant to this Agreement, Importer shall provide notice to CIMAB within sixty
(60) days after receipt of such shipment. In the case of any non-conformity that
results from delivery of less than the ordered quantity of Licensed Product,
CIMAB shall promptly deliver the undelivered portion of the ordered quantity of
such Licensed Product to the Importer. In such case, the Importer shall pay for
the quantity actually received. In the case of any non-conformity that results
from delivery of more than the ordered quantity of any Licensed Product, the
Importer may elect to (i) return to CIMAB any Licensed Product in excess of the
quantity of such Licensed Product ordered, or (ii) accept any Licensed Product
in excess of the quantity ordered as an offset against any future order(s) of
such Licensed Product, in which case the Importer shall pay for the quantity
actually received and accepted.

            7.6.2 In the event that the Importer disputes any invoice due to
non-conformance of any Licensed Product supplied by CIMAB with the
Specifications for such Licensed Product, such dispute shall be resolved in
accordance with the Dispute Resolution procedures. Pending resolution of such
dispute, the Importer shall pay any undisputed amount of such invoice. Upon
resolution of any such dispute in favor of CIMAB, the Importer shall pay the
unpaid disputed amount properly due within twenty (20) business days of such
resolution, together with, if applicable, interest on such amount from the date
payment would otherwise have been due at the rate of 1% per month, or such
lesser amount as required under Applicable Law. Upon resolution of any such
dispute in favor of the Importer, CIMAB shall refund any excess amounts paid by
the Importer to the Importer within thirty (30) days of such resolution.

                                       38
<PAGE>

                                                                    CONFIDENTIAL

      7.7 Records. CIMAB shall maintain, and shall cause its Affiliates and
agents to maintain, all records necessary to comply with all Applicable Laws
relating to the manufacture, filling, packaging, testing, storage and shipment
of Licensed Product. All such records shall be maintained for such period as may
be required by Applicable Laws.

      7.8 Quality Agreement. Concurrent with the execution of this Agreement,
the Operating Parties agree to enter in to a Quality Agreement in the form
attached hereto as Exhibit C.

                                    ARTICLE 8

                      PRODUCT WARRANTY AND NON-CONFORMANCE

      8.1 Licensed Product Warranty by CIMAB. CIMAB represents and warrants
that, upon delivery of any Licensed Product to the Delivery Location, such
Licensed Product will have been manufactured, filled, packaged, stored and
shipped materially in accordance with the Specifications for such Licensed
Product, applicable Regulatory Approvals and all Applicable Laws. CIMAB shall be
responsible for obtaining and maintaining all necessary licenses, permits or
approvals required by Applicable Laws in connection with the manufacture,
filling, package, testing, storage, and shipment of each such Licensed Product,
including, without limitation, permits related to manufacturing facilities.
TARCANTA LTD. and TARCANTA shall be responsible for obtaining all necessary
import licenses, permits or approvals required by Applicable Laws, other than
Cuban law, for the importation of each such Licensed Product into the Other
Countries as requested by TARCANTA LTD. and TARCANTA.

      8.2. Licensed Product Warranty by TARCANTA. TARCANTA and TARCANTA LTD.
represent and warrant that any Licensed Product manufactured by TARCANTA,
TARCANTA LTD. or their Sublicensees, if any, will have been manufactured,
filled, packaged, stored and shipped materially in accordance with the
Specifications for such Licensed Product, applicable Regulatory Approvals and
all Applicable Laws.

      8.3. Licensed Product Non-Conformance

            8.3.1. TARCANTA and/or TARCANTA LTD. may elect in their discretion
to conduct laboratory testing and other chemical analyses of any shipment of
Licensed Product. If TARCANTA or TARCANTA LTD. reasonably determines that any
shipment of Licensed Product does not conform to the Specifications for such
Licensed Product, TARCANTA or TARCANTA LTD. shall give CIMAB notice thereof
(including a sample from such shipment and copies of the results of any testing
supporting TARCANTA or TARCANTA LTD.'s determination) within sixty (60) days
after receipt thereof. If CIMAB confirms such non-conformity, it shall promptly
so notify TARCANTA and TARCANTA LTD. If CIMAB does not confirm such
non-conformity, it shall promptly notify TARCANTA and TARCANTA LTD., and the
Parties shall promptly submit samples of such disputed shipment for testing to
an

                                       39
<PAGE>

                                                                    CONFIDENTIAL

independent testing laboratory in the Territory or other independent Third
Party expert in the Territory that is mutually acceptable to the Parties. The
findings of the testing laboratory or Third Party expert shall be binding on the
Parties. The expenses of such testing or other investigation shall be borne by
CIMAB if the non-conformity is confirmed, and otherwise by TARCANTA or TARCANTA
LTD.

            8.3.2. If any Licensed Product upon delivery to the Delivery
Location, does not conform to the warranty provided in Section 8.1 for any
reason other than the willful or negligent acts or omissions of the Importer or
its customers or agents, CIMAB shall credit the Importer with the price for such
non-conforming Licensed Product and a credit for the Importer's actual
out-of-pocket costs for return of such Licensed Product to CIMAB. Thereafter,
CIMAB shall promptly replace the non-conforming Licensed Product with substitute
conforming Licensed Product.

      8.4. Safety Procedures. CIMAB, TARCANTA and TARCANTA LTD. shall maintain
and enforce health and safety procedures for the handling and manufacture of
Licensed Product that comply in all respects with all Applicable Laws.

      8.5. Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 8, NEITHER
CIMAB, TARCANTA NOR TARCANTA LTD. MAKE ANY REPRESENTATIONS OR WARRANTIES OF ANY
KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, INCLUDING, WITHOUT
LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY, WARRANTY OF FITNESS FOR A
PARTICULAR PURPOSE, OR WARRANTY OF NON- INFRINGEMENT.

                                    ARTICLE 9

                    REPRESENTATIONS, WARRANTIES AND COVENANTS

      9.1. Representations and Warranties of the Parties. Each Party represents
and warrants to the other Parties that:

      (a) Such Party is duly organized and validly existing and in good standing
under the laws of the jurisdiction of its organization.

      (b) Such Party has the full corporate power and is duly authorized to
enter into, execute and deliver this Agreement, and to carry out and otherwise
perform its obligations thereunder.

      (c) This Agreement has been duly executed and delivered by, and is the
legal and valid obligations binding upon such Party and the entry into, the
execution and delivery of, and the carrying out and other performance of its
obligations under this Agreement by such Party (i) does not conflict with, or
contravene or constitute any default under, any agreement, instrument or
understanding, oral or written, to which it is a Party, including, without
limitation

                                       40
<PAGE>

                                                                    CONFIDENTIAL

its certificate of incorporation or by-laws, and (ii) does not violate
Applicable Law or any judgment, injunction, order or decree of any Government
Authority having jurisdiction over it.

      9.2. Representations and Warranties of CIMAB. CIMAB represents and
warrants to TARCANTA and TARCANTA LTD. that:

      (a) As of the Effective Date, Exhibit A contains a complete and accurate
list of all intellectual property owned or Controlled By CIMAB or its Licensors
that comprises the Licensed Patent Rights, and CIMAB owns or controls all of the
Licensed Patent Rights listed therein and all of the Licensed Know-How;

      (b) The License and Supply Agreement with CIM and the License and Supply
Agreement with HEBER BIOTEC attached hereto as Exhibits D and E, respectively,
are full, true and correct English translations of said agreements; such
agreements are currently, and shall remain in full force and affect, without
amendment, throughout the Term of this Agreement, unless agreed to the contrary
in writing by the Parties; and CIMAB's execution, delivery and performance of
this Agreement and all other agreements contemplated thereby will not result in
any such violation, or be in conflict with or constitute, with or without the
passage of time and giving of notice, either a default under any such provision,
instrument, judgment, order, writ, decree or contract or an event that results
in the creation of any lien, charge or encumbrance upon any assets of CIMAB or
the suspension, revocation, impairment, forfeiture or non-renewal of any permit,
license, authorization or approval applicable to CIMAB, its business or
operations or any of its assets or properties .

      (c) As of the Effective Date, there are no claims, whether legal,
administrative, or regulatory, that are threatened, commenced or pending against
the Licensed Patent Rights or the Licensed Know-How; and CIMAB or the licensors
of the Licensed Patent Rights have taken all necessary and desirable actions to
maintain and protect the Licensed Patent Rights and the Licensed Patent Rights
are currently in compliance in all material respects with all applicable legal
requirements (including timely payment of filing, examination and maintenance
fees). CIMAB's Licensors and CIMAB have taken all necessary and desirable
actions to maintain and protect the Licensed Patent Rights that are subject to
such licenses.

      (d) Neither CIMAB nor its Licensors have received any written notice or
claim, and there have been no claims made against the Licensed Patent Rights or
the licensors of any such rights, asserting the invalidity, misuse or
unenforceability of the Licensed Patent Rights, and there are no valid grounds
for the same.

      (e) None of the Licensed Patent Rights are involved in any interference,
reissue, reexamination, opposition or cancellation proceeding or any other
material litigation or proceeding of any kind in the U.S.U.S. or in any other
jurisdiction in the Territory.

      (f) Neither CIMAB nor its Licensors are parties to any action or
proceeding that involves a claim of infringement, misappropriation or other
wrongful use or exploitation of any of the Licensed Patent Rights. Neither CIMAB
nor its Licensors have received any notices of,

                                       41
<PAGE>

                                                                    CONFIDENTIAL

nor are they aware of any facts which indicate a likelihood of any infringement
or misappropriation by, or conflict with, any Third Party with respect to
Licensed Patent Rights (including, without limitation, any demand or request
that CIMAB or its licensors license any intellectual property rights from or to
a Third Party).

      (g) CIMAB maintains and shall maintain throughout the term of this
Agreement a work force suitably qualified and trained, and facilities and
equipment sufficient, to enable it to perform its obligations as set forth under
this Agreement.

      (h) CIMAB and its Licensors represents and warrants that, to the best of
their knowledge, the making, using, offer for sale and sale of any of the
Licensed Products in any Territory does not infringe or interfere with any
patent, patent application or other intellectual property right of any third
party.

      (i) CIMAB hereby represents and warrants that this project will be carried
out without the use, lease, purchase or other involvement of any confiscated
U.S. property in Cuba.

      9.3 Representations and Warranties of TARCANTA and TARCANTA LTD.

      (a) ARCANTA and TARCANTA LTD. represent and warrant to CIMAB that the
financial statements of their Affiliate, CancerVax Corporation, filed with the
U.S. Securities and Exchange Commission by CancerVax Corporation in its
Quarterly Report on Form 10-Q for the period ending March 31, 2004, were, to the
best of their knowledge as of the Effective Date, true and correct on the date
of the filing of said document with the U.S. Securities and Exchange Commission,
and that there has been no material change thereto that would materially
adversely impact TARCANTA or TARCANTA LTD.'s capacity to carry out the terms of
this Agreement.

      (b) TARCANTA maintains and shall maintain throughout the term of this
Agreement a work force suitably qualified and trained, and facilities and
equipment sufficient, to enable it to perform its obligations as set forth under
this Agreement.

      9.4. Representations and Warranties of YMB and CIMYM. YMB and CIMYM
represent and warrant to CIMAB, TARCANTA and TARCANTA LTD. that:

      (a) YMB and CIMYM shall timely provide TARCANTA, TARCANTA LTD. and CIMAB
with copies of all written data, documentation, information, correspondence,
reports, test results, summaries, analyses and opinions with respect to: (i)
pre-clinical testing and clinical trials (including without limitation copies of
clinical report forms); (ii) the prosecution of patent applications; and (iii)
Regulatory Applications, developed by or on behalf of CIMYM and/or YMB in
relation to the Licensed Products and the EGF Vaccine licensed to CIMYM under
the CIMAB-CIMYM Vaccine Agreement prior to the Effective Date

      (b) YMB and CIMYM's execution, delivery and performance of this Agreement
and all other agreements contemplated thereby will not result in any violation,
or be in conflict with or constitute, with or without the passage of time and
giving of notice, either a default under any

                                       42
<PAGE>

                                                                    CONFIDENTIAL

such provision, instrument, judgment, order, writ, decree or contract or an
event that results in the creation of any lien, charge or encumbrance upon any
assets of CIMAB or the suspension, revocation, impairment, forfeiture or
non-renewal of any permit, license, authorization or approval applicable to
CIMAB, its business or operations or any of its assets or properties.

      (c) As of the Effective Date, there are no pending claims, whether legal,
administrative, or regulatory, that are threatened, commenced or pending against
the Licensed Patent Rights or the Licensed Know-How; and YMB and CIMYM have
taken all necessary and desirable actions to maintain and protect the Licensed
Patent Rights and the Licensed Patent Rights within the Territory and are
currently in compliance in all material respects with all applicable legal
requirements (including timely payment of filing, examination and maintenance
fees).

      (d) Neither YMB nor CIMYM have received any written notice or claim, and
there have been no claims made against the Licensed Patent Rights or the
licensors of any such rights, asserting the invalidity, misuse or
unenforceability of the Licensed Patent Rights, and there are no valid grounds
for the same.

      (e) None of the Licensed Patent Rights are involved in any interference,
reissue, reexamination, opposition or cancellation proceeding or any other
material litigation or proceeding of any kind in the U.S. or in any other
jurisdiction in the Territory.

      (f) Neither YMB nor CIMYM are parties to any action or proceeding that
involves a claim of infringement, misappropriation or other wrongful use or
exploitation of any of the Licensed Patent Rights within the Territory. Neither
YMB nor CIMYM have received any notices of, nor are they aware of any facts
which indicate a likelihood of any infringement or misappropriation by, or
conflict with, any Third Party with respect to Licensed Patent Rights
(including, without limitation, any demand or request that CIMAB, YMB or CIMYM
license any intellectual property rights from or to a Third Party).

                                   ARTICLE 10

                          INTELLECTUAL PROPERTY MATTERS

      10. 1. Ownership of Intellectual Property. As between the Parties, subject
only to the licenses and covenants set forth herein, CIMAB and its Licensors
shall retain all right, title and interest in and to the Licensed Patent Rights
and the Licensed Know-How, and CIMAB, TARCANTA and TARCANTA LTD. shall jointly
own all Improvements. For the purpose of clarification, except as expressly set
forth in this Agreement, no right, license or interest is granted by either
Party to the other Party, expressly or impliedly, under any of such Party's
respective intellectual property. CIMAB, TARCANTA and TARCANTA LTD., and their
Affiliates and Sublicensees, may use any of the Improvements, during and after
the Term of this Agreement, without payment of any royalty, fee or consideration
to one another.

                                       43
<PAGE>

                                                                    CONFIDENTIAL

      10.2 Ownership of Regulatory Applications and Regulatory Approvals:

            10.2.1 In the Territory, TARCANTA and/or TARCANTA LTD. shall own all
right, title and interest in all Regulatory Applications necessary to obtain
Regulatory Approvals required to conduct clinical trials for Licensed Product or
for marketing and sale of Licensed Product, together with any Regulatory
Approval obtained in connection therewith. All Regulatory Applications in the
Territory, together with any Regulatory Approvals obtained in connection
therewith, shall be filed in the name of TARCANTA or TARCANTA LTD.

            10.2.2 Each Party shall retain ownership and control of any of its
Confidential Information included in any Regulatory Application. Notwithstanding
the previous sentence, each Party agrees that it shall, except as restricted
under License number CU-73444 issued by the U.S. Department of Treasury to
CancerVax Corporation, or any subsequent modification thereof, not withhold from
the other Party any Confidential Information necessary for the filing,
maintenance, modification or protection of any Regulatory Application by such
other Party, or as required under any reporting obligation under the Applicable
Laws.

      10.3 Prosecution and Maintenance of Licensed Patent Rights. Except as
otherwise agreed by the Parties, beginning on the Effective Date, TARCANTA and
TARCANTA LTD. shall be responsible for the preparation, filing, prosecution and
maintenance of any and all patent applications and patents in the Territory that
are included in the Licensed Patent Rights, including all payment obligations,
with the exception of (a) those patents and patent applications designated in
Exhibit A as related to the "Neisseria P64K Protein" technology, which shall be
prepared, filed, prosecuted and maintained by HEBER or its Licensor, consistent
with its obligations to CIMAB, and (b) the patents and patent applications
designated in Exhibit A as "HER-1" technology, which shall be prepared, filed,
prosecuted and maintained by CIM, in consultation with TARCANTA and TARCANTA
LTD., consistent with its obligations to CIMAB and with CIMAB's obligations to
TARCANTA and TARCANTA LTD.; provided, however, that if the Parties agree in the
future to separate the claims thereof into applications which solely cover the
HER-1 technology, then TARCANTA and TARCANTA LTD. shall from such point forward,
bear the responsibility for the preparation, filing, prosecution and maintenance
of patents and patent applications which relate solely to the HER-1 technology.

            10.3.1 CIMAB shall execute all necessary documents and otherwise
provide reasonable assistance, free of charge, to TARCANTA and TARCANTA LTD. for
all actions TARCANTA and TARCANTA LTD. reasonably deem necessary to undertake
relating to the preparation, filing, prosecution, and maintenance of any and all
patent applications and patents in the Territory that are included in the
Licensed Patent Rights.

            10.3.2 CIMAB shall promptly inform TARCANTA and TARCANTA LTD. as to
all matters that come to its attention or to the attention of its Licensors that
may affect the preparation, filing, prosecution or maintenance of the Licensed
Patent Rights in the Territory or elsewhere, including, without limitation, all
information with respect to the preparation, filing, prosecution and maintenance
of those patent applications designated in Exhibit A as related to the
"Neisseria P64K Protein" technology and to the "HER-1" technology.

                                       44
<PAGE>

            10.3.3 Upon thirty (30) days written notice to CIMAB, TARCANTA
and/or TARCANTA LTD. may abandon their rights under this Agreement in any
country(ies) in the Territory and thereafter owe no payment under Section 10.3
or any other obligation of this Agreement in those country(ies) as of the
effective date of such written notice. CIMAB shall thereafter have a right, but
not an obligation, to assume the responsibility for the preparation, filing,
presentation and maintenance of any and all patent applications and patents that
are included in the Licensed Patent Rights in such country(ies) in the Territory
where TARCANTA or TARCANTA LTD. has elected to abandon its rights. In the event
that CIMAB has assumed the responsibility for the preparation, filing,
presentation and maintenance of any and all patent applications and patents that
are included in the Licensed Patent Rights in such country(ies) in the Territory
where TARCANTA and/or TARCANTA LTD. have elected to abandon such rights,
TARCANTA and TARCANTA LTD.'s rights, as the case may be, with respect to the
Licensed Product in such country(ies) under this Agreement shall no longer be of
any effect, and YMB's rights under the CIMAB-CIMYM Vaccine Agreement with
respect to such country(ies), but only with respect to such country(ies), shall
be reinstated.

      10.4. Enforcement of Licensed Patent Rights

            10.4.1. If any patent within the Licensed Patent Rights is or might
reasonably be infringed by a Third Party in the Territory (an "Infringement"),
the Party first having knowledge of such Infringement shall promptly notify the
other Parties in writing. Such notice shall set forth the facts of such
Infringement in reasonable detail.

            10.4.2. TARCANTA and/or TARCANTA LTD. shall have the right, but not
the obligation, to take action in their own names and at their sole expense to
secure the cessation of any Infringement or to institute, prosecute and control
legal proceedings to prevent or restrain such Infringement. CIMAB agrees to
timely assist TARCANTA and TARCANTA LTD. in the prosecution of any action or
legal proceedings related to such Infringement, and agrees to be joined, and to
cause its Licensors to be joined, as party plaintiffs and to give the TARCANTA
and TARCANTA LTD. reasonable assistance and authority to control, file,
prosecute and settle the suit. Subject to the foregoing, CIMAB shall have the
right, but not the obligation, to participate at its own cost and expense in any
suit or other proceeding wherein the validity or enforceability of any Licensed
Patent Right is at issue in the context of a claim or defense. All of TARCANTA
and TARCANTA LTD.'s costs and expenses in bringing such suits (including
TARCANTA and TARCANTA LTD.'s internal costs and expenses that are specifically
attributable thereto) shall be reimbursed first out of any damages or other
monetary awards recovered in favor of the Parties. Any remaining damages or
other monetary awards shall be allocated [***] to CIMAB and [***] to TARCANTA
and TARCANTA LTD.

            10.4.3 If TARCANTA and TARCANTA LTD. elect not to exercise their
right to prosecute or take other appropriate action in connection with an
Infringement or fail to take any such action within ninety (90) days of first
receiving notice of such Infringement, CIMAB may do so at its own expense. If
such case, TARCANTA and TARCANTA LTD. agrees to assist CIMAB in the prosecution
of any action or legal proceedings related to such Infringement. Notwithstanding
anything in this Agreement to the contrary, TARCANTA and TARCANTA

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       45
<PAGE>

                                                                    CONFIDENTIAL

LTD. shall have the right, but not an obligation, to participate at their own
cost and expense in any suit or other proceeding wherein the validly or
enforceability of any Licensed Patent Right is being invoked in the context of a
claim or defense. All of CIMAB's costs and expenses in bringing such suits
(including CIMAB's internal costs and expenses that are specifically
attributable thereto) shall be reimbursed first out of any damages or other
monetary awards recovered in favor of the Parties. Any remaining damages or
other monetary awards shall be allocated [***] to TARCANTA and TARCANTA LTD. and
[***] to CIMAB.

            10.4.4 The Party that takes action or prosecutes legal proceedings
relating to the Infringement in accordance with this Agreement shall be
responsible for the selection of counsel to prosecute legal proceedings.

            10.4.5 In no event shall either Operating Party settle an action or
proceeding against an infringer with respect to an Infringement in the Territory
without the prior written consent of the other Operating Party. Such consent
shall not be unreasonably withheld or delayed, and may be withheld only if such
settlement would materially and adversely affect the interest of such other
Operating Party.

            10.4.6. Infringement of Third Party(ies) Rights. If any activities
by TARCANTA or TARCANTA LTD. under this Agreement, including the practice of the
Licensed Patent Rights, the Licensed Know-How, or the manufacture, use or sale
of the Licensed Product by TARCANTA or TARCANTA LTD., their Affiliates or
Sublicensees, consistent with the rights granted under this Agreement within the
Territory results in a claim of infringement of the intellectual property rights
of a Third Party against TARCANTA or TARCANTA LTD., their Affiliates or
Sublicensees, TARCANTA and TARCANTA LTD. shall have the right, using counsel of
their own choice, to defend such claim. CIMAB agrees to cooperate fully with
TARCANTA and TARCANTA LTD. in their defense of the claim. Notwithstanding
anything in this Agreement to the contrary, CIMAB shall have the right, but not
the obligation, to participate at its own cost in the defense of such claim. All
of TARCANTA and TARCANTA LTD.'s costs and expenses in defending such claims
(including TARCANTA and TARCANTA LTD.'s internal costs and expenses which are
specifically attributable thereto) shall be offset by TARCANTA and TARCANTA LTD.
exclusively against [***] of any Royalties and any other amounts due to CIMAB
under this Agreement. Such offset rights shall be made only where the claim of
infringement arises from the sale, use, manufacture or importation of the
Licensed Products, provided that such claim of infringement does not arise due
to any invention or improvement incorporated into the Licensed Products by
TARCANTA or TARCANTA LTD. without the knowledge of CIMAB.

            10.5. Trademarks and Identification

            10.5.1. TARCANTA and TARCANTA LTD. shall, at their own expense
select, register and maintain the trademarks used by each such entity with
respect to the Licensed Products. Neither CIMAB nor any of its Affiliates,
licensors or sublicensees other than TARCANTA and TARCANTA LTD. shall have any
rights in respect of such trademarks, and CIMAB agrees to use its best efforts
to prevent any of its Licensors and sublicensees other than TARCANTA and
TARCANTA LTD. from using such trademarks in any way.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       46
<PAGE>

                                                                    CONFIDENTIAL

            10.5.2. CIMAB agrees to give TARCANTA and TARCANTA LTD. prompt
written notice of any unlicensed use by Third Parties of any trademark used by
TARCANTA or TARCANTA LTD. with respect to the Licensed Products of which CIMAB
has knowledge.

            10.5.3. TARCANTA and TARCANTA LTD. shall have the exclusive right,
but not the obligation, to take action in their own names and at their sole
expense to secure the cessation of any infringement or misappropriation of its
trademarks or to institute, prosecute and control legal proceedings to prevent
or restrain such infringement or misappropriation of its trademarks. CIMAB
agrees to use its best efforts to assist TARCANTA and TARCANTA LTD., at TARCANTA
or TARCANTA LTD.'s expense, in the prosecution of any action or legal
proceedings related to the infringement or misappropriation of such trademarks.

            10.5.4. If permitted by Applicable Laws, all Licensed Products shall
bear labeling that states that such products are either manufactured under
license from CIMAB, in the case of Licensed Products manufactured by or on
behalf of TARCANTA or TARCANTA LTD., their Sublicensees and Contract
Manufacturers, or, in the case of Licensed Products purchased from CIMAB, that
identifies CIMAB, with its address, as the manufacturer of the Licensed
Products. TARCANTA and TARCANTA LTD. shall mark all Licensed Products that they
manufacture for commercial sale with a legend identifying the issued patents
that pertain thereto.

                                   ARTICLE 11

                                 CONFIDENTIALITY

      11.1 Confidentiality; Exceptions. Except as otherwise provided in this
Agreement, the Parties agree that, during the term of this Agreement and for
five (5) years thereafter, all non-public, proprietary or "confidential" marked
invention disclosures, know-how, data, and technical, financial and other
information of any nature whatsoever (collectively, "Confidential Information"),
disclosed or submitted, either orally or in writing (including, without
limitation by electronic means) or through observation, by one Party (the
"Disclosing Party") to the other Party (the "Receiving Party") hereunder shall
be received and maintained by the Receiving Party in strict confidence, shall
not be used for any purpose other than the purposes expressly permitted by this
Agreement, and shall not be disclosed to any Third Party (including, without
limitation in connection with any publications, presentations or other
disclosures). Notwithstanding the foregoing, the Receiving Party may, subject to
the provisions of this Agreement, disclose the Disclosing Party's Confidential
Information to those of its and its Affiliates' and its Sublicensees' directors,
officers, employees, agents, consultants, clinical investigators and
Subcontractors that have a need to know such Confidential Information to achieve
the purposes of this Agreement; provided, however, that such Party shall ensure
that it and its Affiliates', Sublicensees' directors, officers, employees,
agents, consultants, clinical investigators or Contract Manufacturers to whom
disclosure is to be made are bound by, and take reasonable efforts to ensure
compliance with, the confidentiality terms hereof. Each Party will promptly
notify the other upon discovery of any unauthorized use or disclosure of the
Confidential Information. Confidential Information belongs to and shall remain
the property of

                                       47
<PAGE>

                                                                    CONFIDENTIAL

the Disclosing Party. The provisions of this Article 11 shall not apply to any
information that can be shown by the Receiving Party:

      (a) To have been known to or in the possession of the Receiving Party
prior to the date of its actual receipt from the Disclosing Party;

      (b) To be or to have become readily available to the public other than
through any act or omission of the Receiving Party in breach of this Agreement
or any other agreement between the Parties;

      (c) To have been disclosed to the Receiving Party, other than under an
obligation of confidentiality, by a Third Party which had no obligation to the
Disclosing Party not to disclose such information to others; or

      (d) To have been subsequently independently developed by the Receiving
Party without use of the Confidential Information as demonstrated by competent
written records.

      11.2. Authorized Disclosures. Notwithstanding anything in Section 11.1 to
the contrary, each Party may disclose Confidential Information hereunder solely
to the extent such disclosure is reasonably necessary in connection with
submissions to any Government Authority or in filing or prosecuting patent
applications contemplated or prosecuting or defending litigation or complying
with Applicable Laws or conducting Development Work for the purposes expressly
permitted by this Agreement; provided that in the event of any such disclosure
of the Disclosing Party's Confidential Information by the Receiving Party, the
Receiving Party will, except where impracticable, give reasonable advance notice
to the Disclosing Party of such disclosure requirement (so that the Disclosing
Party may seek a protective order and or other appropriate remedy or waive
compliance with the confidentiality provisions of this Article 11) and will use
its reasonable efforts to secure confidential treatment of such Confidential
Information required to be disclosed. Notwithstanding the above, each Party may
disclose pre-clinical and clinical data and results relating to Licensed Product
to qualified medical professionals for the limited purposes of marketing
Licensed Product and conducting medical education initiatives reasonably
designed to increase sales of Licensed Product.

      11.3. Return of Confidential Information. The Receiving Party shall keep
Confidential Information belonging to the Disclosing Party in appropriately
secure locations. Upon the expiration or termination of this Agreement, any and
all Confidential Information possessed in tangible form by a Receiving Party,
its Affiliates or Sublicensees, or its or any of their officers, directors,
employees, agents, consultants or clinical investigators and belonging to the
Disclosing Party, shall, upon written request, be immediately returned to the
Disclosing Party (or destroyed if so requested) and not retained by the
Receiving Party, its Affiliates or Sublicensees, or any of their officers,
directors, employees, agents, consultants or clinical investigators; provided
however that a Party may retain one (1) copy of any Confidential Information in
an appropriately secure location, which by Applicable Laws it must retain, for
so long as such Applicable Laws require such retention but thereafter shall
dispose of such retained Confidential Information in accordance with Applicable
Laws or this Section 11.3.

                                       48
<PAGE>

                                                                    CONFIDENTIAL

      11.4 Publications and Announcements. Except as otherwise permitted under
this Agreement or as required by law, regulation, or court order, each Party
agrees not to publish any Confidential Information received from the other
Party. Except as required by law, regulation or court order, each Party agrees
that, without obtaining the other Party's prior written approval for any
publication or any presentation, which shall not be unreasonably withheld, such
Party shall not publish or present (i) any Confidential Information generated by
either Party related to the development or commercialization of Licensed
Product, or (ii) the results of any clinical trial studies or non-clinical
studies or investigations carried out by either Party related to the development
of Licensed Product. At least sixty (60) days prior to any such publication or
presentation, the Party seeking to publish such information (the "Publishing
Party") shall provide the other Party with a copy of the proposed abstract,
manuscript or presentation (including, without limitation information to be
presented verbally) for review. The other Party shall respond in writing to the
Publishing Party within such time period with either approval of the proposed
material or a specific statement of (a) concern based upon the need to seek
patent protection, (b) concern regarding competitive disadvantage arising from
the proposal, or (c) concern regarding the timing and circumstances of such
disclosure in light of the other Party's business. In the event that the other
Party has concerns about disclosure of Confidential Information, the Publishing
Party agrees to provide the other Party with any additional information relating
to the proposed disclosure, as reasonably requested. In the event of concern
relating to patent protection, the Publishing Party agrees not to submit such
abstract or manuscript for publication or to make such presentation until the
other Party has had a reasonable period of time to seek patent protection for
any material in such publication or presentation which it believes is patentable
or to resolve any other issues, such period not to exceed sixty (60) additional
days. In the event of concern regarding competitive disadvantage or the timing
and other circumstances relevant to the disclosure, the Parties will negotiate
in good faith to attempt to arrive at a compromise to permit the Publishing
Party an opportunity to publish or present the disclosure within a reasonable
period of time. The Publishing Party also agrees to delete from any such
abstract or manuscript or presentation any Confidential Information that the
other Party reasonably believes has commercial value based upon the secrecy of
such information. Once approval for a publication or presentation has been
granted, the Publishing Party shall be entitled to use information contained in
such publication or presentation after the date of its publication or
presentation without seeking further approval. It is understood that general
comments made by either Party relating to the relationship between the Parties
established by this Agreement, including, for example, general comments made in
response to inquiries at professional meetings and other similar circumstances,
are not intended to be restricted by the provisions of this Article 11 provided
that such information has been disclosed to the public previously or cleared for
such disclosure by the non-disclosing Party. It is understood further that
Confidential Information may be disclosed by either Party to Third Parties bound
by non-disclosure agreements to the extent such Confidential Information (1) is
not specific to the Licensed Product and (2) is disclosed in relation to matters
outside the Parties' collaboration efforts with respect to Licensed Product.
Prior to any such disclosure, the disclosing Party will provide such disclosures
to the other Party for such Party's approval, which shall not be unreasonably
withheld.

                                       49
<PAGE>

                                                                    CONFIDENTIAL

                                   ARTICLE 12

                              TERM AND TERMINATION

      12.1. Term

            12.1.1. This Agreement shall commence as of the Effective Date and
shall expire by its own terms on the later of (i) the earlier of, on a
country-by-country basis (a) the expiration of the term of the last patent
within the Licensed Patent Rights or (b) a determination by a court or
administrative agency of competent jurisdiction that the last claim in the last
patent within the Licensed Patent Rights is invalid or unenforceable, or (ii) on
a country by country basis, fifteen (15) years after the First Commercial Sale
of a Licensed Product developed under this Agreement, unless the term of such
right and license is earlier terminated pursuant to the provisions of this
Article 12 (the "Term").

            12.1.2. Notwithstanding the provisions of Section 12.1.1 above, this
Agreement may be terminated prior to expiration in accordance with the terms and
conditions of this Article 12.

      12.2. Termination at Will. TARCANTA and TARCANTA LTD. may terminate this
Agreement at any time in TARCANTA and TARCANTA LTD.'s sole discretion, upon not
less than one hundred eighty (180) days' prior written notice to CIMAB.

      12.3. Termination for Cause. Any Operating Party may terminate this
Agreement for cause if any other Operating Party commits a material breach of a
material term of this Agreement, which material breach is not materially cured
within sixty (60) days after written notice from the non-breaching Operating
Party specifying the material breach, or, if such material breach is not
susceptible of material cure within such period, the breaching Operating Party
is not making diligent, good faith, best efforts to materially cure such
material breach. The Parties acknowledge and agree that failure to exercise any
right or option, or to take any action expressly within the discretion of a
Operating Party shall not be deemed to be a material breach hereunder.

      12.4. Other Terminations. Notwithstanding anything in this Article 12 or
any other provision of this Agreement to the contrary, CIMAB shall have the
right to terminate this Agreement pursuant to Sections 5.9.6, 5.12.5 and 5.12.7
according to the terms of such sections or in case of the occurrence of one of
the following events:

      (i) If TARCANTA and/or TARCANTA LTD. have not used Reasonable Commercial
Efforts to file an IND Submission for a Phase 2 clinical trial of the Licensed
Products, or any other therapeutic cancer vaccine of which the Licensed Products
comprises a portion thereof, is not commenced by TARCANTA or NEWNCVX-IR in the
Territory within two (2) years after the Effective Date, provided, however, that
CIMAB has timely complied with all of its obligations under this Agreement.

                                       50
<PAGE>

                                                                    CONFIDENTIAL

      (ii) If the first Regulatory Approval for marketing the Licensed Products
in the Territory is not obtained within twelve (12) years after the Effective
Date, provided, however, that CIMAB has timely complied with all of its
obligations under this Agreement.

      12.5. Termination for Insolvency. To the extent permitted by Applicable
Laws, any Operating Party may terminate this Agreement upon written notice to
the other Operating Parties on or after the occurrence of any of the following
events: (i) the appointment of a trustee, receiver or custodian for all or
substantially all of the property of the other Party, or for any lesser portion
of such property, if the result materially and adversely affects the ability of
the other Party to fulfill its obligations hereunder or thereunder, which
appointment is not dismissed within sixty (60) days, (ii) the determination by a
court or tribunal of competent jurisdiction that the other Party is insolvent
such that a Party's liabilities exceed the fair market value of its assets,
(iii) the filing of a petition for relief in bankruptcy by the other Party on
its own behalf, or the filing of any such petition against the other Party if
the proceeding is not dismissed or withdrawn within sixty (60) days thereafter,
(iv) an assignment by the other Party for the benefit of creditors, or (v) the
dissolution or liquidation of the other Party. All rights and licenses granted
under or pursuant to this Agreement by one Party to the other Party are, and
shall otherwise be deemed to be, for the purposes of Section 365(n) of the
Bankruptcy Code of the U.S., licenses of rights to "intellectual property." The
Parties agree that both Parties, as a licensees of such rights and licenses,
shall retain and may fully exercise all of their rights and elections under such
Bankruptcy Code.

      12.6 Rights on Termination.

            12.6.1 In the event that CIMAB terminates this Agreement pursuant to
Sections 12.2 (Termination at Will), 12.3 (Termination for Cause), Section 12.4
(Other Terminations) or pursuant to Section 12.5 (Termination for Insolvency),
or Sections 5.9.6, 5.12.5 or 5.12.7, CIMAB shall not have any obligation to
complete any clinical or other study in progress or any project underway
pursuant to the Development Plan, as of the effective date of such termination;
neither CIMAB nor YMB shall have any obligation to refund any monies previously
paid to CIMAB or YMB; and TARCANTA, TARCANTA LTD. and their Sublicensees shall
pay to CIMAB and YMB, respectively all monetary obligations that were due and
owing to CIMAB and YMB, respectively, under the terms of this Agreement prior
the effective date of such termination.

            12.6.2. Except as otherwise required to effect the other provisions
of this Article 12, in the event this Agreement is terminated for any reason,
(i) all rights and obligations of the Parties and sublicenses under this
Agreement shall terminate and YMB's rights under the CIMAB-CIMYM Vaccine
Agreement shall be reinstated in accordance with the provisions of Section 2.1.1
of this Agreement; (ii) TARCANTA, TARCANTA LTD. and their Sublicensees shall
surrender to CIMAB, or, at CIMAB's sole option, TARCANTA, TARCANTA LTD. and
their Sublicensees shall destroy and provide CIMAB with a certificate signed by
a Vice-President or higher ranking executive of TARCANTA, TARCANTA LTD. and
their Sublicensees attesting to the destruction of, copies of any Licensed
Know-How or other Confidential Information provided by CIMAB hereunder, except
as noted to the contrary below

                                       51
<PAGE>

                                                                    CONFIDENTIAL

in this Section 12.6.2, and the Transferred Assets; (iii) CIMAB shall surrender
to TARCANTA, TARCANTA LTD. and their Sublicensees, or, at TARCANTA, TARCANTA
LTD. and their Sublicensee's sole option, CIMAB shall destroy and provide
TARCANTA and TARCANTA LTD. with a certificate signed by a Vice-President or
higher ranking executive of CIMAB attesting to the destruction of, all copies of
any Confidential Information provided by TARCANTA, TARCANTA LTD. and their
Sublicensees hereunder, except as noted to the contrary in this Section 12.6.2;
(iv) TARCANTA, TARCANTA LTD. or their Sublicensees will immediately upon
termination, take all steps necessary for the issuance (or re-issuance, if
appropriate) in the name of CIMAB or its designee of all Regulatory Approvals
theretofore obtained or held by TARCANTA, TARCANTA LTD. and their Sublicensees
with respect to Licensed Products; and (v) neither TARCANTA, TARCANTA LTD. nor
their Sublicensees will have the right to use the Licensed Products, Licensed
Know How, Licensed Patent Rights, Confidential Information, Transferred Assets
and/or any other right granted to TARCANTA, TARCANTA LTD. or their Sublicensees
under this Agreement, except as noted to the contrary in this Section 12.6.2.
Notwithstanding anything in this Section or elsewhere in this Agreement to the
contrary, in the event of any termination or expiration of this Agreement prior
to its expiration, TARCANTA, TARCANTA LTD. and their Sublicensees may retain a
copy of all Licensed Know-How or other Confidential Information solely for
purposes related to any litigation arising out of this Agreement, including
without limitation, the sale of any of the Licensed Products by TARCANTA,
TARCANTA LTD. and their respective Affiliates, subsidiaries and Sublicensees.

      12.7. Accrued Rights . Termination, relinquishment or expiration of this
Agreement for any reason shall be without prejudice to any right that shall have
accrued to the benefit of either Party prior to such termination, relinquishment
or expiration, including damages arising from any breach under this Agreement.
Such termination, relinquishment or expiration shall not relieve either Party
from obligations that are expressly indicated to survive termination or
expiration of this Agreement.

      12.8. Survival The following articles and sections of this Agreement shall
survive the expiration or termination of this Agreement for any reason: Section
3.9, 5.13, 8.1, 8.2, 8.4, 10.1, 10.2, 10.3, 10.5.1, 12.6, 12.7, 12.8, and
Articles 11, 13, 14 and 15.

      12.9. One hundred and eighty days (180 days) before expiration of this
Agreement in accordance with Section 12.1.1 of this Agreement, CIMAB shall have
the option to initiate negotiations for CIMAB to supply the Licensed Products to
TARCANTA and TARCANTA LTD. and their Affiliates and Sublicensees for sale in
those portions of the Territory where CIMAB had supplied same under this
Agreement. If CIMAB exercises this option, the Parties agree to negotiate in
good faith, and shall enter into such a supply agreement, provided that (i) the
terms offered by CIMAB for the supply agreement are commercially reasonable and
are at least as favorable to TARCANTA and TARCANTA LTD., in the aggregate, as
terms offered by any other party, (ii) TARCANTA or TARCANTA LTD. are not able to
supply the Licensed Products more economically than CIMAB, (iii) CIMAB has
consistently complied with its obligations to comply with all Applicable Laws
during the Term of this Agreement, and (iv) the

                                       52
<PAGE>

quality of the Licensed Products supplied by CIMAB has been consistently
acceptable to TARCANTA and TARCANTA LTD. throughout the Term of this Agreement.

                                   ARTICLE 13

               INDEMNIFICATION; INSURANCE; LIMITATION OF LIABILITY

      13.1. Indemnification by CIMAB. CIMAB shall, at its sole cost and expense,
indemnify, defend and hold harmless TARCANTA, TARCANTA LTD., their Affiliates,
Sublicensees, officers, directors, employees and agents from and against any and
all losses, liabilities, claims, obligations, damages, costs, expenses
(including, without limitation, reasonable attorneys' fees) which result from,
arise in connection with or are related in any way to claims by a Third Party
arising out of or in connection with (a) CIMAB's breach of the representations
and warranties made by CIMAB in this Agreement; (b) CIMAB's willful misconduct
or gross negligence; (c) any violations of Applicable Laws or regulations by
CIMAB; or (d) CIMAB's material breach of the provisions of this Agreement;
provided that: (i) TARCANTA or TARCANTA LTD. promptly notifies CIMAB in writing
of the claim; and (ii) TARCANTA and TARCANTA LTD. provide CIMAB with all
reasonable assistance, information and authority to perform the foregoing.

      13.2 Indemnification by TARCANTA and TARCANTA LTD.. TARCANTA and TARCANTA
LTD. shall, at their sole cost and expense, indemnify, defend and hold harmless
CIMAB, YMB and CIMYM and their officers, directors, employees and agents from
and against any and all losses, liabilities, claims, obligations, damages,
costs, expenses (including, without limitation, reasonable attorneys' fees)
which result from, arise in connection with or are related in any way to claims
by a Third Party arising out of or in connection with (a) TARCANTA or TARCANTA
LTD.'s breach of the representations and warranties made by TARCANTA or TARCANTA
LTD. in this Agreement; (b) TARCANTA or TARCANTA LTD.'s willful misconduct or
gross negligence; (c) any violations of Applicable Laws or regulations by
TARCANTA or TARCANTA LTD.; or (d) TARCANTA or TARCANTA LTD.'s material breach of
the provisions of this Agreement; provided that: (i) CIMAB promptly notifies
TARCANTA and TARCANTA LTD. in writing of the claim; and (ii) CIMAB provides
TARCANTA and TARCANTA LTD. with all reasonable assistance, information and
authority to perform the foregoing.

      13.3. Insurance. TARCANTA and TARCANTA LTD. shall, during the Term and at
their sole cost and expense, be insured under a comprehensive, commercial
general liability insurance policy against claims for damage (including, without
limitation, claims for bodily and personal injury, death and property damage)
caused by or occurring in connection with the performance or breach of this
Agreement. At TARCANTA and TARCANTA LTD.'s cost, and if permitted under
Applicable Laws, TARCANTA and TARCANTA LTD. shall use Reasonable Commercial
Efforts to name CIMAB as an additional insured Party on each insurance policy.
The coverage shall be maintained under one or more policies of insurance from a
financially sound and reputable insurance company reasonably acceptable to
CIMAB, providing a minimum

                                       53
<PAGE>

                                                                    CONFIDENTIAL

liability protection in the amount of [***] per occurrence. Such insurance shall
be primary for all purposes, and contain standard cross-liability or
severability provisions. All of the policies of insurance shall contain a
provision or endorsement that the coverage afforded will not be canceled,
materially changed, or have renewal refused unless at least thirty (30) days'
prior written notice has been given to TARCANTA, TARCANTA LTD. and CIMAB. If
requested, TARCANTA and/or TARCANTA LTD. shall deliver to CIMAB insurance
certificates in form and substance reasonably acceptable to CIMAB.

      13.4 Limitation of Liability; Remedies Cumulative

            13.4.1 IN NO EVENT SHALL ANY PARTY BE LIABLE UNDER THIS AGREEMENT
FOR ANY CONSEQUENTIAL, INCIDENTAL, PUNITIVE OR SPECIAL DAMAGES OF ANY KIND,
INCLUDING, WITHOUT LIMITATION, LOSS OF PROFITS, WHETHER SUCH DAMAGES ARE ALLEGED
AS A RESULT OF TORTIOUS CONDUCT OR BREACH OF CONTRACT OR OTHERWISE EVEN IF THE
OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.THESE
LIMITATIONS SHALL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY
LIMITED REMEDY.

      13.4.2 THE REMEDIES PROVIDED IN THIS AGREEMENT ARE CUMULATIVE AND NOT
EXCLUSIVE OR IN LIMITATION OF ANY OTHER REMEDY AVAILABLE UNDER THIS AGREEMENT OR
AT LAW OR IN EQUITY.

                                   ARTICLE 14

                   GOVERNING LAW AND FORUM; DISPUTE RESOLUTION

      14.1. Governing Law. This Agreement shall be governed by the laws of
England and Wales, excluding that body of law known as the conflicts of law.

      14.2. Dispute Resolution.

            14.2.1 In the event of any dispute, controversy or claim arising out
of or in connection with or related to this Agreement (a "Dispute"), the Parties
shall first seek to settle the Dispute in good faith by negotiation and
consultation between themselves, including referral of the Dispute to the chief
executive officers of each Party. When a Party believes that a Dispute has
arisen, that Party will give the other Parties prompt written notice of the
Dispute (a "Dispute Notice"). All negotiations pursuant to this Section 14.2,1
shall be on a without prejudice basis, and nothing said or disclosed, nor any
document produced, in the course of such negotiations which is not otherwise
independently discloseable shall be offered or received as evidence or for any
other purpose in any current or future arbitration or litigation. In the event
the Parties do not resolve the Dispute (or agree upon a mechanism to resolve the
Dispute) within thirty (30) days of the date of the Dispute Notice, such Dispute
shall be referred by any Party to arbitration proceedings pursuant to Section
14.2.2.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       54
<PAGE>

                                                                    CONFIDENTIAL

            14.2.2 Subject to Section 14.2.1, the Parties agree that any Dispute
shall be finally settled under the Rules of Arbitration of the International
Chamber of Commerce (the "Rules"), to the extent that the Rules are not varied
by the terms of this Section 14.2.2. The seat of the arbitration shall be
London, England, unless another location is mutually agreed by the Parties,
provided always that the seat of the arbitration is in a state which has
ratified the New York Convention on the Recognition and Enforcement of Foreign
Arbitral Awards (the "New York Convention"). The arbitral tribunal shall be
composed of three (3) independent arbitrators, two (2) of whom shall be
nominated by the Parties to the Dispute and the third, who shall act as
Chairman, who shall be jointly nominated by the party-nominated arbitrators. In
the event that there are three Parties to the Dispute, the Claimant party(ies)
shall (together) nominate one arbitrator and the Respondent Party(ies) shall
(together) nominate one arbitrator. None of the arbitrators shall be nationals
of the U.S. or Cuba. The joint languages of the arbitration shall be Spanish and
English, unless the Parties agree otherwise. The arbitral tribunal may award
interim or ancillary relief. Judgment on the award, and on any interim or
ancillary relief, may be entered in any court having jurisdiction thereof or
having jurisdiction over the Parties or their assets, or over the subject matter
at issue. The arbitral tribunal shall have the power to rule on its own
jurisdiction, including any objections with respect to the existence or validity
of this arbitration agreement. The arbitral award shall be final and binding on
the Parties, who hereby waive any right of appeal. Such award shall be
enforceable pursuant to the New York Convention. The Parties agree that this
Agreement and any Dispute are commercial in nature under the laws of the
Republic of Cuba, the U.S. and England and Wales, including the laws relating to
arbitration. This paragraph shall be treated as an agreement independent of the
other terms of this Agreement. A decision by the arbitral tribunal that this
Agreement is null and void shall not entail ipso jure the invalidity of this
arbitration clause.

                                  ARTICLE 15.

                                  MISCELLANEOUS

      15.1 Assignment

            15.1.1 None of the Parties may assign or otherwise transfer their
rights or obligations under this Agreement without the prior written consent of
the other Party, such consent not to be unreasonably withheld, except that a
Party may assign or otherwise transfer its rights or obligations in whole or in
part without such consent (i) to an Affiliate of such Party, provided that no
such assignment shall relieve any Party as the primary obligor hereunder, or
(ii) to a Third Party in connection with the merger, consolidation, or sale of
substantially all of the assets of the assigning Party, or reorganization
affecting substantially all of the assets or voting control of the assigning
Party, providing that no such assignment shall relieve any Party as the primary
obligor hereunder.

            15.1.2 This Agreement shall be binding upon and inure to the benefit
of the successors and permitted assigns of the Parties. Any assignment not in
accordance with this Agreement shall be void.

                                       55
<PAGE>

                                                                    CONFIDENTIAL

      15.2 Force Majeure Except as provided for in Sections 5.9.6, 5.12.5 and
5.12.7, no Party shall lose any rights hereunder or be liable to the other
Parties for damages or losses on account of failure of performance by the
defaulting Party if the failure is occasioned by government action, war, fire,
explosion, flood, strike, lockout, embargo, act of God, or any other similar
cause beyond the control of the defaulting Party, provided that the Party
claiming force majeure shall promptly notify the other Party in writing setting
forth the nature of such force majeure, shall use its best efforts to eliminate,
remedy or overcome such force majeure and shall resume performance of its
obligations hereunder as soon as reasonably practicable after such force majeure
ceases.

      15.3 Separate Entities. Without limitations, CIMAB and its property are
not and shall not be responsible for the acts, omissions, obligations or debts
of the Republic of Cuba or any of its agencies or instrumentalities. Neither the
Republic of Cuba nor any of its agencies or instrumentalities, nor any of their
property, are responsible, or shall be responsible, for the acts, omissions,
obligations or debts of CIMAB.

      15.4 Further Actions. Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.

      15.5 Governmental Approvals; Compliance with Law. The Parties shall make
all filings with Government Authorities as shall be required by Applicable Laws
in connection with this Agreement and the activities contemplated hereunder or
thereunder. It is understood and agreed that neither TARCANTA nor TARCANTA LTD.
shall be required to undertake, and TARCANTA and TARCANTA LTD. shall not
undertake, to sell any CIMAB product unrelated to the Licensed Products. It is
understood and agreed that neither TARCANTA nor TARCANTA LTD. shall be required
to transfer, and neither TARCANTA nor TARCANTA LTD. (including their officers,
directors, employees and agents) will transfer to CIMAB, any technology or
know-how unrelated to the Licensed Products.

      15.6 Public Announcement. No announcement, news release, public statement,
publication or presentation relating to the existence of this Agreement, or the
terms hereof or thereof, will be made without the other Party's prior written
approval, which approval shall not be unreasonably withheld. Notwithstanding the
foregoing, each Party consents to references to this Agreement in reports or
documents or other disclosures sent to stockholders or filed with or submitted
to any Government Authority or stock exchange or as may be required by law to be
made. The Parties each agree that once approval for disclosure of information
subject to this Section 15.6 has been obtained, the Party that requested such
approval shall be entitled to use such information substantially in the form
initially presented without an obligation to seek further approval.

      15.7 Notices. All notices required or permitted to be given under this
Agreement shall be deemed given if delivered personally, on the date of
delivery, or sent by express courier service, on the date of receipt, or by
email or facsimile if receipt is acknowledged by email or by

                                       56
<PAGE>

                                                                    CONFIDENTIAL

fax by the other Party, on the date of receipt acknowledged, to the Parties at
the following addresses, or at such other address for a Party as shall be
specified by like notice:

            If to CIMAB, addressed to:
            CIMAB, S.A.
            Address: Calle 206, No. 1926, e/ 19 y 21
            Atabey, Playa
            Ciudad de La Habana, Cuba
            Attention: Norkis Arteaga Morales
            Title:      Vice President
            Facsimile:  53 (7) 273 3509

            If to TARCANTA addressed to:
            TARCANTA Inc.
            Address: 2110 Rutherford Road
            Carlsbad, CA 92008
            U.S.
            Attention: General Counsel
            Facsimile: (760) 494-4282

            If to TARCANTA LTD. addressed to:
            TARCANTA LTD. Ltd.
            Address: 2110 Rutherford Road
            Carlsbad, CA 92008
            U.S.
            Attention: General Counsel
            Facsimile:  (760) 494-4282

            If to YMB addressed to:
            YM Biosciences, Inc.
            Address: 5045 Orbitor Drive,
            Building 11, Suite 400
            Mississauga, Ontario
            Canada L4W 4Y4
            Attention: ________________
            Facsimile: ________________

            If to CIMYM addressed to:
            CIMYM, Inc.
            Address: Chelston Park,
            Building 2, Collymore Rock St.
            St. Michael, Barbados

                                       57
<PAGE>

                                                                    CONFIDENTIAL

            West Indies
            Attention: ________________
            Facsimile:  _______________

      15.8. Waiver. No failure of any Party to exercise and no delay in
exercising any right or remedy in connection with this Agreement will operate as
a waiver thereof, nor will any single or partial exercise of any right or remedy
preclude any other or further exercise of such right or remedy or the exercise
of any other right or remedy.

      15.9. Disclaimer of Agency. The relationship between the Parties
established by this Agreement is that of independent contractors, and nothing
contained herein shall be construed to (i) give any Party the power to direct or
control the day-to-day activities of the other, (ii) constitute the Parties as
the legal representative or agent of the other Parties or as partners, joint
venturers, co-owners or otherwise as participants in a joint or common
undertaking, or (iii) allow any Party to create or assume any liability or
obligation of any kind, express or implied, against or in the name of or on
behalf of the other Parties for any purpose whatsoever, except as expressly set
forth in this Agreement.

      15.10. Severability. If any term, covenant or condition of this Agreement
or the application thereof to any Party or circumstance shall, to any extent, be
held to be invalid or unenforceable by a court or administrative agency of
competent jurisdiction, then (i) the remainder of such documents, or the
application of such term, covenant or condition to Parties or circumstances
other than those as to which it is held invalid or unenforceable, shall not be
affected thereby and each term, covenant or condition of such documents shall be
valid and be enforced to the fullest extent permitted by law; and (ii) the
Parties hereto covenant and agree to renegotiate any such term, covenant or
application thereof in good faith in order to provide a reasonably acceptable
alternative to the term, covenant or condition of such documents or the
application thereof that is invalid or unenforceable, it being the intent of the
Parties that the basic purposes of this Agreement are to be effectuated.

      15.11 Third Party Beneficiaries. This Agreement and each and every
provision thereof is for the exclusive benefit of the Parties hereto and not for
the benefit of any third party other than as expressly stated herein.

      15.12 Entire Agreement. This Agreement, including all schedules and
exhibits attached thereto, which are hereby incorporated herein by reference,
set forth all covenants, promises, agreements, warranties, representations,
conditions and understandings between the Parties hereto and supersedes and
terminates all prior and contemporaneous agreements and understandings between
the Parties. There are no covenants, promises, agreements, warranties,
representations, conditions or understandings, either oral or written, between
the Parties other than as set forth in this Agreement. No subsequent alteration,
amendment, change or addition to this Agreement shall be binding upon the
Parties hereto unless reduced to writing and signed by the respective authorized
officers of the Parties.

                                       58
<PAGE>

                                                                    CONFIDENTIAL

      15.13 Compliance with U.S. Law and Court Orders. Notwithstanding anything
in this agreement to the contrary, the Parties understand and agree that any and
all actions that can or must be taken by TARCANTA, TARCANTA LTD., and/or their
Affiliates or Sublicensees, or from which any such persons can or must refrain
hereunder from performing, including, without limitation, the obligations for
each such entity set forth under Sections 5.10.5, 5.10.7, 12.6.2 and 15.1.1, are
and shall continue to be limited to the extent that the performance or
non-performance of such obligations is permitted by U.S. law and/or any
applicable Court order, but that non-performance or other failure to fully
perform by TARCANTA, TARCANTA LTD. and/or their Affiliates and Sublicensees on
account of U.S. law and/or any applicable Court order in no way limits CIMAB'S
rights and remedies as delineated in Sections 5.10, 12.6.2 and 15.1.1.

                  (Remainder of page intentionally left blank)

                                       59
<PAGE>

                                                                    CONFIDENTIAL

      15.14 Counterparts. This Agreement may be executed in counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

      IN WITNESS WHEREOF, the Parties have executed this Agreement by their
proper officers as of the date and year first above written.

   TARCANTA INC. CIMAB, S.A.

   By:/s/ Hazel M. Aker                       By:/s/ Norkis Arteaga Morales
      ---------------------------------       --------------------------------
   Name:  Hazel M. Aker                       Name:  Norkis Arteaga Morales
   Title: SVP, General Counsel                Title: Vice President

   TARCANTA LTD., LTD.

   By:/s/ Hazel M. Aker
      ---------------------------------
   Name:  Hazel M. Aker
   Title: SVP, General Counsel

   YM BIOSCIENCES, INC.                       CIMYM, INC.

   By:/s/ David G. P. Allan                   By: /s/ Philip S. Young
      ---------------------------------       ----------------------------------
   Name:  David G. P. Allan                   Name:   Philip S. Young
   Title: Chairman and Chief Executive        Title:  Director
          Officer

   WITNESSED BY:                              WITNESSED BY:

   /s/ David F. Hale                          /s/ Agustin Bienvenido Lage Davila
   ------------------------------------       ----------------------------------
   David F. Hale,                             Agustin Bienvenido Lage Davila
   President and CEO,                         Director General,
   CancerVax Corporation                      Centro de Inmunologia Molecular

                                       60
<PAGE>

                                    EXHIBIT A
          TGF(alpha)-HER 1 AGREEMENT: PATENTS AND PATENT APPLICATIONS
                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       2
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       3
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       4
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       5
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       6
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       7
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       8
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       9
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       10
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       11
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       12
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       13
<PAGE>

                                    EXHIBIT B
                      FOR THE TGF ALPHA AND HER 1 AGREEMENT
                                      [***]

CONFIDENTIAL

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                  page 1 of 3
<PAGE>

                                      [***]

CONFIDENTIAL

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                  page 2 of 3
<PAGE>

                                      [***]

CONFIDENTIAL

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                  page 3 of 3
<PAGE>

                                                                    CONFIDENTIAL

                                    EXHIBIT C

                                     FORM OF
                                QUALITY AGREEMENT
                                     BETWEEN
                          TARCANTA INC. / TARCANTA LTD.
                                       AND
                                   CIMAB, S.A.

      THIS QUALITY AGREEMENT (the "Quality Agreement") is made effective as of
the ___ day of ___________, 2004 (the "Effective Date") by and between CIMAB,
S.A., a corporation organized under the laws of Cuba, having offices at Calle
206, No. 1926, e/ 19 y 21, Atabey, Playa, Ciudad de La Habana, Cuba ("CIMAB"),
on the one hand, and TARCANTA Inc., a corporation organized under the laws of
the State of Delaware, United States of America, having offices at 2110
Rutherford Road, Carlsbad, California 92008 ("TARCANTA") and TARCANTA, Ltd., a
corporation organized under the laws of the Republic of Ireland, having offices
at 30 Herbert Street, Dublin 2, Ireland ("TARCANTA LTD."), on the other hand.
TARCANTA, TARCANTA LTD. and CIMAB are sometimes referred to herein individually
as a "Party" and collectively as the "Parties."

                                    RECITALS

      1. CIMAB, TARCANTA and TARCANTA LTD. have entered into a License,
Development, Manufacturing and Supply Agreement (the "Agreement"), which governs
the supply by CIMAB of certain Licensed Products (as defined in the Agreement;
collectively, the "Products") to TARCANTA and TARCANTA LTD.; and

      2. CIM has assigned the right to enter into this Agreement to CIMAB.

      3. CIMAB, TARCANTA and TARCANTA LTD. intend that this Agreement shall
provide certain quality assurance requirements appertaining to the supply of the
Products.

      In consideration of the premises and of the mutual covenants and
obligations set forth herein, the Parties hereby agree as set forth below.

1.0 DEFINITIONS

      1.1 All initially capitalized terms not defined in this Quality Agreement
shall have the meaning ascribed to such terms in the Agreement.

      1.2 "Vendor" means any supplier of goods or services used by CIMAB in the
manufacture, testing, quality control, quality assurance, shipping, distribution
or storage of the Products or the facilities where CIMAB manufactures the
Products.

2.0 SUPPLY OF PRODUCTS

      2.1 Adherence to Specifications.

                                       1
<PAGE>

                                                                    CONFIDENTIAL

            2.1.1 CIMAB shall manufacture the Products in accordance with the
Specifications applicable thereto in effect at the time of the manufacture of
the Products.

            2.1.2 CIMAB may change the Specifications to ensure the safety and
efficacy of, or to comply with Applicable Laws related to, the Products;
however, before making any such change, CIMAB shall give TARCANTA and TARCANTA
LTD. one hundred and eighty (180) days advance written notification of such
proposed change and the date the change will be made. The Parties shall
cooperate in good faith to attempt to resolve any objections or concerns
TARCANTA and TARCANTA LTD. may have with all such proposed changes.

            2.1.3 TARCANTA and TARCANTA LTD. may request a change to the
Specification to ensure the safety and efficacy of, or to comply with Applicable
Laws related to, the Products. TARCANTA and TARCANTA LTD. shall give CIMAB one
hundred and eighty (180) days advance written notification of such proposed
change and the date the change is requested to be made. Such changes shall be
made unless CIMAB raises objections or concerns with the proposed change, in
which event the Parties shall cooperate in good faith to attempt to resolve
those objections or concerns.

            2.1.4 Except to the extent Sections 2.1.2 or 2.1.3 apply, either
Party may suggest or request a change to the Specifications (including but not
limited to new, changed or unforeseen clinical patterns or usage, circumstances
or developments). Such suggestions and requests shall be made in writing. The
Parties agree to confer in good faith to consider adoption of, and either
Party's objections to or concerns with, any such changes or related or
comparable changes. The Parties agree to establish jointly reasonable schedules
for implementing any such agreed upon changes.

            2.1.5 No other change shall be made to the Specifications except
pursuant to this Section 2.1. Any change made to the Specifications pursuant to
Section 2.1 shall be effective on the date specified or as otherwise mutually
agreed. Products provided thereafter shall conform to the Specifications as
amended, unless otherwise mutually agreed.

      2.2 Change of Vendors.

            2.2.1 CIMAB may change Vendors, to ensure the safety and efficacy
of, or to comply with regulatory requirements related to, the Products; however,
before making any such change, CIMAB shall, as far as practically possible, give
TARCANTA and TARCANTA LTD. one hundred and eighty (180) days advance written
notification of such proposed change and the date the change will be made. The
Parties shall cooperate in good faith to attempt to resolve any objections or
concerns TARCANTA and TARCANTA LTD. may have with the proposed change.

            2.2.2 TARCANTA and TARCANTA LTD. may request a change of Vendors to
ensure the safety and efficacy of, or to comply with regulatory requirements
related to, the Products. TARCANTA and TARCANTA LTD. shall, as far as
practically possible, give CIMAB one hundred and eighty (180) days advance
written notification of such proposed

                                       2
<PAGE>

                                                                    CONFIDENTIAL

change and the date the change is requested to be made. Such changes shall be
made unless CIMAB raises objections or concerns with the proposed change, in
which event the Parties shall cooperate in good faith to attempt to resolve
those objections or concerns.

            2.2.3 Except to the extent Sections 2.2.1 or 2.2.2 apply, either
Party may suggest or request a change of Vendors, for any other reason
(including but not limited to new, changed or unforeseen clinical patterns or
usage, circumstances or developments). Such suggestion or request shall be made
in writing. The Parties agree to confer in good faith to consider adoption of,
and either Party's objections to or concerns with, such change or a related or
comparable change. The Parties agree to establish jointly a reasonable schedule
for implementing any such agreed upon change.

            2.2.4 No other change of Vendors shall be made except pursuant to
this Section 2.2. Any change made pursuant to Section 2.2 shall be effective on
the date specified or as otherwise mutually agreed.

      2.3 Quality System Regulations. CIMAB shall manufacture all Products, and
shall operate and manage its facilities, in compliance with all Applicable Laws.
It shall be the sole responsibility of CIMAB to maintain regulatory compliance
at its facilities.

      2.4 Vendors. CIMAB shall have in place appropriate Standard Operating
Procedures (SOPs) and other written procedures governing the review and audit of
its Vendors. CIMAB shall ensure that its Vendors have in place and follow
appropriate written procedures and SOPs for the provision of products and
services as necessary for CIMAB to remain in compliance with all Applicable
Laws.

      2.5 Inspections. CIMAB shall permit TARCANTA and TARCANTA LTD. to (a)
periodically review and take copies of CIMAB's production and quality control
procedures, manufacturing, quality control and regulatory documents and records
related to the Products at CIMAB's facilities, and (b) visit CIMAB's facilities
in order to assure satisfaction of the requirements of this Agreement and the
Applicable Laws by CIMAB. Any such review or visit shall be at TARCANTA and
TARCANTA LTD.'s expense, upon reasonable advance written request to CIMAB, to
which CIMAB shall promptly respond and cooperate, and, if at a CIMAB facility,
shall be during CIMAB's normal business hours for that facility and with a
representative of CIMAB present. CIMAB shall permit TARCANTA and TARCANTA LTD.
to conduct Audits no less frequently than semi-annually.

3.0 CORRECTIVE ACTION

      3.1 Corrective Action. In the event that CIMAB or TARCANTA and TARCANTA
LTD. believes it necessary to take any corrective action with respect to any of
the Products provided to TARCANTA and TARCANTA LTD., regardless of whether such
action is initiated to comply with Applicable Laws or for other reasons, the
Parties hereto agree that, after discussion between the Parties hereto, TARCANTA
and TARCANTA LTD. and CIMAB will jointly "define the action to be taken" and
CIMAB agrees to implement such action. As used herein, "define the action to be
taken" means: (a) defining the corrective action strategy and (b)

                                       3
<PAGE>

                                                                    CONFIDENTIAL

defining the effectiveness check procedure (to establish that the corrective
action has been completed).

      3.2 Complaints.

            3.2.1 TARCANTA and TARCANTA LTD. shall be responsible for filing all
reports required to be filed under Applicable Laws in order to maintain any
Regulatory Approvals for manufacturing, marketing, and sale of Licensed Products
in the Territory, including, without limitation, adverse drug experience
reports. Each Party shall cooperate with the other Party in preparing and filing
all such reports and, upon the filing Party's request, provide the filing Party
with any information in the non-filing Party's control which the filing Party
deems to be relevant to any such report. Notwithstanding the foregoing, to the
extent that either Party has or receives any information regarding any adverse
drug experience which may be related to the use of any Licensed Product, CIMAB
shall promptly provide TARCANTA and TARCANTA LTD. with all such information.
Promptly after the Effective Date, the Parties shall, as part of the Development
Agreement, determine the procedures to be followed with respect to reporting
adverse drug experiences, such procedures to be consistent with each of the
Parties' obligations under Applicable Laws.

            3.2.2 Within ten (10) working days after receiving notification
about any Licensed Product that has been the subject of a complaint or adverse
event, CIMAB shall, to the extent possible based upon the information available
to CIMAB, provide TARCANTA and TARCANTA LTD. with: (a) the results of CIMAB's
failure investigation on the complaint; (b) a corrective and, where applicable,
preventative action plan; and (c) documentation of the completion of the
corrective action and/or preventative action plan, in accordance with applicable
provisions of the United States Code of Federal Regulations ("CFR") and other
Applicable Laws. The Parties shall cooperate with each other concerning the
investigation of such complaints and adverse events, including information about
specific complaints, on request.

            3.2.3 CIMAB shall maintain a complaint management process compliant
with Applicable Laws for reporting of adverse events outside the Territory,
including, but not be limited to, government product approvals, post-market
surveillance, product complaint management and reporting, corrective actions,
and all activities related to safety alerts and recalls.

      3.3 Warning Letters and Regulatory Actions

      CIMAB agrees to give prompt written notice to TARCANTA and TARCANTA LTD.
of any reports of observations on form 483, warning letters, "untitled" letters
or other similar notices of non-compliance with Applicable Laws with respect to
its facilities or operations used in the provision of Products that it receives
from any Government Authority. CIMAB shall cooperate with TARCANTA and TARCANTA
LTD. and make available to TARCANTA and TARCANTA LTD. such information as
TARCANTA and TARCANTA LTD. reasonably requests from CIMAB as necessary to
respond to any Government Authority in the Territory. CIMAB agrees to keep
TARCANTA and TARCANTA LTD. apprised as to the status of such

                                       4
<PAGE>

                                                                    CONFIDENTIAL

regulatory actions and shall promptly notify TARCANTA and TARCANTA LTD. when
such matters have been resolved.

      IN WITNESS WHEREOF, the Parties have executed this Agreement by their
proper officers as of the date and year first written above.

TARCANTA, INC.                               CIMAB, S.A.

By:                                          By:
   ________________________________              _______________________________
   Name:                                         Name:
   Title:                                        Title:

TARCANTA, LTD.

By:
   ________________________________
   Name:
   Title:

                      [SIGNATURE PAGE TO QUALITY AGREEMENT]

                                       5
<PAGE>

                                    EXHIBIT D
                      PATENT AND KNOW HOW LICENSE AGREEMENT
                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                                                               1
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                                                               2
<PAGE>

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                                                               3
<PAGE>

                                  [CIMAB LOGO]

                                    EXHIBIT E
                            PATENT LICENSE AGREEMENT
                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

<PAGE>

                                  [CIMAB LOGO]

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

<PAGE>

                                  [CIMAB LOGO]

                                      [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]